<SEC-DOCUMENT>0001047469-20-001059.txt : 20200226
<SEC-HEADER>0001047469-20-001059.hdr.sgml : 20200226
<ACCEPTANCE-DATETIME>20200226162541
ACCESSION NUMBER:		0001047469-20-001059
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		10
FILED AS OF DATE:		20200226
DATE AS OF CHANGE:		20200226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXACT SCIENCES CORP
		CENTRAL INDEX KEY:			0001124140
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				204782291
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-218535
		FILM NUMBER:		20656099

	BUSINESS ADDRESS:	
		STREET 1:		441 CHARMANY DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53719
		BUSINESS PHONE:		608-284-5700

	MAIL ADDRESS:	
		STREET 1:		441 CHARMANY DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53719

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXACT CORP
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>a2240838z424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg76301_table_of_contents">  TABLE OF CONTENTS</A> <BR>
<A HREF="#bg76302_table_of_contents">  Table of Contents</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>Filed Pursuant to Rule&nbsp;424(b)(5)<BR>
Registration No.&nbsp;333-218535  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CALCULATION OF REGISTRATION FEE  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="26%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:5pt;text-indent:-5pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Title of Each Class of Securities<BR>
to be Registered</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount to be<BR>
Registered(1)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Aggregate Offering<BR>
Price Per<BR>
Security</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Aggregate Offering<BR>
Price(1)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount of<BR>
Registration Fee(2)</B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:4pt;text-indent:-4pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=2>0.3750% Convertible Senior Notes due 2028</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$1,150,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>100.00%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$1,150,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$149,270</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:5pt;text-indent:-5pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common Stock, par value $0.01 per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;(4)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:5pt;text-indent:-5pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Registration Fee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$149,270</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:5pt;text-indent:-5pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Equals
the aggregate principal amount of the 0.3750% Convertible Senior Notes due 2028 (the "notes") being offered hereunder, including $150,000,000 in aggregate
principal amount of notes that may be offered and sold pursuant to the exercise in full of the underwriters' over-allotment option.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Calculated
in accordance with Rule&nbsp;457(r) of the Securities Act of 1933, as amended (the "Securities Act"). This "Calculation of Registration Fee" table shall
be deemed to update the "Calculation of Registration Fee" table in the registrant's Registration Statement on Form&nbsp;S-3ASR (File No.&nbsp;333-218535) in accordance with Rules&nbsp;456(b) and
457(r) under the Securities Act.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
an indeterminate number of shares of common stock that may be issued from time to time upon conversion of the notes, subject to adjustment in accordance
with the terms of the notes and the indenture governing the notes.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Pursuant
to Rule&nbsp;457(i) under the Securities Act, there is no additional filing fee with respect to the shares of common stock issuable upon conversion of the
notes because no additional consideration will be received in connection with the exercise of the conversion privilege.  </FONT></DD></DL>
<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=1007063,FOLIO='blank',FILE='DISK128:[20ZBC1.20ZBC76301]AA76301A.;6',USER='CHE106460',CD='26-FEB-2020;00:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>
<U>PROSPECTUS SUPPLEMENT</U><BR>
(To prospectus dated June&nbsp;6, 2017) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4>$1,000,000,000 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>
<IMG SRC="g930856.jpg" ALT="LOGO" WIDTH="195" HEIGHT="67">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5>Exact Sciences Corporation </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3>0.3750% Convertible Senior Notes due 2028 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=3>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are offering $1.0 billion aggregate principal amount of 0.3750% Convertible Senior Notes due 2028. We will pay
interest on the notes on
March&nbsp;1 and September&nbsp;1 of each year, beginning September&nbsp;1, 2020. The notes will mature on March&nbsp;1, 2028, unless earlier converted. </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders
may convert their notes at their option prior to the close of business on the business day immediately preceding September&nbsp;1, 2027 only under the following circumstances:
(1)&nbsp;on any date during any calendar quarter (and only during such calendar quarter) beginning after March&nbsp;31, 2020 if the closing sale price of our common stock was more than 130% of the
applicable conversion price on each applicable trading day for at least 20 trading days (whether or not consecutive) in the period of the 30 consecutive trading days ending on the last trading day of
the immediately preceding calendar quarter; (2)&nbsp;during the five business day period following any five consecutive trading day period in which the trading price per $1,000 principal amount of
notes for each trading day during such five trading day period was less than 98% of the product of the closing sale price of our common stock and the applicable conversion rate on each such trading
day; or (3)&nbsp;upon the occurrence of specified corporate events. On or after September&nbsp;1, 2027 until the close of business on the second scheduled trading day immediately preceding the
maturity date, holders may convert all or a portion of their notes at any time. Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash
and shares of our common stock, at our election, as described in this prospectus supplement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
initial conversion rate for the notes will be 8.2076 shares of common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $121.84
per share of common stock). The conversion rate will be subject to adjustment in certain events but will not be adjusted for accrued interest as described herein. Following certain corporate
transactions, we will increase the applicable conversion rate for a holder that elects to convert its notes in connection with such corporate transactions by a number of additional shares of our
common stock as described in this prospectus supplement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we undergo a fundamental change (as defined herein) prior to maturity of the notes, holders will have the right, at their option, to require us to repurchase for cash all or a
portion of their notes at a repurchase price equal to 100% of the principal amount of the notes being repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase
date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may not redeem the notes prior to the maturity date. </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
notes will rank senior in right of payment to all of our future indebtedness that is expressly subordinated in right of payment to the notes; rank equally in right of payment to all
of our existing and future liabilities that are not so subordinated; be effectively junior to all of our existing and future secured indebtedness and other secured obligations, to the extent of the
value of the assets securing that indebtedness and other secured obligations; and be structurally subordinated to all liabilities (including trade payables) of our subsidiaries. </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock trades on the Nasdaq Capital Market under the symbol "EXAS". On February&nbsp;24, 2020, the last sale price of the shares as reported on the Nasdaq Capital Market was
$95.56 per share. </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Investing in the notes involves risks that are described in the "Risk Factors" section beginning on page&nbsp;S-11 of
this prospectus supplement.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:65%;margin-left:17%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="324pt" style="font-family:times;"></TD>
<TD WIDTH="4%" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per Note </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Public offering price(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>100.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,000,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Underwriting discount(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Proceeds, before expenses, to us</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>97.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>978,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:17%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Plus
accrued interest from February&nbsp;27, 2020, if settlement occurs after that date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>We
refer you to the "Underwriting" section of this prospectus supplement for additional information regarding underwriter compensation.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have granted the underwriters an option to purchase up to an additional $150.0&nbsp;million aggregate principal amount of notes, solely to cover over-allotments, if any, for
30&nbsp;days after the date of this prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the
accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
notes will be ready for delivery in book-entry form only through the facilities of The Depository Trust Company for the accounts of its participants on or about February&nbsp;27,
2020. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>Sole Book-Running Manager  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>BofA Securities  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=5><B>


<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=4><B>Baird</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Cowen</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=4><B> William Blair</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=1>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>BTIG</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Stifel</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=1>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=1>
The date of this prospectus supplement is February&nbsp;24, 2020. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=61349,FOLIO='blank',FILE='DISK128:[20ZBC1.20ZBC76301]BC76301A.;20',USER='CHE107555',CD='26-FEB-2020;11:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_bg76301_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="BG76301A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg76301_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG76301_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="34pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Prospectus Supplement</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#BI1"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>About This Prospectus Supplement</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#BI1"><FONT SIZE=2>S-ii</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#BI2"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cautionary Statement About Forward-Looking Information</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#BI2"><FONT SIZE=2>S-iv</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#CA"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Summary</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#CA"><FONT SIZE=2>S-1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#CC"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Offering</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#CC"><FONT SIZE=2>S-6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#DA"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#DA"><FONT SIZE=2>S-11</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#DC1"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#DC1"><FONT SIZE=2>S-21</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#DC2"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalization</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#DC2"><FONT SIZE=2>S-22</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#DC3"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of the Notes</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#DC3"><FONT SIZE=2>S-24</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#DM"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Material U.S. Federal Income Tax Considerations</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#DM"><FONT SIZE=2>S-58</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#DO1"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#DO1"><FONT SIZE=2>S-67</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#DO2"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notice to Investors</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#DO2"><FONT SIZE=2>S-71</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#DO3"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#DO3"><FONT SIZE=2>S-75</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#DO4"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#DO4"><FONT SIZE=2>S-75</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#DO5"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You Can Find More Information</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#DO5"><FONT SIZE=2>S-75</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#DO6"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Incorporation of Certain Information by Reference</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#DO6"><FONT SIZE=2>S-75</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Prospectus</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da76302_about_this_prospectus"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>About This Prospectus</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da76302_about_this_prospectus"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da76302_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You Can Find More Information</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da76302_where_you_can_find_more_information"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da76302_incorporation_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Incorporation by Reference</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da76302_incorporation_by_reference"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da76302_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forward-Looking Statements</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da76302_forward-looking_statements"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da76302_the_company"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Company</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da76302_the_company"><FONT SIZE=2>3</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da76302_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use Of Proceeds</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da76302_use_of_proceeds"><FONT SIZE=2>3</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da76302_ratio_of_earnings_to_fixed_charges"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ratio Of Earnings To Fixed Charges</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da76302_ratio_of_earnings_to_fixed_charges"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da76302_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da76302_risk_factors"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da76302_description_of_securities_we_may_offer"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description Of Securities We May Offer</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da76302_description_of_securities_we_may_offer"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da76302_description_of_common_stock_we_may_offer"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description Of Common Stock We May Offer</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da76302_description_of_common_stock_we_may_offer"><FONT SIZE=2>5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da76302_description_of_preferred_stock_we_may_offer"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description Of Preferred Stock We May Offer</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da76302_description_of_preferred_stock_we_may_offer"><FONT SIZE=2>5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da76302_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Plan Of Distribution</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da76302_plan_of_distribution"><FONT SIZE=2>8</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da76302_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da76302_legal_matters"><FONT SIZE=2>9</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da76302_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da76302_experts"><FONT SIZE=2>9</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=901262,FOLIO='S-i',FILE='DISK128:[20ZBC1.20ZBC76301]BG76301A.;9',USER='CHE106460',CD='24-FEB-2020;00:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_bi76301_1_2"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="BI1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement and the accompanying prospectus form part of a registration statement on Form&nbsp;S-3 that we filed with the
Securities and Exchange Commission, or the "SEC," using a "shelf" registration process. This document contains two parts. The first part consists of this prospectus supplement, which provides you with
specific information about this offering. The second part, the accompanying prospectus, provides more general information, some of which may not apply to this offering. Generally, when we refer only
to the "prospectus," we are referring to both parts combined together with all documents incorporated by reference. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
this prospectus supplement, the "Company," "we," "us" and "our" and similar terms refer to Exact Sciences Corporation and its subsidiaries. References to our "common stock" refer to
the common stock of Exact Sciences Corporation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus supplement, and the information incorporated herein by reference, may add, update or change information in the accompanying prospectus and in any free writing
prospectuses we may provide to you in connection with this offering. You should read both this prospectus supplement and the accompanying prospectus together with additional information described
under the headings "Where You Can Find More Information" and "Incorporation of Certain Information by Reference." If there is any inconsistency between the information in this prospectus supplement
and the accompanying prospectus, you should rely on the information in this prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>You should rely only on the information contained in or incorporated by reference to this prospectus supplement and the accompanying prospectus. Neither we nor
the underwriters have authorized any other person to provide information different from that contained in this prospectus supplement, the accompanying prospectus and the documents incorporated by
reference herein and therein. If anyone provides you with different or inconsistent information, you should not rely on it. The information in this prospectus supplement, the accompanying prospectus
and in any free writing prospectuses we may provide to you in connection with this offering is accurate only as of their respective dates, regardless of time of delivery. Our business, financial
condition, results of operations and prospects may have changed since those dates.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the
offering of the securities in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement must inform themselves about, and
observe any restrictions relating to, the offering of the securities and the distribution of this prospectus supplement outside the United States. This prospectus supplement does not constitute, and
may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement by any person in any jurisdiction in which it is
unlawful for such person to make such an offer or solicitation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
references in this prospectus to our consolidated financial statements include, unless the context indicates otherwise, the related notes. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
industry and market data and other statistical information contained in this prospectus supplement, the accompanying prospectus and the documents we incorporate by reference are
based on management's own estimates, independent publications, government publications, reports by market research firms or other published independent sources, and, in each case, are believed by
management to be reasonable estimates. Although we believe these sources are reliable, we have not independently verified the information. None of the independent industry publications used in this
prospectus supplement, the accompanying prospectus or the documents we incorporate by reference were prepared on our or our affiliates' behalf and none of the sources cited by us consented to the
inclusion of any data from its reports, nor have we sought their consent. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-ii</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=421061,FOLIO='S-ii',FILE='DISK128:[20ZBC1.20ZBC76301]BI76301A.;8',USER='CHE106460',CD='25-FEB-2020;22:38' -->
<A NAME="page_bi76301_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus and the documents incorporated by reference herein include trademarks, tradenames and service marks that are our property or the property of licensors or other third
parties. Solely for convenience, such trademarks and tradenames may appear without any "&#153;" or "&reg;" symbol. However, failure to include such symbols is not intended to suggest,
in any way, that we will not assert our rights or the rights of any applicable licensor or other third party to such trademarks, tradenames and service marks. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-iii</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=680868,FOLIO='S-iii',FILE='DISK128:[20ZBC1.20ZBC76301]BI76301A.;8',USER='CHE106460',CD='25-FEB-2020;22:38' -->
<A NAME="page_bi76301_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="BI2"></A>CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING INFORMATION  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain information set forth in this prospectus supplement, set forth in the accompanying prospectus or incorporated by reference herein or
therein, may contain forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section&nbsp;21E of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain
assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would,"
"could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this prospectus
supplement, the accompanying prospectus or incorporated by reference herein or therein regarding our strategies, prospects, expectations, financial condition, operations, costs, plans and objectives
are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales,
marketing and patient adherence efforts, expectations concerning payer reimbursement and regulatory matters, the anticipated results of our product development efforts and the anticipated benefits of
our combination with Genomic Health,&nbsp;Inc., including estimated synergies and other financial impacts. Forward-looking statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and
trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are
difficult to predict and many of which are outside of our control. Our actual results and financial condition may
differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual
results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our
products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance
companies and other payers to cover our products and services and adequately reimburse us for such products and services; the amount and nature of competition in the cancer detection, treatment
guidance and monitoring space; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as
a result of any judicial, executive or legislative action; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the
Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Society of
Clinical Oncology, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new
products and services and assess potential market opportunities; our ability to effectively utilize strategic partnerships, such as through our Promotion Agreement with Pfizer,&nbsp;Inc., and
acquisitions; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; our
ability to manage an international business and our expectations regarding our international expansion and opportunities; the potential effects of foreign currency exchange rate fluctuations and our
efforts to hedge such effects; the possibility that the anticipated benefits from our combination with Genomic Health cannot be realized in full or at all or may take longer to realize than expected;
the possibility that costs or difficulties related to the integration of Genomic Health's operations will be greater than expected and the possibility of disruptions to our business during integration
efforts and strain on management time and resources; the outcome of any litigation, government investigations, enforcement actions or other legal proceedings; and the other risks and uncertainties
included in this prospectus </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-iv</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=262741,FOLIO='S-iv',FILE='DISK128:[20ZBC1.20ZBC76301]BI76301A.;8',USER='CHE106460',CD='25-FEB-2020;22:38' -->
<A NAME="page_bi76301_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>supplement
under the caption "Risk Factors," and those risks and uncertainties described in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus.
Therefore, you should not rely on any of these forward-looking statements. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. All subsequent written
and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the applicable cautionary statements. We further caution readers
not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as may be required by law, we undertake no obligation to publicly update any
forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-v</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=943721,FOLIO='S-v',FILE='DISK128:[20ZBC1.20ZBC76301]BI76301A.;8',USER='CHE106460',CD='25-FEB-2020;22:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ca76301_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="CA"></A>SUMMARY  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The information below is only a summary of more detailed information included elsewhere in or incorporated by reference
in this prospectus supplement and the accompanying prospectus. This summary may not contain all the information that is important to you or that you should consider before making an investment
decision. Please read this entire prospectus supplement and the accompanying prospectus, including the risk factors, as well as the information incorporated by reference in this prospectus supplement
and the accompanying prospectus, carefully.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Business Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a leading global cancer diagnostics company. We have developed some of the most impactful brands in cancer diagnostics, and we are
currently working on the development of additional tests for other types of cancer, with the goal of bringing new innovative cancer tests to patients throughout the world. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
November&nbsp;8, 2019, we completed the acquisition of Genomic Health,&nbsp;Inc. ("Genomic Health"), a leading provider of genomic-based diagnostic tests that help to optimize
cancer care, and its Oncotype&nbsp;IQ&reg; Genomic Intelligence Platform comprised of its flagship line of Oncotype&nbsp;DX&reg; gene expression tests. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Cologuard&reg; Test  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Colorectal cancer is the second leading cause of cancer deaths in the United States ("U.S.") and the leading cause of cancer deaths in the U.S.
among non-smokers. In 2020 in the U.S. there are projected to be approximately:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 148,000 new cases of colorectal cancer </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 53,000 deaths from colorectal cancer </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is widely accepted that colorectal cancer is among the most preventable, yet least prevented cancers. Colorectal cancer can take up to 10-15&nbsp;years to progress from a
pre-cancerous lesion to metastatic cancer and death. Patients who are diagnosed early in the progression of the disease&#151;with pre-cancerous lesions or polyps or early-stage
cancer&#151;are more likely to have a complete recovery and to be treated less expensively. Poor compliance with screening guidelines has meant that nearly two-thirds of colorectal cancer
diagnoses are made in the disease's late stages. The five-year survival rates for stages&nbsp;3 and 4 are 71&nbsp;percent and 14&nbsp;percent, respectively, compared to a 90&nbsp;percent
survival rate if the disease is diagnosed in stage&nbsp;1. We believe the large underserved population of unscreened and inadequately screened patients represents a significant opportunity for a
patient-friendly screening test. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Cologuard test is a non-invasive stool-based DNA ("sDNA") screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal
cancer and pre-cancer. Eleven biomarkers are targeted that have been shown to be strongly associated with colorectal cancer and pre-cancer. Methylation, mutation, and hemoglobin results are combined
in the laboratory analysis through a proprietary algorithm to provide a single positive or negative reportable result. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes
in DNA methylation, and the occurrence of mutations, alter gene expression and other mechanisms for cell cycle regulation and differentiation. As a result, the affected cells
continue to proliferate, often resulting in malignancies associated with colorectal cancer and pre-cancer. Hemoglobin is the protein complex responsible for transporting oxygen in red blood cells.
During the progression of cancer, the probability of bleeding into the colon increases. The presence of hemoglobin, released from red blood cells, can be detected in the stool. Using sDNA, Cologuard
purifies, amplifies </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=8,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=883240,FOLIO='S-1',FILE='DISK128:[20ZBC1.20ZBC76301]CA76301A.;6',USER='CHE106831',CD='23-FEB-2020;19:44' -->
<A NAME="page_ca76301_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>and
detects increased levels of methylation, and presence of mutations, in specific genes. By combining these DNA indicators with a test for hemoglobin, Cologuard produces a multi-marker result
effective for the detection of colorectal cancer and pre-cancerous adenomas. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
August 2014 the U.S. Food and Drug Administration ("FDA") granted premarket approval ("PMA") to Cologuard for use as a colorectal cancer screening test in adults 50&nbsp;years of
age and older who are at average-risk for colorectal cancer. Upon approval, Cologuard became the first and only FDA-approved sDNA non-invasive colorectal cancer screening test. In September 2019, the
FDA expanded Cologuard's indication to include average-risk individuals ages 45-49. Cologuard is now indicated for average risk adults 45&nbsp;years of age and older. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
original PMA submission to the FDA for Cologuard included the results of our pivotal DeeP-C clinical trial that had over 10,000 patients enrolled at 90 sites in the U.S. and Canada.
The results of our DeeP-C clinical trial for Cologuard were published in the New England Journal of Medicine in April 2014. The peer-reviewed study, "Multi-target Stool DNA Testing for
Colorectal-Cancer Screening," highlighted the performance of Cologuard in the trial population:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Cancer Sensitivity: 92% </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Stage&nbsp;I and II Cancer Sensitivity: 94% </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> High-Grade Dysplasia Sensitivity: 69% </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Specificity: 87% </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe the competitive advantages of sDNA screening provide a significant market opportunity. There are nearly 106&nbsp;million Americans between the ages of 45 and 85 who are at
average-risk for colorectal cancer. At a three-year screening interval and an average revenue per test of approximately $500 this represents a potential $18&nbsp;billion market for Cologuard, of
which our current share is
approximately 5.4&nbsp;percent. We estimate that the FDA's recent expansion of Cologuard's indication to average-risk individuals ages 45-49 added approximately 19&nbsp;million eligible people in
the U.S. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Approximately
an estimated 45 percent of Americans between the ages of 45 and 85 who are at average-risk for colorectal cancer are not up-to-date with screening according to the
American Cancer Society's ("ACS") colorectal cancer screening guidelines. We believe Cologuard helps more people get screened for colorectal cancer . Internal studies have shown that nearly 50% of
surveyed Cologuard users were previously unscreened for colorectal cancer. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Oncotype&nbsp;DX Tests  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With our Oncotype&nbsp;IQ Genomic Intelligence Platform we are applying our world-class scientific and commercial expertise and
infrastructure to lead the translation of clinical and genomic data into clinically actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment
selection and monitoring. Our Oncotype&nbsp;IQ Genomic Intelligence Platform is currently comprised of our flagship line of Oncotype&nbsp;DX gene expression tests for breast, prostate and colon
cancers, as well as Oncotype&nbsp;DX AR-V7 Nucleus Detect&reg; test, a liquid-based test for advanced stage prostate cancer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the U.S., approximately 1.8&nbsp;million new cancer cases are expected to be diagnosed in 2020 according to ACS. Cancer incidence and mortality are growing worldwide. In 2018,
there were approximately 17&nbsp;million newly diagnosed cancer cases and 9.5&nbsp;million cancer-related deaths occurred worldwide. The most common types of cancer include breast, prostate, lung,
colorectal and pancreatic. Cancer treatment decisions may include whether to perform surgery and whether to administer chemotherapy, radiation therapy or utilize other targeted therapies. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=9,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=665891,FOLIO='S-2',FILE='DISK128:[20ZBC1.20ZBC76301]CA76301A.;6',USER='CHE106831',CD='23-FEB-2020;19:44' -->
<A NAME="page_ca76301_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
treat cancer effectively, healthcare providers diagnose and gauge the stage of a patient's disease to determine the best course of therapy. Surgery, radiation therapy, and
chemotherapy are commonly used as treatment options, with varying degrees of benefit and side effects that may not always justify the cost of the therapy or the physical and mental burden patients
endure. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically,
the key determinant used by healthcare providers in making cancer treatment decisions has been tumor pathology grade and stage, which is used to predict the likelihood of
recurrence. Because tumor pathology grade and stage determinations are heavily dependent on visual assessment and human interpretation, healthcare providers and patients may make treatment decisions
that rely on subjective and qualitative information and do not account for the molecular nature of the patient's cancer. As a result, many patients may be misclassified as high risk for disease
recurrence when in fact they are low risk or, conversely, low risk for disease recurrence when they are high risk, resulting in over-treatment for some and under-treatment for others. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe our Oncotype&nbsp;DX tests provide information that has the following benefits: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Improved Quality of Treatment Decisions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;We believe our approach to
genomic-based cancer analysis improves the quality of cancer treatment decisions by providing an individualized analysis of each patient's tumor that is correlated to clinical outcome, rather than
solely using subjective, anatomic and qualitative factors to determine treatments. Our Oncotype&nbsp;DX tests for breast cancer, Ductal Carcinoma in Situ ("DCIS"), prostate cancer, and colon cancer
have been analytically and clinically validated in multiple published studies. The Recurrence Score&reg; results from our tests have been demonstrated to classify patients into recurrence risk
categories different than classifications based primarily on clinical and pathologic features. Additionally, multiple decision impact studies conducted worldwide consistently show that the Recurrence
Score result changes treatment decisions in more than 30% of patients. As a result, we believe our tests enable patients and healthcare providers to make more informed decisions about the risks and
benefits of various treatments, and consequently design an individualized treatment plan.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Improved Health Economics of Cancer Care.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;We believe that improving the
quality of treatment decisions can result in significant economic benefits. For example, as described below, the results of a number of clinical studies have demonstrated that by using the
Oncotype&nbsp;DX Breast Recurrence Score&reg; test, physicians and patients can better evaluate treatment options, such as whether a patient will or will not benefit from chemotherapy,
thereby improving the patient's prospects for better clinical outcomes by avoiding unnecessary chemotoxicities, secondary cancers, distant recurrences, and shortened survival and by saving the patient
as well as the healthcare system significant costs. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


International Business Background and Products  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to our combination with Genomic Health, we did not have international revenue. We now commercialize our Oncotype&nbsp;DX tests
internationally through employees in Canada, Japan and six European countries, as well as through exclusive distribution agreements. We have provided our Oncotype&nbsp;DX tests in more than 90
countries outside of the United States. We do not offer Cologuard outside of the U.S. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inclusion
of our products in guidelines and quality measures will be critical to our international success. The Oncotype&nbsp;DX breast cancer test is recognized in international
guidelines issued by the St.&nbsp;Gallen International Breast Cancer Expert Panel and European Society for Medical Oncology. In addition, the National Institute for Health and Care Excellence in
England recommends the Oncotype&nbsp;DX breast cancer test for use in clinical practice to guide chemotherapy treatment decisions for certain patients with early-stage, N-, hormone
receptor-positive, HER2 negative, invasive breast cancer, as well as certain patients with micrometastases. In June 2019, the German Federal Joint </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=10,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=761113,FOLIO='S-3',FILE='DISK128:[20ZBC1.20ZBC76301]CA76301A.;6',USER='CHE106831',CD='23-FEB-2020;19:44' -->
<A NAME="page_ca76301_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>Committee
issued a positive reimbursement decision for our Oncotype&nbsp;DX Breast Recurrence Score test following a conclusion by the German Institute for Quality and Efficiency in Health Care that
there is sufficient evidence supporting the ability of the test to guide breast cancer adjuvant chemotherapy decisions. Also, each of the Gynecologic Oncology Working Group in Germany and the Japan
Breast Cancer Society updated their guidelines to recommend Oncotype&nbsp;DX as the only breast cancer gene expression test to predict chemotherapy benefit in early-stage, hormone receptor-positive
invasive breast cancer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect the international sales of our tests will be heavily dependent on the availability of reimbursement. In many countries, governments are primarily responsible for financing and
establishing reimbursement for diagnostic tests. The majority of our international Oncotype&nbsp;DX test revenues come from direct payer reimbursement, payments from our distributors, and patient
self-pay. We have
obtained coverage for our invasive breast cancer test outside of the U.S., including coverage for certain patients in Canada, France, Spain, Germany, Italy, Ireland, Israel, Saudi Arabia, Switzerland,
and the United Kingdom. We expect that broadening coverage and reimbursement for our Oncotype&nbsp;DX tests outside of the United States will take years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
countries, such as China, have prohibitions against exporting tissue samples, which will limit our ability to offer our tests in those countries without local laboratories or a
method of test delivery that does not require samples to be transported to our U.S. laboratory. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pipeline Research and Development  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our research and development efforts are focused on developing new products and enhancing existing products to address new cancer areas and
expand the clinical utility and addressable patient populations for our existing tests. These development efforts may lead to a variety of possible new products, including risk assessment, screening
and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection and patient monitoring. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Through
our collaboration with Mayo Foundation for Medical Education and Research, we have successfully performed validation studies on multiple types of cancer using tissue, blood and
other samples. We are currently focusing our research and development efforts on building a pipeline of potential future products and services with a focus on improving Cologuard's performance
characteristics and on developing blood or other fluid-based ("liquid biopsy") tests. We expect to advance liquid biopsy through biomarker discovery and validation in tissue, blood, or other fluids. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Colon Cancer Screening  </I></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are seeking opportunities to improve upon Cologuard's performance characteristics. For example, we are evaluating whether new biomarkers
would increase specificity while maintaining sensitivity. If we could increase the specificity of Cologuard, we believe that would enhance its adoption as a front-line screening test. We are also
evaluating ways that we might make Cologuard even easier for patients to use and opportunities for lowering the cost of providing Cologuard. In October 2019, we and Mayo presented at the American
College of Gastroenterology's 2019 Annual Scientific Meeting findings from a blinded-case control study showing enhanced colorectal cancer and advanced adenoma detection using newly discovered
methylation biomarkers and hemoglobin. To establish the performance of the novel multi-target stool DNA test, we recently launched the BLUE-C
study, a multi-center, prospective study. We expect to enroll more than 10,000 patients 40&nbsp;years of age and older in the BLUE-C study. The timing of any such enhancements to Cologuard is
unknown and would be subject to FDA approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also working to develop a blood-based screening test for colorectal cancer. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=11,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=694785,FOLIO='S-4',FILE='DISK128:[20ZBC1.20ZBC76301]CA76301A.;6',USER='CHE106831',CD='23-FEB-2020;19:44' -->
<A NAME="page_ca76301_1_5"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hepatocellular Carcinoma ("HCC") Test Development  </I></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are currently seeking to develop a blood-based biomarker test to serve as an alternative to ultrasound and alpha-fetaprotein ("AFP") for use
in HCC testing. HCC is the most common type of liver cancer. Our goal is to develop a patient-friendly test that performs better than the current standard of care. We are finalizing our HCC test
development and plan to make the test available in the second half of 2020. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ACS estimates that liver cancer would be diagnosed in 43,000 Americans and cause 30,000 deaths in 2020, approximately 90&nbsp;percent of which would be HCC. Incidence and
mortality rates are both increasing at approximately three percent per year. People who have been diagnosed with cirrhosis of the liver or Hepatitis B are at high risk of developing HCC. Evidence
shows that HCC testing in these high-risk groups leads to earlier detection and improved outcomes. The NCCN and American Association for the Study of Liver Diseases guidelines recommend that these two
groups be tested for HCC every six months using ultrasound and AFP. However, ultrasound and AFP are documented to have poor sensitivity for early stage cancer, which is the primary target of testing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2019, we released the results of a 443-patient study which demonstrated 80% sensitivity at 90% specificity with a novel combination of six blood-based biomarkers for HCC.
The study also
showed 71% sensitivity for early stage HCC at 90% specificity. The study compared performance to the AFP test, which demonstrated 45% sensitivity at 90% specificity for early stage HCC. Our HCC test
has been granted Breakthrough Device designation by the FDA. The FDA's Breakthrough Devices program expedites development, assessment, and review processes to provide patients and healthcare providers
with timely access to new technologies. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


In Vitro Device ("IVD") Version of Oncotype&nbsp;DX Breast Cancer Test  </I></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe developing IVD versions of our Oncotype&nbsp;DX products that can be performed locally, rather than in our centralized Redwood
City, California, laboratory, may open up additional international opportunities. We are currently developing an IVD version of the Oncotype&nbsp;DX Breast Recurrence Score test and may explore
additional IVD versions of our Oncotype&nbsp;DX tests. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Development Studies for Oncotype&nbsp;DX Products  </I></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may also conduct or fund clinical studies that could support additional opportunities for our products. For example, we may explore clinical
studies to expand the use of genomic testing to address additional populations, including higher-risk patients. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were incorporated in the State of Delaware on February&nbsp;10, 1995. Our corporate headquarters are located at 441&nbsp;Charmany Drive,
Madison, Wisconsin&nbsp;53719. Our telephone number is&nbsp;(608)&nbsp;284-5700. Our Internet website address is </FONT><FONT SIZE=2><I>www.exactsciences.com</I></FONT><FONT SIZE=2>. The
information contained on, or that can be accessed through, our website is not a part of this prospectus. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=12,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=806598,FOLIO='S-5',FILE='DISK128:[20ZBC1.20ZBC76301]CA76301A.;6',USER='CHE106831',CD='23-FEB-2020;19:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cc76301_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="CC"></A>THE OFFERING  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The summary below describes the principal terms of the notes. Certain of the terms and conditions described below are subject to important
limitations and exceptions. For a more detailed description of the terms and conditions of the notes, see the section entitled "Description of the Notes." With respect to the discussion of the terms
of the notes on the cover page, in this section and in the section entitled "Description of the Notes," references to "the Company," "we," "our," and "us" refer solely to Exact Sciences Corporation
and not its subsidiaries. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Issuer:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Exact Sciences Corporation</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Notes Offered:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$1,000,000,000 aggregate principal amount of 0.3750% Convertible Senior Notes due 2028. We have granted the underwriters an
option to purchase up to an additional $150.0&nbsp;million aggregate principal amount of notes solely to cover over-allotments.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Maturity Date:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>March&nbsp;1, 2028, unless earlier converted.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Interest and Payment Dates:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>0.3750% per year, payable semi-annually in arrears on March&nbsp;1 and September&nbsp;1 of each year, beginning
September&nbsp;1, 2020. We will pay additional interest, if any, at our election as the sole remedy relating to the failure to comply with our reporting obligations as described under "Description of the Notes&#151;Events of Default; Notice and
Waiver."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Ranking:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The notes will be our senior unsecured obligations that will:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>rank senior in right of
payment to all of our future indebtedness that is expressly subordinated in right of payment to the notes;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>rank equally in right of
payment to all of our existing and future liabilities that are not so subordinated;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>be effectively junior to
all of our existing and future secured indebtedness and other secured obligations, to the extent of the value of the assets securing that indebtedness and other secured obligations; and</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>be structurally
subordinated to all indebtedness and other liabilities (including trade payables) of our subsidiaries.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>See "Description of the Notes&#151;Ranking."</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>
</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=67221,FOLIO='S-6',FILE='DISK128:[20ZBC1.20ZBC76301]CC76301A.;12',USER='CHE107555',CD='26-FEB-2020;10:58' -->
<A NAME="page_cc76301_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>As of December&nbsp;31, 2019, our total consolidated indebtedness was approximately $1,187.5&nbsp;million (including $415.0&nbsp;million of
our 1.0% Convertible Senior Notes due 2025 (the "2025 notes") and $747.5&nbsp;million of our 0.375% Convertible Senior Notes due 2027 (the "2027 notes")), $25.0&nbsp;million of which was secured. As of December&nbsp;31, 2019, our subsidiaries had
$14.3&nbsp;million of indebtedness and other liabilities (including trade payables). After giving effect to the issuance of the notes (assuming no exercise of the underwriters' option to purchase additional notes) and the use of proceeds thereof as
described below under "Use of Proceeds," our total consolidated indebtedness would have been approximately $2,087.5&nbsp;million as of December&nbsp;31, 2019.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The indenture governing the notes will not limit our ability to incur additional indebtedness in the future, including
senior secured indebtedness.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Conversion Rights:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prior to the close of business on the business day immediately preceding September&nbsp;1, 2027, you may, at your option,
convert your notes, in multiples of $1,000 principal amount, but only under the following circumstances:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>on any date during any
calendar quarter (and only during such calendar quarter) beginning after March&nbsp;31, 2020 if the closing sale price (as defined in "Description of the Notes&#151;Conversion Rights&#151;Conversion Upon Satisfaction of Sale Price Condition") of our
common stock was more than 130% of the applicable conversion price on each applicable trading day for at least 20 trading days (whether or not consecutive) in the period of the 30 consecutive trading days ending on the last trading day of the
immediately preceding calendar quarter;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>during a specified period
if we distribute to all or substantially all holders of our common stock any rights, options or warrants (other than pursuant to a stockholders rights plan) entitling them to purchase, for a period of 45 calendar days or less from the announcement
date for such distribution, shares of our common stock at a price per share less than the average of the closing sale prices for the ten consecutive trading day period ending on, and including, the trading day immediately preceding the announcement
date for such distribution;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>during a specified period
if we distribute to all or substantially all holders of our common stock cash or other assets, debt securities or rights to purchase our securities (other than pursuant to a stockholders rights plan), which distribution has a per share value
exceeding 10% of the closing sale price of our common stock on the trading day immediately preceding the announcement date for such distribution;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>
</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=908680,FOLIO='S-7',FILE='DISK128:[20ZBC1.20ZBC76301]CC76301A.;12',USER='CHE107555',CD='26-FEB-2020;10:58' -->
<A NAME="page_cc76301_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>during a specified period
if a fundamental change occurs or if we engage in certain corporate transactions; or</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>during the five business
day period following any five consecutive trading day period in which the trading price (as defined in "Description of the Notes&#151;Conversion Rights&#151;Conversion Upon Satisfaction of Trading Price Condition") per $1,000 principal amount of
notes for each trading day during such five trading day period was less than 98% of the product of the closing sale price of our common stock and the applicable conversion rate on each such trading day.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>On or after September&nbsp;1, 2027 until the close of business on the second scheduled trading day immediately preceding the
maturity date, you may, at your option, convert all or any portion of your notes, in multiples of $1,000 principal amount, at any time, regardless of the foregoing circumstances.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The conversion rate for the notes is initially 8.2076&nbsp;shares of common stock per $1,000 principal amount of notes
(equivalent to an initial conversion price of approximately $121.84&nbsp;per share of common stock), subject to adjustment as described in this prospectus supplement.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Settlement Upon Conversion:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock (and cash in lieu of
fractional shares) or a combination of cash and shares of our common stock, at our election. If we satisfy our conversion obligation solely in cash or through payment and delivery, as the case may be, of a combination of cash and shares of our common
stock, the amount of cash and shares of common stock, if any, due upon conversion will be based on a daily conversion value or a daily settlement amount, as applicable (as described herein) calculated on a proportionate basis for each VWAP trading
day (as defined herein) in a 30 VWAP trading day observation period (as defined herein). You will not receive any separate cash payment or additional shares for interest, if any, accrued and unpaid to the conversion date, except in limited
circumstances. Instead, interest will be deemed paid by the cash, shares of our common stock or a combination of cash and shares of our common stock paid or delivered, as the case may be, to you upon conversion of a note. See "Description of the
Notes&#151;Conversion Rights."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>No Redemption:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We may not redeem the notes prior to the maturity date, and no "sinking fund" is provided for the notes, which means we are
not required to redeem or retire the notes periodically.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>
</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=15,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=336730,FOLIO='S-8',FILE='DISK128:[20ZBC1.20ZBC76301]CC76301A.;12',USER='CHE107555',CD='26-FEB-2020;10:58' -->
<A NAME="page_cc76301_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Adjustment to Conversion Rate Upon a Make-Whole Fundamental Change:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>If the effective date (as defined herein) of a make-whole fundamental change (as defined herein) occurs prior to the maturity date of the
notes and a holder elects to convert its notes in connection with such make-whole fundamental change, we will increase the conversion rate by a number of additional shares. The number of additional shares will be determined by reference to the table
in "Description of the Notes&#151;Conversion Rights&#151;Adjustment to Conversion Rate Upon a Make-Whole Fundamental Change," based on the effective date and the price paid (or deemed paid) per share of our common stock in such make-whole fundamental
change. If holders of our common stock receive only cash in a make-whole fundamental change, the price paid (or deemed paid) per share will be the cash amount paid per share. Otherwise, the price paid (or deemed paid) per share will be equal to the
average of the closing sale prices of our common stock over the five trading day period ending on, and including, the trading day immediately preceding the effective date of such make-whole fundamental change.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Fundamental Change Repurchase Right of Holders:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>If we undergo a fundamental change (as defined under "Description of the Notes&#151;Fundamental Change Put") prior to
maturity of the notes, subject to certain conditions, you will have the right, at your option, to require us to repurchase for cash all or a portion of your notes in minimum principal amounts of $1,000 or whole multiples thereof at a repurchase price
equal to 100% of the principal amount of the notes being repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. See "Description of the Notes&#151;Fundamental Change Put."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Book-Entry Form:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The notes will be issued in book-entry form and will be represented by permanent global certificates deposited with, or on
behalf of, The Depository Trust Company ("DTC") and registered in the name of Cede&nbsp;&amp;&nbsp;Co. as DTC's nominee. Beneficial interests in any of the notes will be shown on, and transfers will be effected only through, records maintained by DTC
or its nominee and any such interest may not be exchanged for certificated securities, except in limited circumstances.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Listing:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We do not intend to apply for listing of the notes on any securities exchange or any automated dealer quotation system. Our
common stock is listed on the Nasdaq Capital Market under the symbol "EXAS."</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>
</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=16,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=496475,FOLIO='S-9',FILE='DISK128:[20ZBC1.20ZBC76301]CC76301A.;12',USER='CHE107555',CD='26-FEB-2020;10:58' -->
<A NAME="page_cc76301_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Use of Proceeds:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We estimate that our net proceeds from this offering, after deducting underwriting discounts and estimated offering fees and expenses, will
be approximately $978.0&nbsp;million (or $1,124.7 million if the underwriters exercise in full their option to purchase $150.0&nbsp;million in additional notes from us).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We intend to use the net proceeds from this offering for general corporate purposes, which may include the repayment of debt,
 working capital and possible acquisitions. In addition, we expect to use approximately $150.0 million of the net proceeds to repurchase a portion of our existing 2025 notes. See "Use of Proceeds."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Trustee:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>U.S. Bank National Association</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Absence of a Public Market for the Notes:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The notes are new securities, and there is currently no established market for the notes. Accordingly, we cannot assure you
as to the development or liquidity of any market for the notes. See "Underwriting&#151;New Issue of Notes." We have been advised by certain of the underwriters that they presently intend to make a market in the notes after completion of the offering.
However, they are under no obligation to do so and may discontinue any market-making activities at any time without notice. We do not intend to apply for a listing of the notes on any securities exchange or any automated dealer quotation
system.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Risk Factors:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>You should read the "Risk Factors" beginning on page&nbsp;S-11 of this prospectus supplement and the other information
included or incorporated by reference in this prospectus supplement and the accompanying prospectus for a discussion of factors you should consider carefully before deciding to invest in the notes.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>U.S. Federal Income Tax Considerations:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>For the U.S. federal income tax considerations of the holding, disposition and conversion of the notes, and the holding and
disposition of our common stock, see "Material U.S. Federal Income Tax Considerations."</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=17,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=498932,FOLIO='S-10',FILE='DISK128:[20ZBC1.20ZBC76301]CC76301A.;12',USER='CHE107555',CD='26-FEB-2020;10:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_da76301_1_11"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DA"></A>RISK FACTORS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Investing in the notes involves risk. We operate in a rapidly changing environment that involves a number of risks,
some of which are beyond our control. You should carefully consider the following risk factors and the risk factors discussed under the section entitled "Risk Factors" contained in our Annual Report
on Form&nbsp;10-K for the year ended December&nbsp;31, 2019, which is incorporated by reference into this prospectus supplement in its entirety, together with all of the other information
contained in this prospectus supplement and the accompanying prospectus or incorporated by reference into this prospectus supplement and the accompanying prospectus. The risks and uncertainties
described in these documents are not the only ones we face. Additional risks and uncertainties not presently known to us, which we currently deem immaterial or which are similar to those faced by
other companies in our industry or business in general, may also impair our business operations. This could cause the value of the notes to decline, and you may lose all or part of your
investment.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Indebtedness and the Notes  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The notes are our unsecured senior obligations and will be effectively junior to all of our existing and
future secured indebtedness and other secured obligations, to the extent of the value of the assets securing that indebtedness, and be structurally subordinated to all indebtedness and other
liabilities (including trade payables) of our subsidiaries.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The notes are our senior unsecured obligations and will effectively rank junior in right of payment to any of our secured indebtedness and
other secured obligations to the extent of the value of the assets securing such indebtedness and be structurally subordinated to all indebtedness and other liabilities (including trade payables, but
excluding intercompany obligations) of our subsidiaries. Additionally, the notes will rank </FONT><FONT SIZE=2><I>pari passu</I></FONT><FONT SIZE=2> with our outstanding unsubordinated liabilities
and will not be guaranteed by any subsidiary. In the event of our bankruptcy, liquidation, reorganization or other winding up, our assets that secure indebtedness or other obligations effectively
ranking senior in right of payment to the notes will be available to pay obligations on the notes only after the secured indebtedness or other secured obligations has been repaid in full from these
assets. There may not be sufficient assets remaining to pay amounts due on any or all of the notes then outstanding. The indenture governing the notes will not prohibit us from incurring additional
indebtedness in the future, including senior secured indebtedness, and such indebtedness may be substantial, nor will the indenture prohibit our subsidiaries from incurring additional indebtedness or
other liabilities. See "Description of the Notes&#151;Ranking." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2019, our total consolidated indebtedness was approximately $1,187.5&nbsp;million, $25.0&nbsp;million of which was secured. As of December&nbsp;31, 2019,
our subsidiaries had approximately $14.3&nbsp;million of indebtedness and other liabilities (including trade payables). After giving effect to the issuance of the notes offered hereby (assuming no
exercise of the underwriters' option to purchase additional notes) and the use of proceeds thereof as described below under "Use of Proceeds," our total consolidated indebtedness would have been
approximately $2,087.5&nbsp;million as of December&nbsp;31, 2019. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our indebtedness could adversely affect our business, financial condition and results of operations and our
ability to meet our payment obligations under such indebtedness.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2019, there was outstanding $1,162.5 million aggregate principal amount of our 1.0% and 0.375% convertible senior
notes due 2025 and 2027 and we had a construction loan outstanding of $25.0&nbsp;million as of December&nbsp;31, 2019. After giving effect to this offering of notes and the use of proceeds thereof
as described below under "Use of Proceeds," our indebtedness would increase by $900.0&nbsp;million (or $1,050.0&nbsp;million if the underwriters exercise their option to purchase additional notes
in full) (which amount, with respect to the notes, reflects the face amount of the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=18,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=14931,FOLIO='S-11',FILE='DISK128:[20ZBC1.20ZBC76301]DA76301A.;12',USER='CHE106460',CD='26-FEB-2020;00:12' -->
<A NAME="page_da76301_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>notes).
The indenture governing the notes will not restrict our ability to incur additional indebtedness. This level of debt could have significant consequences on our future operations,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> increasing our vulnerability to adverse economic and industry conditions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> making it more difficult for us to meet our payment and other obligations under the 2025 notes, 2027 notes and the notes offered hereby; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> making it more difficult to obtain any necessary future financing for working capital, capital expenditures, debt service requirements or other
purposes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> requiring the dedication of a substantial portion of any cash flow from operations to service our indebtedness, thereby reducing the amount of
cash flow available for other purposes, including capital expenditures; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital than we
have; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limiting our flexibility in planning for, or reacting to, changes in our business and the markets in which we compete. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of the above-listed factors could have an adverse effect on our business, financial condition and results of operations and our ability to meet our payment obligations under the
notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ability to meet our payment and other obligations under the notes depends on our ability to generate significant cash flow in the future. This, to some extent, is subject to general
economic, financial, competitive, legislative and regulatory factors as well as other factors that are beyond our control. We cannot assure you that our business will generate cash flow from
operations, or that future borrowings will be available to us, in an amount sufficient to enable us to meet our payment obligations under the notes and to fund other liquidity needs. If we are not
able to generate sufficient cash flow to service our debt obligations, we may need to refinance or restructure our debt, including the 2025 notes, the 2027 notes and the notes offered hereby, sell
assets, reduce or delay capital investments, or seek to raise additional capital. If we are unable to implement one or more of these alternatives, we may not be able to meet our payment obligations
under the notes, and this default could cause us to be in default on any other currently existing or future outstanding indebtedness. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may incur substantially more debt or take other actions which would intensify the risks discussed above.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We and our subsidiaries may be able to incur substantial additional debt in the future, some of which may be secured debt. We and our
subsidiaries are not restricted under the terms of the indenture governing the notes from incurring additional debt, securing existing or future debt, recapitalizing our debt or taking a number of
other actions that are not limited by the terms of the indenture governing the notes that could have the effect of diminishing our ability to make payments on the notes when due. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our
business to pay amounts due under our indebtedness, including the notes.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness, including the 2025 notes, the
2027 notes and the notes offered hereby, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not continue to
generate cash flow from operations in the future sufficient to service our debt, including the 2025 notes, the 2027 notes and the notes offered hereby, and make necessary capital expenditures. If we
are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=19,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=192103,FOLIO='S-12',FILE='DISK128:[20ZBC1.20ZBC76301]DA76301A.;12',USER='CHE106460',CD='26-FEB-2020;00:12' -->
<A NAME="page_da76301_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>additional
equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may
not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The terms of the notes will not contain restrictive covenants and provide only limited protection in the
event of a change of control.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture under which the notes will be issued will not contain restrictive covenants that would protect you from several kinds of
transactions that may adversely affect you. In particular, the indenture will not contain covenants that will limit our ability to pay dividends or make distributions on or redeem our capital stock or
limit our ability to incur additional indebtedness and, therefore, may not protect you in the event of a fundamental transaction, a highly leveraged transaction or other similar transaction. The
requirement that we offer to repurchase the notes upon a change of control is limited to the transactions specified in the definition of a "fundamental change" under "Description of the
Notes&#151;Fundamental Change Put." Similarly, the circumstances under which we are required to adjust the conversion rate upon the occurrence of a "make-whole fundamental change" are limited
to circumstances where a note is converted in connection with such a transaction as set forth under "Description of the Notes&#151;Conversion Rights&#151;Adjustment to Conversion Rate
Upon a Make-Whole Fundamental Change." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accordingly,
subject to restrictions contained in any future debt agreements, we could enter into certain transactions, such as acquisitions, refinancings or recapitalizations that
could affect our capital structure and the value of the notes and common stock but would not constitute a fundamental change under the notes. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Some significant restructuring transactions may not constitute a fundamental change, in which case we would
not be obligated to offer to repurchase the notes.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the occurrence of a fundamental change, you have the right to require us to repurchase your notes. However, the fundamental change
provisions will not afford protection to holders of the notes in the event of certain transactions. For example, transactions such as leveraged recapitalizations, refinancings, restructurings or
acquisitions initiated by us may not constitute a fundamental change requiring us to repurchase the notes. In the event of any such transaction, the holders would not have the right to require us to
repurchase the notes, even though each of these transactions could increase the amount of our indebtedness, or otherwise adversely affect our capital structure or any credit ratings, thereby adversely
affecting the holders of the notes. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not have the ability to raise the funds necessary to settle conversions of the notes or to repurchase
the notes for cash when required by the holders upon a fundamental change.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of the notes will have the right to require us to repurchase the notes upon the occurrence of a fundamental change prior to maturity as
described under "Description of the Notes&#151;Fundamental Change Put." In addition, unless we elect to deliver solely shares of our common stock, we will be required to make cash payments in
respect of the notes being converted as described under "Description of the Notes&#151;Conversion Rights&#151;Settlement Upon Conversion." However, we may not have enough available cash
or be able to obtain financing at the time we are required to make purchases of notes surrendered therefor or notes being converted. In addition, our ability to repurchase the notes or to pay cash
upon conversion of the notes may be limited by law, by regulatory authority or by agreements that will govern our future indebtedness. Our failure to repurchase the notes at a time when the repurchase
is required by the indenture that will govern the notes or to pay cash payable on future conversions of the notes as required by such indenture would constitute a default under such indenture. A
default under the indenture that will govern the notes or the fundamental change itself </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=20,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=814984,FOLIO='S-13',FILE='DISK128:[20ZBC1.20ZBC76301]DA76301A.;12',USER='CHE106460',CD='26-FEB-2020;00:12' -->
<A NAME="page_da76301_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>could
also lead to a default under agreements governing our future indebtedness, the 2025 notes and the 2027 notes. If the repayment of the related indebtedness were to be accelerated after any
applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the notes or make cash payments upon conversions thereof. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Holders of the notes may not be able to determine when a fundamental change giving rise to their right to
have the notes repurchased has occurred following a sale of "substantially all" of our assets.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One of the circumstances under which a fundamental change may occur is upon the sale or disposition of "all or substantially all" of our
assets. There is no precise, established definition of the phrase "substantially all" under applicable law and the interpretation of that phrase will likely depend upon particular facts and
circumstances. Accordingly, the ability of a holder of notes to require us to repurchase its notes as a result of a sale of less than all our assets to another person may be uncertain. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The adjustment to the conversion rate upon the occurrence of a make-whole fundamental change may not
adequately compensate you for the lost option time value of your notes as a result of such transaction.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If a make-whole fundamental change occurs prior to maturity and a holder elects to convert in connection with such transaction, we will
increase the conversion rate under certain circumstances. The number of additional shares by which the conversion rate will be increased will be determined based on the date on which the make-whole
fundamental change becomes effective and the price paid (or deemed paid) per share of our common stock in the make-whole fundamental change, as described under "Description of the
Notes&#151;Conversion Rights&#151;Adjustment to Conversion Rate Upon a Make-Whole Fundamental Change." Although this adjustment is designed to compensate you for the lost option value of
your notes as a result of a make-whole fundamental change, the adjustment may not adequately compensate you for such loss. In addition, if the price paid per share of our common stock in the
make-whole fundamental change is less than $95.56 or greater than $450.00 (in each case, subject to adjustment), there will be no such adjustment. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
obligation to increase the conversion rate as described above could also be considered a penalty, in which case its enforceability would be subject to general principles of
reasonableness and equitable remedies. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The conditional conversion feature of the notes could result in your receiving less than the value of the
common stock into which a note would otherwise be convertible.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to the close of business on the business day immediately preceding September&nbsp;1, 2027, the notes are convertible into cash, shares
of our common stock or a combination of cash and shares of our common stock, at our election, only if specified conditions are met. If these specified conditions are not met, you will not be able to
convert your notes prior to September&nbsp;1, 2027, and you may not be able to receive the value of the consideration into which the notes would otherwise be convertible. Therefore, you may not be
able to realize the appreciation, if any, in the value of our common stock after the issuance of the notes in this offering and prior to such date. In addition, the inability to freely convert may
also adversely affect the trading price of the notes and your ability to resell the notes. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Upon conversion of the notes, you may receive less valuable consideration than expected because the value of
our common stock may decline after you exercise your conversion right but before we settle our conversion obligation.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the notes, a converting holder will be exposed to fluctuations in the value of our common stock during the period from the date such
holder surrenders notes for conversion until the date we settle our conversion obligation. Upon conversion of the notes, the amount of consideration that you will receive upon conversion of your notes
will be determined by reference to the volume </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=21,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=709710,FOLIO='S-14',FILE='DISK128:[20ZBC1.20ZBC76301]DA76301A.;12',USER='CHE106460',CD='26-FEB-2020;00:12' -->
<A NAME="page_da76301_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>weighted
average prices ("VWAP") of our common stock for each VWAP trading day in a 30 VWAP trading day observation period. Although the number of shares (if any) that you receive upon conversion of
your notes with respect to any VWAP trading day during the observation period will be determined based on the volume weighted average price of our common stock on such VWAP trading day, we will not
deliver such shares until the second business day following the end of the applicable observation period. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accordingly,
if the price of our common stock decreases during this period, the amount and/or value of consideration you receive will be adversely affected. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Upon conversion of the notes, we may pay cash in lieu of issuing shares of our common stock with respect to
all or a portion of the converted notes. Therefore, holders of the notes may receive no shares of our common stock or will receive fewer shares than the number underlying their notes.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon conversion, we may pay cash in lieu of issuing shares of our common stock with respect to all or a portion of converted notes. See
"Description of the Notes&#151;Conversion Rights&#151;Settlement Upon Conversion." Accordingly, upon conversion of notes, holders may not receive any shares of our common stock. Further,
our liquidity may be reduced upon conversion of the notes. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The conversion rate of the notes may not be adjusted for all dilutive events that may adversely affect the
trading price of the notes or the common stock issuable upon conversion of the notes.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The conversion rate of the notes is subject to adjustment upon certain events, including the issuance of stock dividends on our common stock,
the issuance of certain rights, options or warrants, subdivisions, combinations, distributions of capital stock, indebtedness or other assets, cash dividends exceeding a specified threshold and issuer
tender or exchange offers as described under "Description of the Notes&#151;Conversion Rights&#151;Conversion Rate Adjustments." However, the conversion rate will not be adjusted for
certain other events, such as issuances of our common stock for cash or issuances of our common stock in connection with acquisitions or third-party tender offers, that may adversely affect the
trading price of the notes or our common stock. An event that adversely affects the value of the notes may occur, and that event may not result in an adjustment to the conversion rate. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Future sales or other dilution of our equity could depress the market price of our common stock.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of our common stock in the public market, or the perception that such sales could occur, could negatively impact the market price of our
common stock. We also have several institutional stockholders that own significant blocks of our common stock. If one or more of these stockholders were to sell large portions of their holdings in a
relatively short time, for liquidity or other reasons, the prevailing market price of our common stock could be negatively affected. We are not restricted from issuing additional shares of common
stock during the life of the notes. If we issue additional shares of common stock, the price of our common stock, and in turn, the price of the notes may decline. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
certain circumstances, shares of our common stock could be issued upon conversion of the notes offered hereby, the 2025 notes or the 2027 notes, which would dilute the ownership
interest of our existing stockholders. In addition, the issuance of additional common stock, or issuances of securities convertible into or exercisable for our common stock or other equity linked
securities, including preferred stock or warrants, would dilute the ownership interest of our common stockholders and could depress the market price of our common stock and impair our ability to raise
capital through the sale of additional equity securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
sales in the public market of any shares of our common stock issuable upon conversion of the notes, the 2025 notes or the 2027 notes could adversely affect the prevailing market
price of our common stock. In addition, the existence of the notes, the 2025 notes and the 2027 notes may encourage short selling by market participants because the conversion of the notes, the 2025
notes or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=22,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=391810,FOLIO='S-15',FILE='DISK128:[20ZBC1.20ZBC76301]DA76301A.;12',USER='CHE106460',CD='26-FEB-2020;00:12' -->
<A NAME="page_da76301_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
2027 notes could be used to satisfy short positions, or anticipated conversion of the notes, the 2025 notes or the 2027 notes into shares of our common stock could depress the price of our common
stock and the value of your notes. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Provisions of the notes could discourage an acquisition of us by a third party.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain provisions of the notes could make it more difficult or more expensive for a third party to acquire us. Upon the occurrence of certain
transactions constituting a fundamental change, holders of the notes will have the right, at their option, to require us to repurchase all of their notes or any portion of the principal amount of such
notes in integral multiples of $1,000. We may also be required to increase the conversion rate in the event of a make-whole fundamental change. In addition, the indenture and the notes will prohibit
us from engaging in certain mergers or acquisitions unless, among other things, the surviving entity assumes our obligations under the notes and the indenture. These and other provisions in the
indenture could deter or prevent a third party from acquiring us even when the acquisition may be favorable to you. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The accounting method for convertible debt securities, such as the notes, could have a material adverse
effect on our reported financial results.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under Financial Accounting Standards Board Accounting Standards Codification 470-20, </FONT><FONT SIZE=2><I>Debt with Conversion and Other
Options</I></FONT><FONT SIZE=2> ("ASC 470-20"), an entity must separately account for the liability and equity components of convertible debt instruments, such as the notes, that may be settled
entirely or partially in cash upon conversion in a manner that reflects the issuer's economic interest cost. ASC 470-20 requires the value of the conversion option of the notes, representing the
equity component, to be recorded as additional paid-in-capital within shareholders' equity in our consolidated balance sheet and as a discount to the notes, which reduces their initial carrying value.
The carrying value of the notes, net of the discount recorded, will be accreted up to the principal amount of the notes from the issuance date until maturity, which will result in non-cash charges to
interest expense in our consolidated statement of operations. Accordingly, we will report lower net income in our financial results because ASC 470-20 will require interest to include both the current
period's accretion of the debt discount (non-cash interest) and the instrument's cash interest, which could adversely affect our reported or future financial results, the trading price of our common
stock and the trading price of the notes. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recent and future regulatory actions and other events may adversely affect the trading price and liquidity of
the notes.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recent and future regulatory actions and other events may adversely affect the trading price and liquidity of the notes. We expect that many
investors in, and potential purchasers of, the notes will employ, or seek to employ, a convertible arbitrage strategy with respect to the notes. Investors would typically implement such a strategy by
selling short the common stock underlying the notes and dynamically adjusting their short position while continuing to hold the notes. Investors may also implement this type of strategy by entering
into swaps on the common stock in lieu of or in addition to short selling the common stock. As a result, any specific rules regulating equity swaps or short selling of securities or other governmental
action that interferes with the ability of market participants to effect short sales or equity swaps with respect to our common stock could adversely affect the ability of investors in, or potential
purchasers of, the notes to conduct the convertible arbitrage strategy that we believe they will employ, or seek to employ, with respect to the notes. This could, in turn, adversely affect the trading
price and liquidity of the notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
SEC and other regulatory and self-regulatory authorities have implemented various rules and taken certain actions, and may in the future adopt additional rules and take other
actions, that may impact those engaging in short selling activity involving equity securities (including our common stock). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=23,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=425760,FOLIO='S-16',FILE='DISK128:[20ZBC1.20ZBC76301]DA76301A.;12',USER='CHE106460',CD='26-FEB-2020;00:12' -->
<A NAME="page_da76301_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Such
rules and actions include Rule&nbsp;201 of SEC Regulation SHO, the adoption by the Financial Industry Regulatory Authority,&nbsp;Inc. and the national securities exchanges of a "Limit
Up-Limit Down" program, the imposition of market-wide circuit breakers that halt trading of securities for certain periods following specific market declines, and the implementation of certain
regulatory reforms required by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 ("Dodd-Frank"). Any governmental or regulatory action that restricts the ability of investors in,
or potential purchasers of, the notes to effect short sales of the common stock, borrow the common stock or enter into swaps on the common stock could adversely affect the trading price and the
liquidity of the notes. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


As a holder of notes, you will not be entitled to any rights with respect to our common stock, but you will
be subject to all changes made with respect to our common stock.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you hold notes, you will not be entitled to any rights with respect to our common stock (including, without limitation, voting rights and
rights to receive any dividends or other distributions on our common stock), but you will be subject to all changes affecting our common stock. If you elect to convert your notes at the close of
business on the conversion date, you will have the rights with respect to (and will be the record holder of) our common stock (if we have elected to settle the relevant conversion by delivering shares
of our common stock). For example, in the event that an amendment is proposed to our certificate of incorporation or bylaws requiring stockholder approval and the record date for determining the
stockholders of record entitled to vote on the amendment occurs prior to the date you are deemed the record owner of the shares of our common stock due upon conversion, you will not be entitled to
vote on the amendment, although you will nevertheless be subject to any changes in the powers, preferences or special rights of our common stock. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


There is currently no public market for the notes, and an active trading market may not develop for the
notes. The failure of a market to develop for the notes could adversely affect the liquidity and value of your notes.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The notes are a new issue of securities, and there is no existing market for the notes. We do not intend to apply for listing of the notes on
any securities exchange or for quotation of the notes on any automated dealer quotation system. We have been advised by certain of the underwriters that they presently intend to make a market in the
notes after completion of the offering. However, they are under no obligation to do so and may discontinue any market-making activities at any time without notice. An active trading market may not
develop for the notes, and there can be no assurance as to the liquidity of any market that may develop for the notes. If an active, liquid market does not develop for the notes, the market price and
liquidity of the notes may be adversely affected. If
any of the notes are traded after their initial issuance, they may trade at a discount from their initial offering price. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
liquidity of the trading market, if any, and future trading prices of the notes will depend on many factors, including, among other things, the market price of our common stock,
prevailing interest rates, our operating results, financial performance and prospects, the market for similar securities and the overall securities market, and may be adversely affected by unfavorable
changes in these factors. Historically, the market for convertible debt has been subject to disruptions that have caused volatility in prices. It is possible that the market for the notes will be
subject to disruptions which may have a negative effect on the holders of the notes, regardless of our operating results, financial performance or prospects. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


An adverse rating of the notes may cause their trading price to fall.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not intend to seek a rating for the notes, but if a rating agency rates the notes, it may assign a rating that is lower than expected by
investors. Ratings agencies also may lower ratings on the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=24,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=215253,FOLIO='S-17',FILE='DISK128:[20ZBC1.20ZBC76301]DA76301A.;12',USER='CHE106460',CD='26-FEB-2020;00:12' -->
<A NAME="page_da76301_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>notes
in the future. If rating agencies assign a lower-than-expected rating or reduce, or indicate that they may reduce, their ratings in the future, the trading price of the notes could significantly
decline. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our board of directors and management will have broad discretion over the use of the proceeds from this
offering and might not apply the proceeds in ways that increase the value of your investment.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors and management will have broad discretion to use the net proceeds from this offering and you will be relying on the
judgment of our board of directors and management regarding the application of these proceeds. We expect to use the net proceeds for general corporate purposes, which may include the repayment of
debt, working capital and possible acquisitions. In addition, we expect to use approximately $150.0 million of the net proceeds to repurchase a portion of our existing 2025 notes. Our board of
directors and management might not apply the net proceeds from the offering in ways that increase the value of your investment and might
not yield a significant return, if any, on any investment of such net proceeds. You will not have the opportunity to influence our decisions on how to use such proceeds. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


You may be subject to tax if we make or fail to make certain adjustments to the conversion rate of the notes
even though you do not receive a corresponding cash distribution.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The conversion rate of the notes is subject to adjustment in certain circumstances, including the payment of cash dividends on our common
stock. If the conversion rate is adjusted as a result of a distribution that is taxable to our common stockholders, such as a cash dividend, you may be deemed to have received a dividend subject to
U.S. federal income tax without the corresponding receipt of any cash. In addition, a failure to adjust (or to adjust adequately) the conversion rate after an event that increases your proportionate
interest in us could be treated as a deemed taxable dividend to you. If a make whole fundamental change occurs prior to the maturity date, under some circumstances, we will increase the conversion
rate for notes converted in connection with the make whole fundamental change. Such increase may also be treated as a distribution subject to U.S. federal income tax as a dividend. See "Material U.S.
Federal Income Tax Considerations." If you are a non U.S. holder (as defined in "Material U.S. Federal Income Tax Considerations"), any deemed dividend generally would be subject to U.S. federal
withholding tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty, which may be set off against subsequent payments on the notes. See "Material U.S. Federal
Income Tax Considerations." </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The notes could be issued with original issue discount.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may not know the issue price of the notes at the time of the first sales of the notes to holders other than the underwriters. If the issue
price at which a substantial amount of the notes is first sold to holders other than the underwriters is less than the stated principal amount by more than a de minimis amount, then the notes will
have original issue discount under applicable tax rules which may require a U.S. holder (as defined in "Material U.S. Federal Income Tax Considerations") to recognize taxable interest income in
advance of the receipt of cash attributable to that income. For a fuller discussion see "Material U.S. Federal Income Tax Considerations&#151;U.S. Holders&#151;Issue Price and Basis in
the Notes." </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The Internal Revenue Service ("IRS") could challenge the issue price of the notes as determined by us, or
that it could challenge our position that all of the notes are part of a single issue and will be fungible under applicable tax rules, in which case the notes may be issued with, or with a greater
amount of, original issue discount.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will sell the notes to the underwriters in this offering for a fixed price but with no limitation on the price at which the underwriters can
resell the notes to investors and there is the potential that such sales could occur over time. If the IRS were to successfully challenge our </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=25,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=926350,FOLIO='S-18',FILE='DISK128:[20ZBC1.20ZBC76301]DA76301A.;12',USER='CHE106460',CD='26-FEB-2020;00:12' -->
<A NAME="page_da76301_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>determination
of the issue price for the notes, certain U.S. federal income tax consequences could result for investors. For example, the notes may be considered to have original issue discount (or a
greater amount of original issue discount) which generally would require a holder to recognize taxable interest income in advance of the receipt of cash attributable to that income and may therefore
affect the market value of the notes. U.S. holders (as defined in "Material U.S. Federal Income Tax Considerations") should consult their own tax advisors as to the U.S. federal income tax
consequences to them of such a successful challenge under the circumstances of this offering. For a fuller discussion see "Material U.S. Federal Income Tax Considerations&#151;U.S.
Holders&#151;Issue Price and Basis in the Notes." </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The market price of our common stock, which may fluctuate significantly, will directly affect the market
price for the notes.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect that the market price of our common stock will affect the market price of the notes. In addition, the trading price of our common
stock has been, and is likely to continue to be, highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. This may result in
greater volatility in the market price of the notes than would be expected for non-convertible notes. The market price of our common stock will likely fluctuate in response to a number of factors,
including our financial condition, operating results and prospects, as well as economic, financial and other factors, reports by industry analysts, investor perceptions or negative announcements by
our customers, competitors or suppliers regarding their own performance, or changes in our industry and competitors and government regulations, many of which are beyond our control. For more
information regarding such factors, see "Risk Factors." Holders who receive common stock upon conversion of the notes will therefore be subject to the risk of volatility and depressed prices of our
common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we expect that the market price of the notes will be influenced by yield and interest rates in the capital markets, our creditworthiness and the occurrence of certain
events affecting us that do not require an adjustment to the conversion rate. Fluctuations in yield rates in particular may give rise to arbitrage opportunities based upon changes in the relative
values of the notes and our common stock. Any such arbitrage could, in turn, affect the market prices of our common stock and the notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
market price of our common stock could also be affected by, among other factors:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> investors' anticipation of the potential resale in the market of a substantial number of additional shares of our common stock received upon
conversion of the notes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> possible sales of our common stock by investors who view the notes as a more attractive means of equity participation in us than owning shares
of our common stock; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> hedging or arbitrage trading activity that may develop involving our common stock. This trading activity could, in turn, affect the trading
prices of the notes. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Conversions of the notes may adversely affect our financial condition.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If one or more holders elect to convert their notes, unless we elect to satisfy our conversion obligation by delivering solely common stock
(other than cash in lieu of any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity.
In addition, even if holders do not elect to convert their notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the notes as a
current rather than long-term liability, which would result in a material reduction of our net working capital. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=26,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=900409,FOLIO='S-19',FILE='DISK128:[20ZBC1.20ZBC76301]DA76301A.;12',USER='CHE106460',CD='26-FEB-2020;00:12' -->
<A NAME="page_da76301_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The notes will initially be held in book-entry form and, therefore, holders must rely on the procedures and
the relevant clearing systems to exercise their rights and remedies.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless and until certificated notes are issued in exchange for book-entry interests in the notes, owners of the book-entry interests will not
be considered owners or holders of the notes. Instead, DTC, or its nominee, will be the sole holder of the notes. Payments of principal, interest (including any additional interest), amounts due upon
conversion, and other amounts owing on or in respect of the notes in global form will be made to the paying agent, which will make the payments to DTC. Thereafter, such payments will be credited to
DTC participants' accounts that hold book-entry interests in the notes in global form and credited by such participants to indirect participants. Unlike holders of the notes themselves, owners of
book-entry interests will not have the direct right to act upon our solicitations for consents or requests for waivers or other actions from holders of the notes. Instead, if a holder owns a
book-entry interest, such holder will be permitted to act only to the extent such holder has received appropriate proxies to do so from DTC or, if applicable, a participant. We cannot assure holders
that the procedures for the granting of such proxies will be sufficient to enable holders to vote on any requested actions on a timely basis. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=27,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=434310,FOLIO='S-20',FILE='DISK128:[20ZBC1.20ZBC76301]DA76301A.;12',USER='CHE106460',CD='26-FEB-2020;00:12' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dc76301_1_21"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DC1"></A>USE OF PROCEEDS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We estimate that our net proceeds from the sale of the notes in this offering will be approximately $978.0&nbsp;million, after deducting the
underwriting discount and estimated offering expenses payable by us. If the underwriters exercise in full their option to purchase additional notes, we estimate that our net proceeds from the sale of
the notes in this offering will be approximately $1,124.7&nbsp;million, after deducting the underwriting discount and estimated offering expenses payable by us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
intend to use the net proceeds from this offering for general corporate purposes, which may include the repayment of debt, working capital and possible acquisitions. In addition, we
expect to use approximately $150.0 million of the net proceeds to repurchase a portion of our existing 2025 notes. The amounts and timing of our use of these proceeds will vary depending on a number
of factors, including the amount of cash generated or used by our operations, and the rate of growth, if any, of our business. As a result, we will retain broad discretion in the allocation of the
remaining net proceeds of this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
we use the net proceeds of this offering, we intend to invest the funds in short-term, investment-grade, interest-bearing securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=28,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=708554,FOLIO='S-21',FILE='DISK128:[20ZBC1.20ZBC76301]DC76301A.;24',USER='CHE107555',CD='26-FEB-2020;15:02' -->
<A NAME="page_dc76301_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DC2"></A>CAPITALIZATION  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows our cash, cash equivalents and marketable securities as well as capitalization, in each case, as of
December&nbsp;31, 2019:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on an actual basis; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on an as adjusted basis giving effect to (1)&nbsp;the sale of $1.0 billion of notes offered in this offering (assuming the underwriters'
over-allotment option is not exercised) and the receipt of $978.0&nbsp;million of net proceeds, after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us, and (2)&nbsp;the use of proceeds thereof as described above in "Use of Proceeds." </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should read this table together with the "Use of Proceeds" section in this prospectus supplement, as well as the information contained in our consolidated financial statements and
related notes incorporated by reference in this prospectus supplement and the accompanying prospectus: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As Adjusted </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands, except par value<BR>
data)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash, cash equivalents and marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>323,655</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,151,655 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term debt, including current portion:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Construction loan agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal amount of 1.0% convertible senior notes due 2025, net(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>415,049</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>315,049</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal amount of 0.3750% convertible senior notes due 2027, net(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>747,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>747,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal amount of 0.3750% convertible senior notes due 2028 offered hereby(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total long-term debt</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,187,549</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,087,549</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' equity:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common Stock, par value $0.01 per share; 200,000,000 shares authorized and 147,625,696 shares issued and outstanding, respectively, actual and as
adjusted(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,477</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,477</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred Stock; par value $0.01 per share; 5,000,000 shares authorized and 0 shares issued and outstanding, respectively, actual and as
adjusted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,406,440</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,406,440</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated other comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,119,756</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,119,756</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,288,061</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,288,061 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total capitalization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,475,610</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,375,610 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="31%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="31%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
accordance with ASC 470-20, a convertible debt instrument that may be wholly or partially settled in cash is required to be separated into a liability and an
equity component, such that the interest expense reflects the issuer's nonexchangeable debt interest rate. As of December&nbsp;31, 2019, the liability value of the 2025 notes and the 2027 notes on
our balance sheet in accordance with ASC&nbsp;470-20 was $319.7&nbsp;million and $483.9&nbsp;million, respectively. Upon issuance, a debt discount is recognized as a decrease in debt and an
increase in equity. The debt component accretes up to the principal amount over the expected term of the debt. ASC&nbsp;470-20 does not affect the actual amount that we are required to repay, and
the amount shown in the above capitalization table for the notes, the 2025 notes and the 2027 notes is the aggregate principal amount of the notes, the 2025 notes and the 2027 notes, respectively,
without reflecting the debt discount or fees and expenses that we are required to recognize or </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=29,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=883894,FOLIO='S-22',FILE='DISK128:[20ZBC1.20ZBC76301]DC76301A.;24',USER='CHE107555',CD='26-FEB-2020;15:02' -->
<A NAME="page_dc76301_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>the
increase in paid-in capital on our consolidated balance sheet. Certain of the amounts set forth in the above capitalization table, as indicated in this footnote, do not reflect the application of
certain adjustments and accounting treatments required by ASC&nbsp;470-20 related to the repurchase transactions. The adjustments and accounting treatments required by ASC 470-20, and other
applicable accounting rules, will be applied to the amounts set forth above in connection with the preparation of our consolidated financial statements, and the amounts ultimately included in our
consolidated financial statements may differ from the amounts set forth in the above capitalization table.  </FONT></P>

</UL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
table above excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 2,700,293 shares of common stock issuable upon the exercise of outstanding stock options as of December&nbsp;31, 2019 at a weighted average
exercise price of $34.01 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 4,327,290 shares subject to outstanding unvested restricted stock units as of December&nbsp;31, 2019; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 9,439,937 additional shares of common stock reserved for future issuance as of December&nbsp;31, 2019 under our equity incentive plans; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the shares of our common stock to be reserved for issuance upon conversion of the notes being offered by us. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=30,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=918007,FOLIO='S-23',FILE='DISK128:[20ZBC1.20ZBC76301]DC76301A.;24',USER='CHE107555',CD='26-FEB-2020;15:02' -->
<A NAME="page_dc76301_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DC3"></A>DESCRIPTION OF THE NOTES  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will issue the notes under a base indenture dated as of January&nbsp;17, 2018 (the "base indenture") between us and U.S. Bank National
Association, as trustee (the "trustee"), as supplemented by a supplemental indenture dated as of the date of initial issuance among us, U.S. Bank National Association as registrar, paying agent and
conversion agent (the "Paying Agent") and the trustee (the "supplemental indenture" and, together with the base indenture, the "indenture"). The terms of the notes include those expressly set forth in
the indenture and those made part of the indenture by reference to the Trust Indenture Act of 1939, as amended, which we refer to as the Trust Indenture Act. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following description is only a summary of the material provisions of the notes and the indenture and does not purport to be complete. This summary is subject to, and is qualified
by reference to, all the provisions of the notes and the indenture, including the definitions of certain terms used in the indenture. We urge you to read the indenture in its entirety because it, and
not this description, defines your rights as a holder of the notes. You may request a copy of the indenture as set forth under the caption "Where You Can Find More Information." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this description, references to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "the Company," "we," "our" and "us" refer only to Exact Sciences Corporation and not its subsidiaries; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "business day" refer to any day other than a Saturday, a Sunday or a day on which the Federal Reserve Bank of New York is authorized or
required by law or executive order to close or be closed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "close of business" refer to 5:00&nbsp;p.m., New York City time, and "open of business" refer to 9:00&nbsp;a.m., New York City time; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "common stock" refer to our common stock, par value $0.01 per share; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "notes" refer to each $1,000 principal amount of 0.3750% Convertible Senior Notes due March&nbsp;1, 2028 offered hereby. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
the context otherwise requires, all references to interest in this prospectus supplement include additional interest, if any, payable at our election as the sole remedy relating
to the failure to comply with our reporting obligations pursuant to the provisions set forth below under the heading "&#151;Events of Default; Notice and Waiver." </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;References
in this prospectus supplement to a "holder" or "holders" of notes that are held through DTC are references to owners of beneficial interests in such notes, unless the context
otherwise requires. However, we and the trustee will treat the person in whose name the notes are registered (Cede&nbsp;&amp;&nbsp;Co., in the case of notes held through DTC) as the owner of such
notes for all purposes. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Brief Description of the Notes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The notes will:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> be our general, unsecured obligations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> initially be limited to $1.0&nbsp;billion aggregate principal amount ($1.15&nbsp;billion aggregate principal amount if the underwriters
exercise their over-allotment option to purchase additional notes in full); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> bear cash interest at a rate of 0.3750% per year, payable semi-annually in arrears, on March&nbsp;1 and September&nbsp;1 of each year,
commencing on September&nbsp;1, 2020; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=31,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=764471,FOLIO='S-24',FILE='DISK128:[20ZBC1.20ZBC76301]DC76301A.;24',USER='CHE107555',CD='26-FEB-2020;15:02' -->
<A NAME="page_dc76301_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> subject to satisfaction of certain conditions and during the periods described below, be convertible by you at any time prior to the close of
business on the second scheduled trading day (as defined below) immediately preceding the maturity date, as described under "&#151;Conversion Rights," into cash, shares of our common stock or a
combination of cash and shares of our common stock, at our election, based on an initial conversion rate of 8.2076 shares of our common stock per $1,000 principal amount of notes (subject to
adjustment as set forth in "&#151;Conversion Rights&#151;Conversion Rate Adjustments" below), which represents an initial conversion price of approximately $121.84&nbsp;per share. In
the event of a make-whole fundamental change (as defined below), we will, under certain circumstances, increase the conversion rate as described herein; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> not be subject to redemption at our option prior to maturity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> be subject to repurchase by us at your option if a fundamental change (as defined below) occurs, at a cash repurchase price equal to 100% of
the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date, as set forth under "&#151;Fundamental Change
Put" and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> mature on March&nbsp;1, 2028 unless earlier converted or repurchased by us at your option. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
we nor any of our subsidiaries will be subject to any financial covenants under the indenture. In addition, neither we nor any of our subsidiaries will be restricted under the
indenture from paying dividends, incurring debt (under the indenture or otherwise) or issuing or repurchasing our securities. You are not afforded protection under the indenture in the event of a
highly leveraged transaction or a change in control of us, except to the extent described below under "&#151;Conversion Rights&#151;Adjustment to Conversion Rate Upon a Make-Whole
Fundamental Change," "&#151;Fundamental Change Put" and "&#151;Consolidation, Merger and Sale of Assets." </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not applied, and do not intend to apply, for listing of the notes on any securities exchange or any automated quotation system. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
notes initially will be issued in book-entry form only in minimum denominations of $1,000 principal amount and whole multiples of $1,000 in excess thereof. Beneficial interests in
the notes will be shown on, and transfers of beneficial interests in the notes will be effected only through, records maintained by The Depository Trust Company, or DTC, or its nominee, and any such
interests may not be exchanged for certificated notes except in limited circumstances. For information regarding conversion, registration of transfer and exchange of global notes held in DTC, see
"&#151;Form, Denomination and Registration&#151;Global Notes, Book-Entry Form." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
certificated notes are issued, you may present them for conversion, registration of transfer and exchange, without service charge, at our office or agency, which will initially be
the office or agency of the trustee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Additional Notes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may, without the consent of, or notice to, the holders of the notes, issue additional notes under the indenture in the future on the same
terms and conditions as the notes offered hereby (other than differences in the issue price, interest accrued prior to the issue date of such additional notes, and the first interest payment date) in
an unlimited aggregate principal amount; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2> that if any such additional notes are not fungible with the notes initially offered hereby for U.S.
federal income tax purposes, such additional notes will have one or more separate CUSIP numbers. The notes offered by this prospectus supplement and any additional notes would rank equally and ratably
and would be treated as a single series for all purposes under the indenture. No additional notes may be issued if any event of default has occurred with respect to the notes. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=32,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=422949,FOLIO='S-25',FILE='DISK128:[20ZBC1.20ZBC76301]DC76301A.;24',USER='CHE107555',CD='26-FEB-2020;15:02' -->
<A NAME="page_dc76301_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Payment at Maturity  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On the maturity date, each holder will be entitled to receive $1,000 in cash for each $1,000 in principal amount of notes, together with any
accrued and unpaid interest to, but excluding, the maturity date, unless earlier converted or repurchased by us at the holder's option. With respect to global notes, we will pay or cause the paying
agent to pay principal and any interest to DTC in immediately available funds. With respect to any certificated notes, principal and any interest will be payable at our office or agency, which
initially will be the office or agency of the trustee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interest  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The notes will bear cash interest at a rate of 0.3750% per year until maturity. Interest on the notes will accrue from February&nbsp;27, 2020
or from the most recent date on which interest has been paid or duly provided for. We will pay interest semi-annually, in arrears on March&nbsp;1 and September&nbsp;1 of each year, commencing on
September&nbsp;1, 2020, to holders of record at the close of business on the preceding February&nbsp;15 and August&nbsp;15, respectively. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will pay or cause the paying agent to pay interest on:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> global notes to DTC in immediately available funds; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any certificated notes having a principal amount of less than $2,000,000, by check mailed to the holders of those notes; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any certificated notes having a principal amount of $2,000,000 or more, either by check mailed to each holder or, upon application by such
holder to the registrar not later than the relevant record date, by wire transfer in immediately available funds to that holder's account within the United States, which application shall remain in
effect until the holder notifies, in writing, the registrar to the contrary. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest
will be calculated on the basis of a 360-day year consisting of twelve 30-day months and, for partial months, on the number of days actually elapsed in a 30-day month. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any interest payment date, the maturity date, any earlier required fundamental change repurchase date or any other due date of a note falls on a day that is not a business day (which
for these purposes, "business day" shall not include days on which the office where the place of payment is authorized or required by law to be closed), the required payment will be made on the next
succeeding business day and no interest on such payment will accrue in respect of the delay. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ranking  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The notes will be our senior unsecured obligations that will:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> rank senior in right of payment to all of our future indebtedness that is expressly subordinated in right of payment to the notes; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> rank equally in right of payment to all of our existing and future liabilities that are not so subordinated; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> be effectively junior to all of our existing and future secured indebtedness and other secured obligations, to the extent of the value of the
assets securing that indebtedness and other secured obligations; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our subsidiaries. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
indenture will not limit our ability to incur additional indebtedness in the future, including senior secured indebtedness, and such indebtedness may be substantial. In the event of
our bankruptcy, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=33,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=819068,FOLIO='S-26',FILE='DISK128:[20ZBC1.20ZBC76301]DC76301A.;24',USER='CHE107555',CD='26-FEB-2020;15:02' -->
<A NAME="page_dc76301_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>liquidation,
reorganization or other winding up, our assets that secure secured indebtedness will be available to pay obligations on the notes only after all such secured indebtedness has been repaid
in
full from such assets. We advise you that there may not be sufficient assets remaining to pay amounts due on any or all the notes then outstanding. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2019, our total consolidated indebtedness was approximately $1,187.5&nbsp;million, $25.0&nbsp;million of which was secured. As of December&nbsp;31, 2019,
our subsidiaries had $14.3&nbsp;million of indebtedness and other liabilities (including trade payables). After giving effect to the issuance of the notes (assuming no exercise of the underwriters'
option to purchase additional notes) and the use of proceeds thereof as described under "Use of Proceeds," our total consolidated indebtedness would have been approximately $2,087.5&nbsp;million as
of December&nbsp;31, 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ability of our subsidiaries to pay dividends and make other payments to us is restricted by, among other things, applicable corporate and other laws and regulations as well as
agreements to which our subsidiaries are currently or may in the future become a party. We may not be able to pay accrued interest, the cash portions of any settlement amount upon conversion of the
notes, the fundamental change repurchase price upon a fundamental change if a holder requires us to repurchase notes as described below or principal due on the maturity date. See "Risk
Factors&#151;Risks Related to Our Indebtedness and the Notes&#151;We may not have the ability to raise the funds necessary to settle conversions of the notes or to repurchase the notes
for cash when required by the holders upon a fundamental change." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


No Redemption  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may not redeem the notes prior to the maturity date, and no sinking fund is provided for the notes, which means that we are not required to
redeem or retire the notes periodically. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion Rights  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to the close of business on the business day immediately preceding September&nbsp;1, 2027, you may convert all or a portion of your
notes only upon the satisfaction of one or more conditions described below under "&#151;Conversion Upon Satisfaction of Sale Price Condition," "&#151;Conversion Upon Specified Corporate
Transactions," "&#151;Conversion Upon a Fundamental Change" and "&#151;Conversion Upon Satisfaction of Trading Price Condition." You may convert fewer than all of your notes so long as
the notes converted are an integral multiple of $1,000 principal amount. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders
may convert, at their option, their notes based on an initial conversion rate of 8.2076 shares of common stock per $1,000 principal amount of notes (equivalent to an initial
conversion price of approximately $121.84 per share of our common stock). The conversion rate will be subject to adjustment as described below. As described under "&#151;Settlement Upon
Conversion," upon conversion, we will satisfy our conversion obligation with respect to the notes to be converted into cash, shares of our common stock or a combination of cash and shares of our
common stock, at our election. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
conversion rate and the equivalent conversion price in effect at any given time are referred to as the "applicable conversion rate" and the "applicable conversion price,"
respectively, and will be subject to adjustment as described below. The "applicable conversion price" at any given time will equal $1,000 divided by the applicable conversion rate at such time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as provided in the next paragraph, upon conversion, you will not receive any separate cash payment of accrued and unpaid interest on the notes. Accrued and unpaid interest to the
conversion date is deemed to be paid in full with the cash paid and shares of our common stock issued, if any, upon conversion rather than cancelled, extinguished or forfeited. With respect to any
conversion of the notes into a combination of cash and shares of our common stock, accrued and unpaid interest will be deemed to be paid first out of any cash paid upon such conversion. For a
discussion of the tax treatment to you of converting your notes, see "Material U.S. Federal Income Tax Considerations." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=34,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=399411,FOLIO='S-27',FILE='DISK128:[20ZBC1.20ZBC76301]DC76301A.;24',USER='CHE107555',CD='26-FEB-2020;15:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_de76301_1_28"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you convert any notes after the close of business on the record date for an interest payment but prior to the corresponding interest payment date,
you will
receive on the earlier of the corresponding interest payment date and the date we deliver the consideration due in respect of such conversion, the interest accrued and unpaid on your notes,
notwithstanding your conversion of those notes prior to the interest payment date, in the event you were the holder of record on the corresponding record date. However, except as provided in the next
sentence, at the time you surrender your notes for conversion (whether or not you were holder of record), you must pay us an amount equal to the interest that has accrued and will be paid on the notes
being converted on the corresponding interest payment date. You are not required to make such payment:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if you convert your notes after the close of business on February&nbsp;15, 2028 which is the regular record date immediately preceding the
maturity date; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if you convert your notes in connection with a fundamental change and we have specified a fundamental change repurchase date that is after a
record date and on or prior to the business day immediately following the corresponding interest payment date; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to the extent of any overdue interest, if overdue interest exists at the time of conversion with respect to your notes. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Therefore,
for the avoidance of doubt, all holders on the regular record date immediately preceding the maturity date and any fundamental change repurchase date will receive and retain
the full interest payment due on the maturity date or other applicable interest payment date regardless of whether their notes have been converted following such record date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as described under "&#151;Conversion Rights&#151;Conversion Rate Adjustments," we will not make any payment or other adjustment for dividends on any common stock
issued upon conversion of the notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
trustee shall have no duty to monitor or notify the holders as to whether any of the conditions to conversion have occurred. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion Upon Satisfaction of Sale Price Condition  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to the close of business on the business day immediately preceding September&nbsp;1, 2027, you will have the right to convert all or a
portion of your notes at any time during any calendar quarter (and only during such calendar quarter) beginning after September&nbsp;1, 2027 if the closing sale price of our common stock was more
than 130% of the applicable conversion price on each applicable trading day for at least 20 trading days (whether or not consecutive) in the period of the 30 consecutive trading days ending on the
last trading day of the immediately preceding calendar quarter. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
"closing sale price" of any share of our common stock on any trading day means:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the closing sale price per share of our common stock (or if no closing sale price is reported, the average of the closing bid and closing ask
prices or, if more than one in either case, the average of the average closing bid and the average closing ask prices) on such trading day as reported in composite transactions for the relevant stock
exchange (as defined below); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if our common stock is not listed on a relevant stock exchange on such date, the last quoted bid price per share for our common stock in the
over-the-counter market on such trading day as reported by OTC Markets Group&nbsp;Inc. or a similar organization; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if our common stock is not so quoted, the average of the mid-point of the closing bid and closing ask price per share of our common stock on
such trading day as determined by a nationally recognized securities dealer retained by us for that purpose, which may include one of the underwriters. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=35,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=537130,FOLIO='S-28',FILE='DISK128:[20ZBC1.20ZBC76301]DE76301A.;11',USER='CHE105577',CD='25-FEB-2020;23:12' -->
<A NAME="page_de76301_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
closing sale price will be determined without reference to early hours, after hours or extended market trading. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Relevant
stock exchange" means the Nasdaq Capital Market or, if our common stock is not then listed on the Nasdaq Capital Market, the principal other U.S. national or regional
securities exchange on which our common stock is then listed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term "trading day" means a day on which:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> trading in our common stock generally occurs on the relevant stock exchange or, if our common stock is not then listed on a relevant stock
exchange, on the principal other market on which our common stock is then traded; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a closing sale price for our common stock is available on such securities exchange or market. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our common stock is not so listed or traded, "trading day" means a business day. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion Upon Specified Corporate Transactions  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to the close of business on the business day immediately preceding September&nbsp;1, 2027, you will have the right to convert all or a
portion of your notes if we:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> distribute to all or substantially all holders of our common stock any rights, options or warrants (other than pursuant to a stockholders
rights plan) entitling them to purchase, for a period of 45 calendar days or less from the announcement date for such distribution, shares of our common stock at a price per share less than the
average of the closing sale prices of our common stock for the ten consecutive trading day period ending on, and including, the trading day immediately preceding the announcement date for such
distribution; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> distribute to all or substantially all holders of our common stock, cash or other assets, debt securities or rights to purchase our securities
(other than pursuant to a stockholders rights plan), which distribution has a per share value, as reasonably determined by our board of directors or a committee thereof, exceeding 10% of the closing
sale price of our common stock on the trading day immediately preceding the announcement date for such distribution. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
either case, we will notify you, the trustee and the conversion agent (if other than the trustee) at least 45 scheduled trading days (as defined below) prior to the ex-dividend date
(as defined below) for such distribution. Once we have given such notice, a holder may convert all or a portion of its notes at any time until the earlier of the close of business on the business day
immediately preceding the ex-dividend date and any announcement by us that such distribution will not take place. You may not convert any of your notes based on this conversion contingency if as a
result of holding the notes you will otherwise participate in the distribution, without conversion as a result of holding the notes, at the same time and on the same terms as holders of our common
stock as if you held a number of shares of our common stock equal to the applicable conversion rate on the record date of such distribution for each $1,000 principal amount of notes held by you
(calculated on an aggregate basis per holder). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Scheduled
trading day" means a day that is scheduled to be a trading day on the relevant stock exchange. If our common stock is not so listed or admitted for trading, "scheduled
trading day" means a business day. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Ex-dividend
date" means the first date on which the shares of our common stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive
the issuance, dividend or distribution in question from us or, if applicable, from the seller of our common stock on such exchange or market (in the form of due bills or otherwise) as determined by
such exchange or market. For the avoidance of doubt, any alternative trading convention on the applicable exchange or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=36,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=191995,FOLIO='S-29',FILE='DISK128:[20ZBC1.20ZBC76301]DE76301A.;11',USER='CHE105577',CD='25-FEB-2020;23:12' -->
<A NAME="page_de76301_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>market
in respect of our common stock under a separate ticker symbol or CUSIP number will not be considered "regular way" for this purpose. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion Upon a Fundamental Change  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to the close of business on the business day immediately preceding September&nbsp;1, 2027, if a fundamental change (as defined under
"&#151;Fundamental Change Put") occurs, or if we are a party to a consolidation, merger, binding share exchange, or sale, conveyance, transfer, lease or other disposition of all or
substantially all of our and our subsidiaries' assets, taken as a whole, in each case, pursuant to which our common stock would be converted into reference property (as defined below) in a transaction
described in "&#151;Change in the Conversion Rights Upon Certain Reclassifications, Business Combinations, Asset Sales and Corporate Events," you will have the right to convert all or a portion
of your notes at any time beginning on the
effective date of such transaction or event until the earlier of (x)&nbsp;35 trading days after the actual effective date of such transaction or event, or if such transaction or event also
constitutes a fundamental change, until the related fundamental change repurchase date and (y)&nbsp;the second scheduled trading day immediately preceding the maturity date. We will notify you, the
trustee and the conversion agent (if other than the trustee) of the effective date of any fundamental change no later than one business day after such effective date. If you convert your notes in
connection with a fundamental change that is a make-whole fundamental change, we will, under certain circumstances, increase the applicable conversion rate by a number of additional shares, as
described under "&#151;Adjustment to Conversion Rate Upon a Make-Whole Fundamental Change." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you have submitted all or a portion of your notes for repurchase, unless you have validly withdrawn such notes in a timely fashion, your conversion rights with respect to the notes
so subject to repurchase will expire at the close of business on the business day immediately preceding the fundamental change repurchase date, unless we default in the payment of the fundamental
change repurchase price. If you have submitted any notes for repurchase, such notes may be converted only if you submit a valid withdrawal notice, and, if the notes submitted are evidenced by a global
note, you comply with appropriate DTC procedures. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion Upon Satisfaction of Trading Price Condition  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to the close of business on the business day immediately preceding September&nbsp;1, 2027, you may convert all or a portion of your
notes during the five business day period following any five consecutive trading day period (the "measurement period") in which the "trading price" per $1,000 principal amount of notes, as determined
following a request by a holder of notes in accordance with the procedures described below, for each trading day of the measurement period was less than 98% of the product of the closing sale price of
our common stock and the applicable conversion rate on such trading day. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
"trading price" of the notes on any date of determination means the average of the secondary market bid quotations per $1,000 principal amount of notes obtained by the bid
solicitation agent for $5,000,000 principal amount of the notes at approximately 3:30&nbsp;p.m., New York City time, on such determination date from three independent nationally recognized
securities dealers we select for this purpose, which may include one of the underwriters, </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2> that if three such bids cannot reasonably be obtained
by the bid solicitation agent but two such bids are obtained, then the average of the two bids shall be used, and if only one such bid can reasonably be obtained by the bid solicitation agent, then
that one bid shall be used. If the bid solicitation agent cannot reasonably obtain at least one bid for $5,000,000 principal amount of the notes from a nationally recognized securities dealer, or, in
its reasonable judgment, the bid quotations are not indicative of the secondary market value of the notes, then, for purposes of the trading price condition only, the trading price of the notes will
be deemed to be less than 98% of the product of the closing sale price of our common stock and the applicable conversion rate on such trading day. If (x)&nbsp;we are not acting as bid solicitation
agent, and we </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=37,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=675797,FOLIO='S-30',FILE='DISK128:[20ZBC1.20ZBC76301]DE76301A.;11',USER='CHE105577',CD='25-FEB-2020;23:12' -->
<A NAME="page_de76301_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>do
not instruct the bid solicitation agent to obtain bids when required (as described below), or if we so instruct the bid solicitation agent but the bid solicitation agent fails to carry out such
instruction, or (y)&nbsp;we are acting as bid solicitation agent and we fail to make such determination, then, in either case, the trading price per $1,000 principal amount of the notes will be
deemed to be less than 98% of the product of the closing sale price of our common stock and the applicable conversion rate on each day the bid solicitation agent or we, as applicable, fail to do so. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
bid solicitation agent (if other than us) shall have no obligation to determine the trading price per $1,000 principal amount of notes unless we have requested such determination;
and we shall have no obligation to make such request (or, if we are acting as bid solicitation agent, we shall have no obligation to determine the trading price) unless and until a holder of a note
provides us with reasonable evidence that the trading price per $1,000 principal amount of notes would be less than 98% of the product of the closing sale price of our common stock and the conversion
rate and such holder requests that we request that the bid solicitation agent determine or, if we are acting as bid solicitation agent, requests that we determine, the trading price of the notes. At
such time, we shall instruct the bid solicitation agent (if other than us) to determine or, if we are acting as bid solicitation agent, we shall determine, the trading price of the notes for each
trading day beginning on the next trading day and on each successive trading day until a trading day occurs on which the trading price per $1,000 principal amount of notes is greater than or equal to
98% of the product of the closing sale price of our common stock and the applicable conversion rate on such trading day. At such time as we direct the bid solicitation agent in writing to solicit bid
quotations, we will provide the bid solicitation agent with the names and contact details of the three independent nationally recognized securities dealers we select, and we will direct those
securities dealers to provide bids to the bid solicitation agent. If the trading price condition has been met, we will so notify the holders, the trustee and the conversion agent (if other than the
trustee). If, at any time after the trading price condition has been met, the trading price per $1,000 principal amount of notes is greater than or equal to 98% of the product of the closing sale
price of our common stock and the conversion rate for such date, we will so promptly notify the holders, the trustee and the conversion agent (if other than the trustee). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will initially act as the bid solicitation agent. We may, however, appoint another person as the bid solicitation agent (including any of our affiliates) without prior notice to the
holders of the notes. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversions on or after September&nbsp;1, 2027  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On or after September&nbsp;1, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date,
you may, at your option, convert all or any
portion of your notes, in multiples of $1,000 principal amount, at any time, regardless of the foregoing circumstances. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion Procedures  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Procedures to be Followed by a Holder  </I></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you hold a beneficial interest in a global note, to convert you must deliver to DTC the appropriate instruction form for conversion pursuant
to DTC's conversion program and, if required, pay funds equal to interest payable on the next interest payment date to which you are not entitled and, if required, pay all taxes or duties, if any. As
such, if you are a beneficial owner of the notes, you must allow for sufficient time to comply with DTC's procedures if you wish to exercise your conversion rights. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you hold a certificated note, to convert you must:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> complete and manually sign the conversion notice on the back of the notes or a facsimile of the conversion notice; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=38,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=935765,FOLIO='S-31',FILE='DISK128:[20ZBC1.20ZBC76301]DE76301A.;11',USER='CHE105577',CD='25-FEB-2020;23:12' -->
<A NAME="page_de76301_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> deliver the completed conversion notice, which is irrevocable, and the notes to be converted to the conversion agent; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if required, furnish appropriate endorsements and transfer documents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if required, pay funds equal to interest payable on the next interest payment date to which you are not entitled; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if required, pay all transfer or similar taxes, if any. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
conversion date will be the date on which you have satisfied all of the foregoing requirements. The notes will be deemed to have been converted immediately prior to the close of
business on the conversion date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will pay any taxes or duties relating to the issuance or delivery of our common stock if you exercise your conversion rights, except that you will be required to pay any tax or duty
that may be payable relating to any transfer involved in the issuance or delivery of the common stock in a name other than your own. Certificates representing common stock will be issued and delivered
only after all applicable taxes and duties, if any, payable by you have been paid in full. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you have already delivered a repurchase notice as described under "&#151;Fundamental Change Put" with respect to a note, you may not surrender that note for conversion until
you have validly withdrawn the repurchase notice in accordance with the indenture, except as to a portion of your note that is not subject to such repurchase notice. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Settlement Upon Conversion  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon conversion, we may choose to pay or deliver, as the case may be:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> cash ("cash settlement"); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> shares of our common stock ("physical settlement"); or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a combination of cash and shares of our common stock ("combination settlement"), as described below. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
refer to each of these settlement methods as a "settlement method." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
conversions occurring on or after September&nbsp;1, 2027 will be settled using the same settlement method and the same relative proportion of cash and/or shares of our common
stock as all other conversions occurring on or after September&nbsp;1, 2027. If we elect a settlement method for conversions occurring on or after September&nbsp;1, 2027, we will inform holders
and the trustee and the conversion agent (if other than the trustee) of the settlement method we have selected no later than September&nbsp;1, 2027. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to conversions occurring prior to September&nbsp;1, 2027, we will use the same settlement method (including the same relative proportion of cash and/or shares of our
common stock) for all conversions occurring on the same conversion date, but we will not have any obligation to use the same settlement method with respect to conversions that occur on different
conversion dates. That is, we may choose for notes converted on one conversion date to settle conversions in physical settlement, and choose for notes converted on another conversion date cash
settlement or combination settlement. If we elect a settlement method, we will inform holders so converting and the trustee and the conversion agent (if other than the trustee) of the settlement
method we have selected no later than the close of business on the second trading day immediately following the related conversion date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we do not timely elect a settlement method, we will no longer have the right to elect cash settlement or physical settlement with respect to that conversion date, and we will be
deemed to have elected combination settlement in respect of our conversion obligation, as described below, and the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=39,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=633819,FOLIO='S-32',FILE='DISK128:[20ZBC1.20ZBC76301]DE76301A.;11',USER='CHE105577',CD='25-FEB-2020;23:12' -->
<A NAME="page_de76301_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>specified
dollar amount (as defined below) per $1,000 principal amount of notes will be equal to $1,000. If we elect combination settlement, but we do not timely notify the conversion agent of the
specified dollar amount per $1,000 principal amount of notes, such specified dollar amount with respect to that conversion date will be deemed to be $1,000. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is our current intent and policy to settle all conversions through combination settlement with a specified dollar amount of $1,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
settlement amount will be computed as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if we elect physical settlement, we will deliver to the converting holder in respect of each $1,000 principal amount of notes being converted a
number of shares of our common stock equal to the conversion rate (plus cash in lieu of any fractional share of our common stock issuable upon conversion); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if we elect cash settlement, we will pay to the converting holder in respect of each $1,000 principal amount of notes being converted cash in
an amount equal to the sum of the daily conversion values (as defined below) for each of the 30 consecutive VWAP trading days (as defined below) during the relevant observation period (as defined
below); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if we elect (or are deemed to have elected) combination settlement, we will pay or deliver, as the case may be, to the converting holder in
respect of each $1,000 principal amount of notes being converted a "settlement amount" equal to the sum of the daily settlement amounts (as defined below) for each of the 30 consecutive VWAP trading
days during the relevant observation period (plus cash in lieu of any fractional share of our common stock issuable upon conversion). </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
more than one note is surrendered for conversion at any one time by the same holder, the conversion obligation with respect to such notes shall be computed on the basis of the
aggregate
principal amount of the notes (or specified portions thereof to the extent permitted by the indenture) surrendered. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
"daily settlement amount," for each of the 30 consecutive VWAP trading days during the relevant observation period, shall consist of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> cash equal to the lesser of (1)&nbsp;the maximum cash amount per $1,000 principal amount of notes to be received upon conversion as specified
(or deemed specified) by us in the notice specifying our chosen settlement method (the "specified dollar amount"), divided by 30 (such quotient, the "daily measurement value") and (2)&nbsp;the daily
conversion value on such VWAP trading day; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if the daily conversion value exceeds the daily measurement value, a number of shares of our common stock equal to (1)&nbsp;the difference
between the daily conversion value and the daily measurement value, divided by (2)&nbsp;the daily VWAP for such VWAP trading day. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
"daily conversion value" means, for each of the 30 consecutive VWAP trading days during the applicable observation period, 1/30th&nbsp;of the product
of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the conversion rate in effect on that VWAP trading day; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the daily VWAP of our common stock on that VWAP trading day. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
"daily VWAP" means, for each of the 30 consecutive VWAP trading days during the applicable observation period, the per share volume-weighted average price as displayed under the
heading "Bloomberg VWAP" on Bloomberg page "EXAS &#60;equity&gt; AQR" (or its equivalent successor if such page is not available) in respect of the period from the scheduled open of trading
until the scheduled close of trading of the primary trading session on such VWAP trading day (or if such </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=40,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=390674,FOLIO='S-33',FILE='DISK128:[20ZBC1.20ZBC76301]DE76301A.;11',USER='CHE105577',CD='25-FEB-2020;23:12' -->
<A NAME="page_de76301_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>volume-weighted
average price is unavailable, the market value of one share of our common stock on such VWAP trading day reasonably determined, using a volume weighted average method, by a nationally
recognized independent investment banking firm retained for this purpose by us). The "daily VWAP" will be determined without regard to after-hours trading or any other trading outside of the regular
trading session trading hours. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
"observation period" with respect to any note surrendered for conversion means:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if the relevant conversion date occurs prior to September&nbsp;1, 2027, the 30 consecutive VWAP trading day period beginning on, and
including, the second VWAP trading day immediately succeeding such conversion date; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if the relevant conversion date occurs on or after September&nbsp;1, 2027, the 30 consecutive VWAP trading day period beginning on, and
including, the 32nd&nbsp;scheduled trading day immediately preceding the maturity date. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"VWAP
trading day" means a day on which:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> there is no market disruption event; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> trading in our common stock generally occurs on the relevant stock exchange. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our common stock is not so listed or admitted for trading on any relevant stock exchange, "VWAP trading day" means a "business day." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Market
disruption event" means:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a failure by the relevant stock exchange to open for trading during its regular trading session; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the occurrence or existence prior to 1:00&nbsp;p.m., New York City time, on any scheduled trading day for our common stock for more than one
half-hour period in the aggregate during regular trading hours of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant stock
exchange or otherwise) in our common stock or in any options contracts or futures contracts relating to our common stock. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as described under "&#151;Adjustment to Conversion Rate Upon a Make-Whole Fundamental Change" and "&#151;Change in the Conversion Rights Upon Certain
Reclassifications, Business Combinations, Asset Sales and Corporate Events," we will deliver the consideration due in respect of conversion as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if we elect physical settlement, (x)&nbsp;with respect to conversions occurring prior to the final regular record date preceding the maturity
date, the second business day immediately following the relevant conversion date and (y)&nbsp;with respect to conversions occurring on or after the final regular record date preceding the maturity
date, on the maturity date; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if we elect cash settlement or combination settlement, the second business day immediately following the last VWAP trading day of the relevant
observation period. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will deliver cash in lieu of any fractional share of common stock issuable upon conversion based on:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the daily VWAP on the relevant conversion date, in the case of physical settlement; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the daily VWAP on the last VWAP trading day of the relevant observation period, in the case of combination settlement. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=41,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=15976,FOLIO='S-34',FILE='DISK128:[20ZBC1.20ZBC76301]DE76301A.;11',USER='CHE105577',CD='25-FEB-2020;23:12' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dg76301_1_35"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each conversion will be deemed to have been effected as to any notes surrendered for conversion on the applicable conversion date; </FONT> <FONT
SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that the person in whose name any shares of our common stock shall be issuable upon
such conversion will be treated as the holder of record of such shares as of the close of business on the conversion date, in the case of physical settlement, or the last VWAP trading day of the
relevant observation period, in the case of combination settlement. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion Rate Adjustments  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will adjust the conversion rate for the following events. However, we will not make any adjustments to the conversion rate if as a result of
holding the notes you will otherwise participate (other than in the case of a share split or share combination), at the same time and upon the same terms as holders of our common stock in any of the
transactions described below without having to convert their notes as if you held a number of shares of our common stock equal to the
applicable conversion rate for each $1,000 principal amount of notes held by you (calculated on an aggregate basis per holder). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;If
we issue shares of our common stock to all or substantially all holders of our common stock as a dividend or distribution on shares of our common stock, or if we
effect a share split or share combination, the conversion rate will be adjusted based on the following formula: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g188286.jpg" ALT="GRAPHIC" WIDTH="114" HEIGHT="39">
  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="14pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>where,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>CR</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the conversion rate in effect immediately after the open of business on the ex-dividend date for such dividend or distribution, or the effective date of such share split or share combination, as the case may
be;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>CR<SUB>0</SUB></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the conversion rate in effect immediately prior to the open of business on the ex-dividend date for such dividend or distribution or the effective date of such share split or share combination, as the case may
be;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>0S<SUB>0</SUB></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the number of shares of our common stock outstanding immediately prior to the open of business on the ex-dividend date for such dividend or distribution or the effective date of such share split or share combination,
as the case may be; and</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>OS</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the number of shares of our common stock that would be outstanding immediately after, and solely as a result of, such dividend, distribution, share split or share combination, as the case may be.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
adjustment made under this clause&nbsp;(1) shall become effective immediately after the open of business on the ex-dividend date for such dividend or distribution, or immediately
after the open of business on the effective date for such share split or share combination, as applicable. If any dividend or distribution of the type described in this clause&nbsp;(1) is declared
but not so paid or made, the conversion rate shall be immediately readjusted, effective as of the date our board of directors or a committee thereof determines not to pay such dividend or
distribution, to the conversion rate that would then be in effect if such dividend or distribution had not been declared. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Effective
date" means the first date on which the shares of our common stock trade on the relevant stock exchange, regular way, reflecting the relevant share split or share
combination, as applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=42,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=571576,FOLIO='S-35',FILE='DISK128:[20ZBC1.20ZBC76301]DG76301A.;10',USER='CHE106460',CD='24-FEB-2020;00:34' -->
<A NAME="page_dg76301_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;If
we issue to all or substantially all holders of our common stock any rights, options or warrants (other than pursuant to a stockholders rights plan) entitling them
to purchase, for a period of 45 calendar days or less from the announcement date for such distribution, shares of our common stock at a price per share that is less than the average of the closing
sale prices of our common stock for the ten consecutive trading day period ending on, and including, the trading day immediately preceding the announcement date for such issuance, the conversion rate
will be increased based on the following formula: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g601999.jpg" ALT="GRAPHIC" WIDTH="142" HEIGHT="39">
  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="14pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>where,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>CR</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>conversion rate in effect immediately after the open of business on the ex-dividend date for such issuance;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>CR<SUB>0</SUB></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the conversion rate in effect immediately prior to the open of business on such ex-dividend date for such issuance;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>0S<SUB>0</SUB></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the number of shares of our common stock outstanding immediately prior to the open of business on such ex-dividend date for such issuance;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the total number of shares of our common stock issuable pursuant to such rights, options or warrants; and</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Y</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the number of shares of our common stock equal to the aggregate price payable to exercise such rights, options or warrants, divided by the average of the closing sale prices of our common stock over the 10 consecutive
trading day period ending on, and including, the trading day immediately preceding the ex-dividend date for such issuance.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
increase made under this clause&nbsp;(2) will be made successively whenever any such rights, options or warrants are issued and shall become effective immediately after the open
of business on the ex-dividend date for such issuance. To the extent that such rights, options or warrants are not exercised prior to their expiration or shares of our common stock are not delivered
upon exercise of such rights, options or warrants, the conversion rate shall be readjusted to the conversion rate that would then be in effect had the increase with respect to the issuance of such
rights, options or warrants been made on the basis of delivery of only the number of shares of common stock actually delivered. If such rights, options or warrants are not so issued, or if such
rights, options or warrants are not so exercised prior to their expiration, the conversion rate shall be decreased to the conversion rate that would then be in effect if such ex-dividend date for such
issuance had not occurred. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining whether any rights, options or warrants entitle the holders of our common stock to subscribe for or purchase shares of our common stock at less than such average of the
closing sale prices for the ten consecutive trading day period ending on, and including, the trading day immediately preceding the announcement date for such issuance, and in determining the aggregate
offering price of such shares of our common stock, there shall be taken into account any consideration received by us for such rights, options or warrants and any amount payable on exercise or
conversion thereof, the value of such consideration (if other than cash) to be determined by our board of directors or a committee thereof. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=43,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=613246,FOLIO='S-36',FILE='DISK128:[20ZBC1.20ZBC76301]DG76301A.;10',USER='CHE106460',CD='24-FEB-2020;00:34' -->
<A NAME="page_dg76301_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;&nbsp;&nbsp;If
we distribute shares of our capital stock, evidences of our indebtedness, other assets or property of ours or rights, options or warrants to acquire our capital
stock or other securities, to all or substantially all holders of our common stock, excluding:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> dividends, distributions or issuances as to which an adjustment was effected pursuant to clause&nbsp;(1) or (2)&nbsp;above; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> rights issued under a stockholders rights plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> dividends or distributions paid exclusively in cash as to which the provisions set forth in clause&nbsp;(4) below shall apply; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> distributions of reference property in a transaction described in "&#151;Change in the Conversion Rights Upon Certain Reclassifications,
Business Combinations, Asset Sales and Corporate Events"; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> spin-offs described below in the second paragraph of this clause&nbsp;(3), </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>then
the conversion rate will be increased based on the following formula: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g827456.jpg" ALT="GRAPHIC" WIDTH="162" HEIGHT="39">
  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="34pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="14pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>where,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>CR</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>conversion rate in effect immediately after the open of business on the ex-dividend date for such distribution;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>CR<SUB>0</SUB></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the conversion rate in effect immediately prior to the open of business on such ex-dividend date for such distribution;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>SP<SUB>0</SUB></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the average of the closing sale prices of our common stock over the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the ex-dividend date for such distribution;
and</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>FMV</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the fair market value (as determined by our board of directors or a committee thereof) of the shares of capital stock, evidences of indebtedness, assets, property, rights, options or warrants distributed with respect
to each outstanding share of our common stock on the ex-dividend date for such distribution.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
increase made under the portion of this clause&nbsp;(3) above will become effective immediately after the open of business on the ex-dividend date for such distribution. If such
distribution is not so paid or made, the conversion rate shall be decreased to be the conversion rate that would then be in effect if such distribution had not been declared. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, if "FMV" (as defined above) is equal to or greater than "SP<SUB>0</SUB>" (as defined above), in lieu of the foregoing increase, each holder of a note
shall receive, in respect of each $1,000 principal amount thereof, at the same time and upon the same terms as holders of our common stock, the amount and kind of our capital stock, evidences of our
indebtedness, other assets or property of ours or rights, options or warrants to acquire our capital stock or other securities that such holder would have received if such holder owned a number of
shares of common stock equal to the conversion rate in effect on the ex-dividend date for the distribution. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to an adjustment pursuant to this clause&nbsp;(3) where there has been a payment of a dividend or other distribution on our common stock in shares of capital stock of any
class or series, or similar equity interest, of or relating to a subsidiary or other business unit that are, or, when issued will be, listed or admitted for trading on a U.S. national securities
exchange, which is referred to in this </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=44,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=895107,FOLIO='S-37',FILE='DISK128:[20ZBC1.20ZBC76301]DG76301A.;10',USER='CHE106460',CD='24-FEB-2020;00:34' -->
<A NAME="page_dg76301_1_38"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>prospectus
supplement as a "spin-off," the conversion rate will be increased based on the following formula: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g971860.jpg" ALT="GRAPHIC" WIDTH="166" HEIGHT="39">
  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="34pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="14pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>where,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>CR</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>conversion rate in effect immediately after the open of business on the ex-dividend date for the spin-off;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>CR<SUB>0</SUB></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the conversion rate in effect immediately prior to the open of business on the ex-dividend date for the spin-off;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>FMV</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the average of the closing sale prices of the capital stock or similar equity interest distributed to holders of our common stock applicable to one share of our common stock over the first 10 consecutive trading day
period immediately following, and including, the ex-dividend date of the spin-off (such period, the "valuation period"); and</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>MP<SUB>0</SUB></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the average of the closing sale prices of our common stock over the valuation period.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
adjustment to the conversion rate under the preceding paragraph of this clause&nbsp;(3) will be made immediately after the open of business on the day after the last day of the
valuation period, but will be given effect as of the open of business on the ex-dividend date for the spin-off. Because we will make the adjustment to the conversion rate at the end of the valuation
period with retroactive effect, notwithstanding anything to the contrary, (i)&nbsp;if the settlement date for a note whose conversion is to be settled pursuant to cash settlement or combination
settlement occurs on or before the last trading day in the valuation period for any spin-off and any VWAP trading day in the observation period for such conversion occurs on any trading day within
such valuation period, then, solely for purposes of determining the consideration due in respect of such conversion, such valuation period will be deemed to be the period from, and including, the
ex-dividend date for such spin-off to, and including, the last VWAP trading day in such observation period (or, if such VWAP trading day is not a trading day, the immediately preceding trading day);
and (ii)&nbsp;if the settlement date for a note whose conversion is to be settled pursuant to physical settlement occurs on or before the last trading day in the valuation period for a spin-off and
the conversion date for such conversion occurs on any trading day within such valuation period, then, solely for purposes of determining the consideration due in respect of such conversion, such
valuation period will be deemed to be the period from, and including, the ex-dividend date for such spin-off to, and including, such conversion date (or, if such conversion date is not a trading day,
the immediately preceding trading day). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;&nbsp;&nbsp;If
we pay any cash dividends or distributions paid exclusively in cash to all or substantially all holders of our common stock (other than dividends or distributions
made in connection with our liquidation, dissolution or winding-up or upon a merger, consolidation or sale, lease, transfer, conveyance or other disposition resulting in a change in the conversion
consideration as described under "&#151;Change in the Conversion Rights Upon Certain Reclassifications, Business Combinations, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=45,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=427282,FOLIO='S-38',FILE='DISK128:[20ZBC1.20ZBC76301]DG76301A.;10',USER='CHE106460',CD='24-FEB-2020;00:34' -->
<A NAME="page_dg76301_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Asset
Sales and Corporate Events"), the conversion rate will be increased based on the following formula: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g244632.jpg" ALT="GRAPHIC" WIDTH="139" HEIGHT="39">
  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="14pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>where,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>CR</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the conversion rate in effect immediately after the open of business on the ex-dividend date for such dividend or distribution;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>CR<SUB>0</SUB></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the conversion rate in effect immediately prior to the open of business on the ex-dividend date for such dividend or distribution;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>SP<SUB>0</SUB></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the average of the closing sale prices of our common stock over the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the ex-dividend date for such dividend or
distribution (or, if we declare such dividend or distribution less than 11 trading days prior to such ex-dividend date, 10 shall be replaced with a smaller number of trading days that will have occurred after, and not including, such declaration date
and prior to, but not including, such ex-dividend date); and</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>C</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the amount in cash per share we distribute to holders of our common stock</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, if "C" (as defined above) is equal to or greater than "SP<SUB>0</SUB>" (as defined above), in lieu of the foregoing increase, each holder of a note shall
receive, in respect of each $1,000 principal amount thereof, at the same time and upon the same terms as holders of shares of our common stock, the amount of cash that such holder would have received
as if such holder owned a number of shares of our common stock equal to the conversion rate in effect on the ex-dividend date for such cash dividend or distribution. To the extent such dividend or
distribution is declared but not made or paid, the conversion rate will be readjusted to the conversion rate that would then be in effect had the adjustment been made on the basis of only the dividend
or distribution, if any, actually made or paid. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
increase made under this clause&nbsp;(4) shall become effective immediately after the open of business on the ex-dividend date for such cash dividend or distribution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;&nbsp;&nbsp;If
we or any of our subsidiaries make a payment in respect of a tender offer or exchange offer for our common stock, to the extent that the cash and value of any other
consideration included in the payment per share of our common stock exceeds the closing sale price of our common stock on the trading day next succeeding the last date on which tenders or exchanges
may be made pursuant to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=46,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=151595,FOLIO='S-39',FILE='DISK128:[20ZBC1.20ZBC76301]DG76301A.;10',USER='CHE106460',CD='24-FEB-2020;00:34' -->
<A NAME="page_dg76301_1_40"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>such
tender or exchange offer (the "expiration date"), the conversion rate will be increased based on the following formula: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g702783.jpg" ALT="GRAPHIC" WIDTH="193" HEIGHT="39">
  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="14pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>where,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>CR</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the conversion rate in effect immediately after the close of business on the trading day immediately following the expiration date;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>CR<SUB>0</SUB></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the conversion rate in effect immediately prior to the close of business on the trading day immediately following the expiration date;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>AC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the aggregate value of all cash and any other consideration (as determined by our board of directors or a committee thereof) paid or payable for shares purchased in such tender or exchange offer;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>SP</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the average of the closing sale prices of our common stock over the 10 consecutive trading day period commencing on, and including, the trading day next succeeding the expiration date (the "averaging period")
;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>OS</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the number of shares of our common stock outstanding immediately after the close of business on the expiration date (after giving effect to such tender offer or exchange offer); and</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>OS<SUB>0</SUB></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>=</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>the number of shares of our common stock outstanding immediately prior to the close of business on the expiration date (prior to giving effect to such tender offer or exchange offer).</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
adjustment to the conversion rate under this clause&nbsp;(5) will be made immediately prior to the open of business on the day following the last day of the averaging period, but
will be given effect as of the open of business on the trading day immediately following the expiration date. Because we will make the adjustment to the conversion rate at the end of the averaging
period with retroactive effect, notwithstanding anything to the contrary, (i)&nbsp;if the settlement date for a note whose conversion is to be settled pursuant to cash settlement or combination
settlement occurs on or before the last trading day in the averaging period for such tender or exchange offer and any VWAP trading day in the observation period for such conversion occurs on any
trading day within such averaging period, then, solely for purposes of determining the consideration due in respect of such conversion, such averaging period will be deemed to be the period from, and
including, the trading day immediately after the expiration date for such tender or exchange offer to, and including, the last VWAP trading day in such observation period (or, if such VWAP trading day
is not a trading day, the immediately preceding trading day); and (ii)&nbsp;if the settlement date for a note whose conversion is to be settled pursuant to physical settlement occurs on or before
the last trading day in the averaging period for such tender or exchange offer and the conversion date for such conversion occurs on any trading day within such averaging period, then, solely for
purposes of determining the consideration due in respect of such conversion, such averaging period will be deemed to be the period from, and including, the trading day immediately after the expiration
date to, and including, such conversion date (or, if such conversion date is not a trading day, the immediately preceding trading day). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent that any stockholder's rights plan adopted by us is in effect upon conversion of the notes, you will receive, in addition to any common stock due upon conversion, the
rights under the applicable rights agreement. However, if, prior to any conversion, the rights have separated from the shares of common stock in accordance with the provisions of the applicable rights
plan, the conversion rate will be adjusted at the time of separation as if we distributed to all or substantially all holders of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=47,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=24900,FOLIO='S-40',FILE='DISK128:[20ZBC1.20ZBC76301]DG76301A.;10',USER='CHE106460',CD='24-FEB-2020;00:34' -->
<A NAME="page_dg76301_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>our
common stock, shares of our capital stock, evidences of indebtedness, assets, property, rights, options or warrants as described above in clause&nbsp;(3), subject to readjustment in the event of
the expiration, termination or redemption of such rights. For the avoidance of doubt, any issuance of stockholder rights (including pursuant to a stockholder rights plan adopted after the date of
initial issuance of the notes) will not cause an adjustment of the conversion rate unless and until such stockholder rights have separated from the common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, if a conversion rate adjustment becomes effective on any ex-dividend date as described above, and a holder that has converted its notes on or after such
ex-dividend date and on or prior to the related record date would be treated as the record holder of shares of our common stock as of the related conversion date as described under
"&#151;Settlement Upon Conversion" based on an adjusted conversion rate for such ex-dividend date, then, notwithstanding the foregoing conversion rate adjustment provisions, the conversion rate
adjustment relating to such ex-dividend date will not be made for such converting holder. Instead, such holder will be treated as if such holder were the record owner of the shares of our common stock
on an unadjusted basis and participate in the related dividend, distribution or other event giving rise to such adjustment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, if a holder converts a note, combination settlement is applicable to such note and the daily settlement amount for any VWAP trading day during the
observation period applicable to such note:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> is calculated based on a conversion rate adjusted on account of any event described in clauses&nbsp;(1) through (5)&nbsp;above; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> includes any shares of our common stock that entitle their holder to participate in such event; </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>then,
notwithstanding the foregoing conversion rate adjustment provisions, such conversion rate adjustment will not be made for such converting holder for such trading day. Instead, such holder will
be treated as if such holder were the record owner of the shares of our common stock on an unadjusted basis and participate in the related dividend, distribution or other event giving rise to such
adjustment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we issue rights, options or warrants that are only exercisable upon the occurrence of certain triggering events, then:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we will not adjust the conversion rate pursuant to the clauses above until the earliest of these triggering events occurs; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we will readjust the conversion rate to the extent any of these rights, options or warrants are not exercised before they expire; </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2> that the rights, options or warrants trade together with our common stock and will be issued in respect of future issuances of the shares of
our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent permitted by applicable law and subject to the applicable rules of the Nasdaq Capital Market, we (a)&nbsp;are permitted to increase the conversion rate of the notes by
any amount for a period of at least 20 business days if we determine that such increase would be in our best interest and (b)&nbsp;may also (but are not required to) increase the conversion rate of
the notes to avoid or diminish income tax to holders of our common stock or rights to purchase shares of our common stock in connection with a dividend or distribution of shares (or rights to acquire
shares) or similar event. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we adjust the conversion rate pursuant to the above provisions, we will deliver a notice to the trustee, conversion agent (if other than the trustee) and record holders of the notes
containing the relevant information. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=48,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=889173,FOLIO='S-41',FILE='DISK128:[20ZBC1.20ZBC76301]DG76301A.;10',USER='CHE106460',CD='24-FEB-2020;00:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_di76301_1_42"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as described above and under "&#151;Adjustment to Conversion Rate Upon a Make-Whole Fundamental Change" below, the conversion rate will not be
adjusted. Without limiting the foregoing, the conversion rate will not be adjusted:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> except as described above, upon the sale of shares of our common stock for a purchase price that is less than the market price per share of our
common stock or less than the conversion price; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> upon the issuance of any shares of our common stock pursuant to any present or future plan providing for the reinvestment of dividends or
interest payable on our securities and the investment of additional optional amounts in shares of our common stock under any plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> upon the issuance of any shares of our common stock or options or rights to purchase those shares pursuant to any present or future employee,
director or consultant benefit plan or program of or assumed by us or any of our subsidiaries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> upon the issuance of any shares of our common stock pursuant to any option, warrant, right or exercisable, exchangeable or convertible security
not described in the preceding bullet and outstanding as of the date the notes were first issued; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for the repurchase of any shares of our common stock that is not a tender offer or exchange offer of the nature described in clause&nbsp;(5)
above, including, but not limited to, pursuant to an open-market share repurchase program, a structured or derivative transaction or other buyback transaction; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> solely for a change in the par value of the common stock; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for accrued and unpaid interest, if any. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of a taxable distribution to holders of our common stock which results in an adjustment of the conversion rate, a holder of the notes may, in certain circumstances (such as
a distribution of a cash dividend), be deemed to have received a distribution subject to U.S. federal income tax as a dividend. In certain other circumstances, the absence of such an adjustment may
result in a taxable dividend to the holders of our common stock. For a discussion of the U.S. federal income tax treatment of an adjustment to the conversion rate, see "Material U.S. Federal Income
Tax Considerations." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will not adjust the conversion rate pursuant to the clauses above unless the adjustment would result in a change of at least 1% in the then-effective conversion rate. However, we
will carry forward any adjustment that we would otherwise have to make and take that adjustment into account in any subsequent adjustment. Notwithstanding the foregoing, all such carried-forward
adjustments shall be
made with respect to the notes&nbsp;(i) in connection with any subsequent adjustment to the conversion rate of at least 1% and (ii)(a) on each trading day of any observation period related to the
conversion of the notes (in the case of cash settlement or combination settlement) or (b)&nbsp;on the conversion date for any notes (in the case of physical settlement). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments
to the conversion rate will be calculated to the nearest 1/10,000th&nbsp;of a share. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Change in the Conversion Rights Upon Certain Reclassifications, Business Combinations, Asset Sales and
Corporate Events  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reclassify or change our common stock (other than changes in par value or from no par value resulting from a subdivision or combination), or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=49,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=489611,FOLIO='S-42',FILE='DISK128:[20ZBC1.20ZBC76301]DI76301A.;13',USER='CHE106460',CD='26-FEB-2020;00:19' -->
<A NAME="page_di76301_1_43"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> consolidate or merge with or into or enter into a binding share exchange with any person or sell, lease, transfer, convey or otherwise dispose
of all or substantially all of our property and assets and the property and assets of our subsidiaries taken as a whole to another person, </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>and,
in either case, holders of our common stock receive stock, other securities or other property or assets (including cash or any combination thereof) with respect to or in exchange for their common
stock, then from and after the effective date of such transaction, the right to convert each outstanding $1,000 principal amount of notes based on our common stock will, without the consent of any
holders of the notes, be changed into a right to convert each such note based on the kind and amount of stock, other securities or other property or assets (including cash or any combination thereof)
(the "reference
property") that a holder of a number of shares of common stock equal to the conversion rate immediately prior to such transaction would have been entitled to receive upon such transaction. We or the
successor or purchasing corporation, as the case may be, will execute with the trustee, without the consent of the holders, a supplemental indenture providing that, at and after the effective date of
the transaction, the right to convert each outstanding $1,000 principal amount of notes will be changed into a right to convert such principal amount of notes into the kind and amount of reference
property that a holder of a number of shares of common stock equal to the conversion rate immediately prior to such transaction would have been entitled to receive upon such transaction. If the
transaction causes our common stock to be converted into or exchanged for the right to receive more than a single type of consideration (determined based in part upon any form of stockholder
election), the reference property into which the notes will become convertible will be deemed to be based on the weighted average of the kind and amount of consideration actually received by holders
of a majority of our common stock that voted for such an election (if electing between two types of consideration) or holders of a plurality of our common stock that voted for such an election (if
electing between more than two types of consideration), as the case may be, and if no holders of our common stock affirmatively make such an election, the types and amounts of consideration actually
received by the holders of our common stock. In all cases the provisions above under "&#151;Settlement Upon Conversion" relating to the satisfaction of our conversion obligation shall continue
to apply with respect to the calculation of the consideration due upon conversion, with the daily conversion value, daily settlement amount and the daily VWAPs determined based on a unit of reference
property that a holder of one share of our common stock would have received in such transaction; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT> <FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that if the holders of our common stock
receive only cash in such transaction, the consideration due upon conversion shall equal the conversion
rate in effect on the conversion date, </FONT><FONT SIZE=2><I>multiplied by</I></FONT><FONT SIZE=2> the price paid per share of common stock in such transaction, and settlement of any conversion
thereafter will occur on the second business day following the applicable conversion date. We may not become a party to any such transaction unless its terms are consistent with the foregoing. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Adjustment to Conversion Rate Upon a Make-Whole Fundamental Change  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the "effective date" (as defined below) of a "fundamental change" (as defined below and determined after giving effect to any exceptions to
or exclusions from such definition, but without regard to the </FONT><FONT SIZE=2><I>proviso</I></FONT><FONT SIZE=2> in clause&nbsp;(2) of the definition thereof, a "make-whole fundamental change")
occurs prior to the maturity date of the notes and a holder elects to convert its notes in connection with such make-whole fundamental change, we will increase the conversion rate as described below.
The number of additional shares by which the conversion is increased (the "additional shares") will be determined by reference to the table below, based on the date on which the make-whole fundamental
change becomes effective (the "effective date") and the price (the "stock price") paid (or deemed paid) per share for our common stock in such make-whole fundamental change. If holders of our common
stock receive only cash in such transaction, the price paid (or deemed paid) per share will be the cash amount paid per share. Otherwise, the price paid (or deemed paid) per share will be the average
of the closing sale prices of our common stock over the five trading day period ending on, and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=50,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=546348,FOLIO='S-43',FILE='DISK128:[20ZBC1.20ZBC76301]DI76301A.;13',USER='CHE106460',CD='26-FEB-2020;00:19' -->
<A NAME="page_di76301_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>including,
the trading day immediately preceding the effective date of such make-whole fundamental change. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will notify you, the trustee and conversion agent (if other than the trustee) of the effective date of any make-whole fundamental change no later than one business day after such
effective date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
conversion of the notes by a holder will be deemed for these purposes to be "in connection with" a make-whole fundamental change if the conversion notice is received by the conversion
agent on or after the effective date of the make-whole fundamental change but before the close of business on the second business day immediately preceding the related fundamental change repurchase
date (or, in the case of a make-whole fundamental change that would have been a fundamental change but for the </FONT><FONT SIZE=2><I>proviso</I></FONT><FONT SIZE=2> in clause&nbsp;(2) of the
definition thereof, the 35th&nbsp;trading day immediately following the effective date of such make-whole fundamental change) as specified in the repurchase notice described under
"&#151;Fundamental Change Put." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of additional shares will be adjusted in the same manner and at the same time as the conversion rate of the notes is adjusted as described above under
"&#151;Conversion Rate Adjustments." The stock prices set forth in the first row of the table below (i.e.,&nbsp;the column headers) will be simultaneously adjusted to equal the stock prices
immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the conversion rate immediately prior to the adjustment and the denominator of which is the conversion rate as
so adjusted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth the number of additional shares per $1,000 principal amount of notes by which the conversion rate shall be increased upon conversion in connection with a
make-whole fundamental change: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=38 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Effective date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$95.56 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$100.00 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$110.00 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$121.84 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$135.00 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$150.00 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$175.00 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$200.00 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$225.00 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$250.00 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$300.00 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$350.00 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$450.00 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>February&nbsp;27, 2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2544</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.8720</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.4897</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.1699</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.8993</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.5923</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.3964</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.2670</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.1794</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0772</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0282</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>March&nbsp;1, 2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2521</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.8610</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.4767</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.1607</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.8838</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.5728</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.3771</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.2496</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.1645</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0675</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0228</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>March&nbsp;1, 2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2484</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.8520</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.4658</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.1287</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.8481</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.5375</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.3457</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.2230</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.1429</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0543</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0158</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>March&nbsp;1, 2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2421</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.8441</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.4229</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.0791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.7965</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.4895</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.3047</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.1898</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.1167</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0395</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0088</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>March&nbsp;1, 2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2310</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.7913</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.3565</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.0065</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.7242</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.4258</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.2529</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.1496</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0866</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0245</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0033</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>March&nbsp;1, 2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2275</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.7083</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.2580</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.9034</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.6251</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.3433</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.1894</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.1029</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0537</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0104</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>March&nbsp;1, 2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.1294</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.5745</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.1052</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.7494</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.4840</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.2356</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.1138</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0528</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0220</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>March&nbsp;1, 2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.9666</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.3432</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.8425</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.4976</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.2734</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.1014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0360</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0105</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>March&nbsp;1, 2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.2570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.7924</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.8833</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>0.0000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
exact stock price and effective date may not be set forth in the table above, in which case, if the stock price is:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> between two stock prices in the table or the effective date is between two effective dates in the table, the number of additional shares by
which the conversion rate will be increased will be determined by a straight-line interpolation between the number of additional shares set forth for the higher and lower stock prices and the earlier
and later effective dates based on a 360-day year; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> greater than $450.00 per share (subject to adjustment in the same manner and at the same time as the stock prices in the table above), we will
not increase the conversion rate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> less than $95.56 per share (subject to adjustment in the same manner and at the same time as the stock prices in the table above), we will not
increase the conversion rate. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, in no event will the total number of shares of our common stock issuable upon conversion exceed 10.4646 shares per $1,000 principal amount of notes,
subject to adjustment in the same manner and at the same time as the conversion rate. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=51,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=641960,FOLIO='S-44',FILE='DISK128:[20ZBC1.20ZBC76301]DI76301A.;13',USER='CHE106460',CD='26-FEB-2020;00:19' -->
<A NAME="page_di76301_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
obligation to increase the conversion rate for notes converted in connection with a fundamental change could be considered a penalty, in which case the enforceability thereof would
be subject to general principles of reasonableness and equitable remedies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of a conversion of notes in connection with a make-whole fundamental change that results in an adjustment of the conversion rate, a holder of notes may be deemed to have
received a distribution subject to U.S. federal income tax as a dividend. See "Material U.S. Federal Income Tax Considerations." </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> Adjustments of Prices  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever any provision of the indenture requires us to calculate the closing sale prices, the daily VWAPs, the daily conversion values or the
daily settlement amounts over, or based on, a span of multiple days (including an observation period and the "stock price" for purposes of a make-whole fundamental change), we will make appropriate
adjustments to each to account for any adjustment to the conversion rate that becomes effective, or any event requiring an adjustment to the conversion rate where the ex-dividend date of the event
occurs, at any time during the period when the closing sale prices, the daily VWAPs, the daily conversion values or the daily settlement amounts are to be calculated. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the avoidance of doubt, the adjustments made pursuant to the foregoing paragraph will be made, solely to the extent we determine in our good faith judgment that any such adjustment
is necessary, without duplication of any adjustment made pursuant to the provision set forth under "&#151;Conversion Rate Adjustments." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Fundamental Change Put  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If a fundamental change (as defined below) occurs at any time prior to the maturity of the notes, you will have the right to require us to
repurchase on the fundamental change repurchase date, at the fundamental change repurchase price described below, all or part of your notes for which you have properly delivered and not withdrawn a
written repurchase notice. The notes submitted for repurchase must be $1,000 in principal amount or whole multiples of $1,000 in excess thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fundamental change repurchase price will be payable in cash and will equal 100% of the principal amount of the notes being repurchased, plus accrued and unpaid interest to, but
excluding, the fundamental change repurchase date. However, if the fundamental change repurchase date is after a record date and on or prior to the corresponding interest payment date, the full amount
of interest due will be paid on the interest payment date to the holder of record on the record date and the fundamental change repurchase price will be equal to 100% of the principal amount of notes
to be repurchased. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
"fundamental change" will be deemed to have occurred when any of the following has occurred: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
"person" or "group," other than us and our wholly owned subsidiaries, files&nbsp;a Schedule&nbsp;TO or any schedule, form or report under the Exchange Act
disclosing that such person or group has become the "beneficial owner" (as these terms are defined in Rule&nbsp;13d-3 and Rule&nbsp;13d-5 under the Exchange Act), directly or indirectly, of more
than 50% of our capital stock that is at the time entitled to vote by the holder thereof in the election of our board of directors (or comparable body);
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
consummation of (A)&nbsp;any recapitalization, reclassification or change of our common stock (other than changes resulting from a subdivision or combination)
as a result of which our common stock would be converted into, or exchanged for, stock, other securities, other property or assets; (B)&nbsp;any share exchange, consolidation or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=52,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=306902,FOLIO='S-45',FILE='DISK128:[20ZBC1.20ZBC76301]DI76301A.;13',USER='CHE106460',CD='26-FEB-2020;00:19' -->
<A NAME="page_di76301_1_46"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>merger
of us pursuant to which our common stock will be converted into cash, securities or other property or assets (or any combination thereof); or (C)&nbsp;any sale, lease or other transfer in one
transaction or a series of transactions of all or substantially all of the consolidated assets of us and our subsidiaries, taken as a whole, to any person other than one of our wholly owned
subsidiaries; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that neither (a)&nbsp;a transaction described in clause&nbsp;(B) in
which the holders of all classes of our common equity immediately prior to such transaction own, directly or indirectly, more than 50% of all classes of common equity of the continuing or surviving
corporation or transferee or the parent thereof immediately after such transaction in substantially the same proportions as such ownership immediately prior to such transaction nor (b)&nbsp;any
reorganization or merger of us solely for the purpose of changing our jurisdiction of incorporation that results in a reclassification, conversion or exchange of outstanding shares of common stock
solely into shares of common stock of the surviving entity shall be a fundamental change pursuant to this clause&nbsp;(2);  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
adoption of a plan relating to our liquidation or dissolution; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>our
common stock or other shares of capital stock or reference property into which the notes are convertible is neither listed for trading on The New York Stock
Exchange, the Nasdaq Capital Market, the Nasdaq Global Market or the Nasdaq Global Select Market (or any of their respective successors). </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, any transaction or event described above will not constitute a fundamental change if, in connection with such transaction or event, or as a result
therefrom, a transaction described in clause&nbsp;(1) or (2)&nbsp;above occurs and at least 90% of the consideration paid for our common stock (excluding cash payments for fractional shares and
cash payments made pursuant to dissenters' appraisal rights) consists of shares of common stock traded on any of the New York Stock Exchange, the Nasdaq Capital Market, the Nasdaq Global Market or the
Nasdaq Global Select Market (or any of their respective successors) (or will be so traded or quoted immediately following the completion of the merger or consolidation or such other transaction) and,
as a result of such transaction, the notes become convertible into a combination of cash (in respect of an amount up to, and including, the principal portion of such notes) and reference property
comprised of such consideration as described under "&#151;Conversion Rights&#151;Change in the Conversion Rights Upon Certain Reclassifications, Business Combinations, Asset Sales and
Corporate Events" above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or before the tenth business day after the occurrence of a fundamental change, we will provide to all record holders of the notes on the date of the fundamental change at their
addresses shown in the register of the registrar and to beneficial owners to the extent required by applicable law, the trustee and the paying agent appointed in connection with the fundamental
change, a written notice of the occurrence of the fundamental change and the resulting repurchase right. Such notice shall state, among other things, the event causing the fundamental change and the
procedures you must follow to require us to repurchase your notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fundamental change repurchase date will be a date specified by us in the notice of a fundamental change that is not less than 20 nor more than 35 business days after the date of the
notice of a fundamental change. The fundamental change repurchase date shall be subject to postponement in order to allow us to comply with applicable law as a result of changes to such applicable law
occurring after the date of the indenture. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
exercise your repurchase right, you must deliver, prior to the close of business on the business day immediately preceding the fundamental change repurchase date, a written notice to
the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=53,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=1010635,FOLIO='S-46',FILE='DISK128:[20ZBC1.20ZBC76301]DI76301A.;13',USER='CHE106460',CD='26-FEB-2020;00:19' -->
<A NAME="page_di76301_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>paying
agent of your exercise of your repurchase right (together with the notes to be repurchased, if certificated notes have been issued). The repurchase notice must
state:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the portion of the principal amount of the notes to be repurchased, which must be $1,000 or whole multiples of $1,000 in excess thereof; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> that the notes are to be repurchased by us pursuant to the applicable provisions of the notes and the indenture. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, if you hold a beneficial interest in a global note, your repurchase notice must comply with appropriate DTC procedures and if you hold certificated notes, your repurchase
notice must identify the relevant notes certificate numbers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may withdraw your repurchase notice at any time prior to the close of business on the business day immediately preceding the fundamental change repurchase date by delivering a
written notice of withdrawal to the paying agent. If a repurchase notice is given and withdrawn during that period, we will not be obligated to repurchase the notes listed in the repurchase notice.
The withdrawal notice must state:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the principal amount of the withdrawn notes (which must be $1,000 or an integral multiple thereof); and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the principal amount, if any (which must be $1,000 or an integral multiple thereof), which remains subject to the repurchase notice. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, if you hold a beneficial interest in a global note, your withdrawal notice must comply with appropriate DTC procedures and if you hold certificated notes, your withdrawal
notice must identify the certificate numbers of the withdrawn notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
of the fundamental change repurchase price for notes for which a repurchase notice has been delivered and not withdrawn is conditioned upon book-entry transfer or delivery of
the notes, together with necessary endorsements, to the paying agent, as the case may be. Payment of the fundamental change repurchase price for the notes will be made promptly following the later of
the fundamental
change repurchase date and the time of book-entry transfer or delivery of the notes, as the case may be. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the paying agent holds on the fundamental change repurchase date cash sufficient to pay the fundamental change repurchase price of the notes that holders have elected to require us
to repurchase, then, as of the fundamental change repurchase date:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the notes will cease to be outstanding and interest will cease to accrue, whether or not book-entry transfer of the notes has been made or the
notes have been delivered to the paying agent, as the case may be; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all other rights of the holders of notes will terminate, other than the right to receive the fundamental change repurchase price upon delivery
or transfer of the notes. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with any repurchase, we will, to the extent applicable:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> comply with the provisions of Rule&nbsp;13e-4 and any other tender offer rules under the Exchange Act that may be applicable at the time of
the offer to repurchase the notes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> file&nbsp;a Schedule&nbsp;TO or any other schedule required in connection with any offer by us to repurchase the notes; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> comply with all other federal and state securities laws in connection with any offer by us to repurchase the notes. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=54,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=985406,FOLIO='S-47',FILE='DISK128:[20ZBC1.20ZBC76301]DI76301A.;13',USER='CHE106460',CD='26-FEB-2020;00:19' -->
<A NAME="page_di76301_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
notes may be repurchased at your option upon a fundamental change if the principal amount of the notes has been accelerated, and such acceleration has not been rescinded, on or prior
to the fundamental change repurchase date (except in the case of an acceleration resulting from a default by us in the payment of the fundamental change repurchase price with respect to such notes). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, we will not be required to purchase, or to make an offer to purchase, the notes upon a fundamental change if a third party makes such an offer in the same
manner, at the same time and otherwise in compliance with the requirements for an offer made by us as set forth above and such third party purchases all notes properly surrendered and not validly
withdrawn under its offer in the same manner, at the same time and otherwise in compliance with the requirements for an offer made by us as set forth above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, we will not be required to give such notice or repurchase the notes as described above upon a fundamental change pursuant to clause&nbsp;(2) of the
definition thereof if (1)&nbsp;such fundamental change results in the notes becoming convertible (pursuant to the provisions described above under "&#151;Conversion Rights&#151;Change
in the Conversion Rights Upon Certain Reclassifications, Business Combinations, Asset Sales and Corporate Events") into an amount of cash per note greater than the fundamental change purchase price
(assuming the maximum amount of accrued interest would be payable based on the latest possible fundamental change repurchase date) and (2)&nbsp;we provide timely notice of the holders' right to
convert their notes based on such fundamental change as described above under "&#151;Conversion Rights&#151;Conversion Upon Specified Corporate Transactions." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
definition of "fundamental change" includes a phrase relating to the sale, lease, transfer, conveyance or other disposition, in one or a series of related transactions, of all or
substantially all of our assets and those of our subsidiaries taken as a whole. There is no precise, established definition of the phrase "substantially all" under applicable law. Accordingly, the
ability of a holder of notes to require us to repurchase the notes as a result of a sale, lease, transfer, conveyance or other disposition of less than all of our assets and those of our subsidiaries
taken as a whole to another person or group may be uncertain. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may be unable to repurchase your notes in cash upon a fundamental change. Our ability to repurchase the notes with cash in the future may be limited by the terms of our then-existing
borrowing agreements or otherwise. In addition, the occurrence of a fundamental change could cause an event of default under the terms of our then-existing borrowing agreements. We cannot assure you
that we would have the financial resources, or would be able to arrange financing, to pay the fundamental change repurchase price in cash. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
fundamental change repurchase right could discourage a potential acquirer of the Company and its subsidiaries. However, this fundamental change repurchase feature is not the result
of management's knowledge of any specific effort to obtain control of us by means of a merger, tender offer, solicitation or otherwise, or part of a plan by management to adopt a series of
anti-takeover provisions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
obligation to repurchase the notes upon a fundamental change would not necessarily afford you protection in the event of a highly leveraged or other transaction involving us that
may adversely affect holders. We also could, in the future, enter into certain transactions, including certain recapitalizations, that would not constitute a fundamental change but would increase the
amount of our (or our subsidiaries') outstanding debt. The incurrence of significant amounts of additional debt could adversely affect our ability to service our then existing debt, including the
notes. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=55,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=916833,FOLIO='S-48',FILE='DISK128:[20ZBC1.20ZBC76301]DI76301A.;13',USER='CHE106460',CD='26-FEB-2020;00:19' -->
<A NAME="page_di76301_1_49"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> Consolidation, Merger and Sale of Assets  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture will provide that we may not, in a single transaction or a series of related transactions, consolidate with or merge with or into
any other person or sell, convey, transfer, lease or otherwise dispose of all or substantially all of the property and assets of the Company and its subsidiaries taken as a whole to another person,
unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> either (a)&nbsp;we are the continuing corporation or (b)&nbsp;the resulting, surviving or transferee person (if other than us) is a
corporation organized and existing under the laws of the United States, any state thereof or the District of Columbia and such person assumes, by a supplemental indenture, all of our obligations under
the notes and the indenture; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> immediately after giving effect to such transaction, no default or event of default has occurred and is continuing; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we have delivered to the trustee certain certificates and opinions of counsel to the extent required by the indenture. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of any transaction described in and complying with the conditions listed in the immediately preceding paragraph in which the Company is not the continuing corporation, the
successor person formed or remaining shall succeed, and be substituted for, and may exercise every right and power of, the Company, and the Company shall be discharged from its obligations, under the
notes and the indenture, except in the case of a lease of all or substantially all of the property of the Company and its subsidiaries taken as a whole. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
covenant includes a phrase relating to the sale, conveyance, transfer, lease and other disposition of "all or substantially all" of the property and assets of the Company and its
subsidiaries. There is no precise, established definition of the phrase "all or substantially all" under applicable law. Accordingly, whether a sale, conveyance, transfer, lease or other disposition
of less than all of the property and assets of the Company and its subsidiaries constitutes a sale or other disposition of "all or substantially all" may be uncertain. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
assumption by any person of the Company's obligations under the notes and the indenture might be deemed for U.S. federal income tax purposes to be a taxable exchange of the notes for
new notes by the holders thereof, resulting in recognition of gain or loss for such purposes and possibly other adverse tax consequences to the holders. Holders should consult their own tax advisors
regarding the tax consequences of such an assumption. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Events of Default; Notice and Waiver  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following will be events of default under the indenture:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we fail to pay any interest on the notes when due and such failure continues for a period of 30 calendar days; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we fail to pay principal of the notes when due at maturity, or we fail to pay the fundamental change repurchase price payable, in respect of
any notes when due; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we fail to comply with our obligation to convert any notes in accordance with the indenture, and such failure continues for five business days
following the scheduled settlement date for such conversion; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we fail to comply with the covenant set forth above under "&#151;Consolidation, Merger and Sale of Assets;" </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we fail to provide notice of any transaction described above under "&#151;Conversion Rights&#151;Conversion Upon Specified
Corporate Transactions"; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=56,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=973011,FOLIO='S-49',FILE='DISK128:[20ZBC1.20ZBC76301]DI76301A.;13',USER='CHE106460',CD='26-FEB-2020;00:19' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dk76301_1_50"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we fail to provide notice of a fundamental change when due as required by the indenture; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we fail to perform or observe any other term, covenant or agreement in the notes or the indenture for a period of 60 consecutive calendar days
after written notice of such failure is given to us by the trustee or to us and the trustee by the holders of at least 25% in aggregate principal amount of the notes then outstanding; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a failure to pay when due (whether at stated maturity or otherwise), or a default that results in the acceleration of maturity, of any
indebtedness for borrowed money of the Company or any of its subsidiaries in an aggregate amount in excess of $50.0&nbsp;million (or its foreign currency equivalent), unless such indebtedness is
paid or discharged, or such acceleration is rescinded, stayed or annulled, within a period of 30 calendar days after written notice of such failure is given to us by the trustee or to us and the
trustee by the holders of at least 25% in aggregate principal amount of the notes then outstanding; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a final judgment for the payment in excess of $50.0&nbsp;million (excluding any amounts covered by insurance) rendered against the Company or
any of its subsidiaries, which judgment is not paid, discharged, bonded, waived or stayed within 60 calendar days after (i)&nbsp;the date on which the right to appeal or petition for review thereof
has expired if no such appeal or review has commenced, or (ii)&nbsp;the date on which all rights to appeal or petition for review have been extinguished; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> certain events involving our bankruptcy, insolvency or reorganization or the bankruptcy, insolvency or reorganization of the Company or any of
its significant subsidiaries (as defined below). </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
"significant subsidiary" is a subsidiary that is a "significant subsidiary" as defined under Rule&nbsp;1-02(w) of Regulation&nbsp;S-X; provided that, in the case of a subsidiary
that meets the criteria of clause&nbsp;(3) of the definition thereof but not clause&nbsp;(1) or (2)&nbsp;thereof, such subsidiary shall not be deemed to be a significant subsidiary unless the
subsidiary's income from continuing operations before income taxes, extraordinary items and cumulative effect of a change in accounting principle, exclusive of amounts attributable to any
non-controlling interests, for the last completed fiscal year prior to the date of such determination exceeds $25,000,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are required to notify the trustee promptly upon becoming aware (and in no event later than 10 calendar days after we become aware) of the occurrence of any default or event of
default under the indenture known to us. The trustee is required within 90 calendar days of obtaining actual knowledge of the occurrence of any event of default to give to the registered holders of
the notes notice of the occurrence and continuation of an event of default known to it. However, the trustee may withhold notice to the holders of the notes of any events of default, except events of
default in payment of principal or interest on the notes or defaults in the failure to deliver the consideration due upon conversion, if the trustee, in good faith, determines that the withholding of
such notice is in the interests of the holders. We are also required to deliver to the trustee, on or before a date not more than 120 calendar days after the end of each fiscal year, a written
statement as to compliance with the indenture, including whether or not any default has occurred. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an event of default specified in the last bullet point listed above occurs and continues with respect to us (and not involving solely one or more of our significant subsidiaries),
the principal amount of the notes and accrued and unpaid interest on the outstanding notes will automatically become due and payable. If any other event of default occurs and is continuing, the
trustee or the holders of at least 25% in aggregate principal amount of the outstanding notes, by written notice to us, may declare the principal amount of the notes and accrued and unpaid interest on
the outstanding notes to be due and payable. Thereupon, the trustee may, in its discretion, proceed to protect and enforce the rights of the holders of the notes by appropriate judicial proceedings. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=57,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=381038,FOLIO='S-50',FILE='DISK128:[20ZBC1.20ZBC76301]DK76301A.;8',USER='CHE106460',CD='24-FEB-2020;00:34' -->
<A NAME="page_dk76301_1_51"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
a declaration of acceleration, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in aggregate principal
amount of the notes outstanding, by written notice to us and the trustee, may rescind and annul such declaration if:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we have paid (or deposited with the trustee a sum sufficient to pay) (1)&nbsp;all overdue interest on all notes; (2)&nbsp;the principal
amount of any notes that have become due otherwise than by such declaration of acceleration; (3)&nbsp;to the extent that payment of such interest is lawful, interest upon overdue interest; and
(4)&nbsp;all sums paid or advanced by the trustee under the indenture and the compensation and reasonable expenses, disbursements and advances of the trustee, its agents and counsel; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all events of default, other than the non-payment of the principal amount and any accrued and unpaid interest that have become due solely by
such declaration of acceleration or the failure to deliver consideration upon conversion, have been cured or waived. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
holders of a majority in aggregate principal amount of the outstanding notes will have the right to direct the time, method and place of any proceedings for any remedy available to
the trustee or the exercise of any other right or power conferred on the trustee, subject to limitations specified in the indenture. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any portion of the amount payable on the notes upon such acceleration thereof as described above is considered by a court to be unearned interest (through the allocation of the value
of the instrument to the embedded warrant or otherwise), the court could disallow recovery of any such portion. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
holder of the notes may pursue any remedy under the indenture, except in the case of a default in the payment of principal or interest on the notes or settlement of our conversion
obligation, unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the holder has given the trustee written notice of an event of default; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the holders of at least 25% in aggregate principal amount of the outstanding notes have made a written request to the trustee to pursue the
remedy, and offer security or indemnity against any costs, liability or expense of the trustee satisfactory to the trustee; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the trustee fails to comply with the request within 60 calendar days after receipt of the request and offer of indemnity; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the trustee has not received an inconsistent direction from the holders of a majority in aggregate principal amount of the outstanding notes. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, the indenture will provide, if we so elect, that the sole remedy for an event of default relating to our failure to comply with the reporting obligations
in the indenture, which are described below under the caption "&#151;Reports" below, will, at our option, for the 365&nbsp;days after the occurrence of such an event of default consist
exclusively of the right to receive additional interest on the notes at an annual rate equal to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 0.25% of the outstanding principal amount of the notes from the first date of the occurrence of such event of default to, but not including,
the 180th&nbsp;day thereafter (or such earlier date on which the event of default relating to the reporting obligations shall have been cured or waived); and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 0.50% of the outstanding principal amount of the notes from the 180th&nbsp;day after the first date of such occurrence of such event of
default to the 365th&nbsp;day thereafter (or such earlier date on which the event of default relating to the reporting obligations shall have been cured or waived). </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=58,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=710817,FOLIO='S-51',FILE='DISK128:[20ZBC1.20ZBC76301]DK76301A.;8',USER='CHE106460',CD='24-FEB-2020;00:34' -->
<A NAME="page_dk76301_1_52"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
additional interest pursuant to the foregoing provisions will be payable in arrears on each interest payment date following accrual in the same manner as regular interest on the
notes. The additional interest will accrue on all outstanding notes from and including the date on which an event of default relating to a failure to comply with the reporting obligations in the
indenture first occurs to, but not including, the 366th&nbsp;day thereafter (or such earlier date on which the event of default relating to the reporting obligations shall have been cured or
waived). On such 366th&nbsp;day, if such event of default is continuing, such additional interest will cease to accrue and the notes will be subject to acceleration as provided above. The provisions
of the indenture described in this paragraph will not affect the rights of holders of notes in the event of the occurrence of any other event of default. In the event we do not elect to pay the
additional interest upon an event of default in accordance with this paragraph or we elected to make such payment but do not pay the additional interest when due, the notes will be immediately subject
to acceleration as provided above. In no event shall additional interest payable pursuant to the foregoing election accrue at a rate per year in excess of the applicable rate specified in the
preceding paragraph, regardless of the number of events or circumstances giving rise to requirements to pay such additional interest pursuant to this paragraph. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Waiver  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of a majority in aggregate principal amount of the notes outstanding may, on behalf of the holders of all the notes, waive any
existing and past default or event of default under the indenture and its consequences, except:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our failure to pay principal of or interest on any notes when due; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our failure to convert any notes into cash and, if applicable, common stock as required by the indenture; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our failure to pay the fundamental change repurchase price on the fundamental change repurchase date in connection with a holder exercising its
repurchase rights; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our failure to comply with any of the provisions of the indenture that would require the consent of the holder of each outstanding notes
affected. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><B> Modification  </B></FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Changes Requiring Approval of Each Affected Holder  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture (including the terms and conditions of the notes) may not be modified or amended without the written consent or the affirmative
vote (including, without limitation, consents obtained in connection with a purchase of, or tender offer or exchange offer for, notes) of the holder of each note affected by such change
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> change the maturity date of any notes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduce the rate or extend the time for payment of interest on any notes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduce the principal amount of any notes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduce any amount payable upon repurchase of any notes upon a fundamental change; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> impair the right of any holder to receive payment of principal (including the fundamental change repurchase price, if applicable) of, accrued
and unpaid interest, if any, on, and the consideration due upon conversion of, its notes on or after the respective due dates expressed or provided for in the indenture or to institute suit for the
enforcement of any such payment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> change the currency in which any note is payable; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=59,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=740808,FOLIO='S-52',FILE='DISK128:[20ZBC1.20ZBC76301]DK76301A.;8',USER='CHE106460',CD='24-FEB-2020;00:34' -->
<A NAME="page_dk76301_1_53"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> change our obligation to repurchase any notes upon a fundamental change in a manner adverse to the holders; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> change the ranking of the notes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> adversely affect the conversion right of a holder to convert its notes pursuant to the terms of the indenture; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> subject to specified exceptions, modify certain provisions of the indenture relating to modification of the indenture or waiver under the
indenture; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> make any change in the modification or amendment provisions that require each holder's consent or in the waiver provisions. </FONT></DD></DL>
</UL>
<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Changes Requiring Majority Approval  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture (including the terms and conditions of the notes) may be modified or amended, except as described above, with the written consent
or affirmative vote (including, without limitation, consents obtained in connection with the purchase of, or tender offer or exchange offer for, notes) of the holders of a majority in aggregate
principal amount of the notes then outstanding. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Changes Requiring No Approval  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture (including the terms and conditions of the notes) may be modified or amended by us and the trustee, without the consent of the
holder of any notes, to, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide for conversion rights of holders of the notes and our repurchase obligations in connection with a fundamental change in the event of
any reclassification of our common stock, merger or consolidation, or sale, conveyance, transfer, lease or other disposition of all or substantially all of the property and assets of the Company and
its subsidiaries taken as a whole; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> secure the notes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide for the assumption of our obligations to the holders of the notes in the event of a merger or consolidation, or sale, conveyance,
transfer, lease or other disposition of all or substantially all of the property and assets of the Company and its subsidiaries taken as a whole; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> surrender any right or power conferred upon us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> add to our covenants or events of default for the benefit of the holders of the notes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> entering into supplemental indentures as described above under "&#151;Consolidation, Merger and Sale of Assets;" </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> cure any ambiguity or correct or supplement any inconsistent or otherwise defective provision or omission contained in the indenture; </FONT> <FONT
SIZE=2><I>provided</I></FONT><FONT SIZE=2> that such modification or amendment does not, in the good faith determination of our board of directors or a committee thereof, adversely
affect the interests of the holders of the notes in any material respect; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>further</I></FONT><FONT SIZE=2>, that any
amendment, supplement or other modification made to conform the provisions of the indenture to the description of the notes contained in the preliminary prospectus supplement dated February&nbsp;24,
2020 relating to the notes as supplemented by the related pricing term sheet will not be deemed to adversely affect the interests of the holders of the notes; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in connection with any share exchange event, provide that the notes are convertible into reference property, subject to the provisions
described under "Conversion Rights&#151; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=60,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=425608,FOLIO='S-53',FILE='DISK128:[20ZBC1.20ZBC76301]DK76301A.;8',USER='CHE106460',CD='24-FEB-2020;00:34' -->
<A NAME="page_dk76301_1_54"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>


<P style="font-family:times;"><FONT SIZE=2>Settlement
Upon Conversion" above, and make certain related changes to the terms of the notes to the extent expressly required by the indenture (as determined in good faith by the board of directors
or a committee thereof); </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> increase the conversion rate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> comply with the requirements of the SEC in order to effect or maintain the qualification of the indenture under the Trust Indenture Act; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> comply with the rules of any applicable securities depositary, including DTC; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> permit or confirm the issuance of additional notes in accordance with the indenture; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> add guarantees of obligations under the notes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> adding or modifying any other provision(s) or omission(s) which we may deem necessary or desirable and which will not adversely affect the
interests of the holders of the notes in any material respect, in the good faith determination of our board of directors or a committee thereof; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> evidence or provide for a successor trustee, including the appointment thereof. </FONT></DD></DL>
</UL>
<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consent of the holders of notes is not necessary under the indenture to approve the particular form of any proposed modification or
amendment. It is sufficient if such consent approves the substance of the proposed modification or amendment. After a modification or amendment under the indenture becomes effective, we are required
to send to the holders a notice briefly describing such modification or amendment. However, the failure to give such notice to all the holders, or any defect in the notice, will not impair or affect
the validity of the modification or amendment. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notes Not Entitled to Consent  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any notes held by us or by any person directly or indirectly controlling or controlled by or under direct or indirect common control with us
shall be disregarded (from both the numerator and the denominator) for purposes of determining whether the holders of the requisite aggregate principal amount of the outstanding notes have consented
to a modification, amendment or waiver of the terms of the indenture. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Discharge  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may satisfy and discharge our obligations under the indenture by delivering to the securities registrar for cancellation all outstanding
notes or by irrevocably depositing with the trustee or delivering to the holders, as applicable, after all of the notes have (i)&nbsp;become due and payable, whether at maturity or at any
fundamental change repurchase date, and/or (ii)&nbsp;been converted (and the related consideration due upon conversion has been determined), cash or cash and/or shares of common stock (solely to
satisfy outstanding conversions), as applicable, sufficient to pay all of the outstanding notes and/or satisfy all conversions, as the case may be, and pay all other sums payable under the indenture
by us. Such discharge is subject to terms contained in the indenture. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Repurchase and Cancellation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may, to the extent permitted by law, repurchase any notes in the open market or by tender offer at any price or by private agreement. Any
notes repurchased by us may, at our option, be surrendered to the trustee for cancellation, but may not be reissued or resold by us. Any notes </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=61,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=78730,FOLIO='S-54',FILE='DISK128:[20ZBC1.20ZBC76301]DK76301A.;8',USER='CHE106460',CD='24-FEB-2020;00:34' -->
<A NAME="page_dk76301_1_55"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>surrendered
for cancellation may not be reissued or resold and will be promptly cancelled (other than notes purchased pursuant to cash-settled swaps or other derivatives). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> Reports  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture will provide that any documents or reports that we are required to file with the SEC pursuant to Section&nbsp;13 or 15(d) of
the Exchange Act must be filed by us with the trustee within 15&nbsp;days after the same are required to be filed with the SEC (giving effect to any grace period provided by Rule&nbsp;12b-25 or
any successor rule under the Exchange Act). Documents filed by us with the SEC via the EDGAR system (or any successor thereto) will be deemed to be filed with the trustee as of the time such documents
are filed via EDGAR (or such successor). The trustee shall have no obligation to determine if and when the Company's statements or reports are publicly available and/or accessible electronically.
Notwithstanding anything to the contrary, we shall in no event be required to file with, or otherwise provide or disclose to, the trustee or any holder any information for which we are seeking, or
have received, confidential treatment from the SEC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delivery
of the reports and documents delivered under the indenture to the trustee is for informational purposes only, and the trustee's receipt of such shall not constitute actual or
constructive notice or knowledge of any information contained therein or determinable from information contained therein, including our compliance with any of our covenants under the indenture (as to
which the trustee is entitled to conclusively rely on an officers' certificate). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Information Concerning the Trustee and Common Stock Transfer Agent and Registrar  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have appointed U.S. Bank National Association, the trustee under the indenture, as paying agent, conversion agent, notes registrar and
custodian for the notes. The trustee or its affiliates may also provide other services to us in the ordinary course of their business. The indenture will contain certain limitations on the rights of
the trustee, if it or any of its affiliates is then our creditor, to obtain payment of claims in certain cases or to realize on certain property received on any claim as security or otherwise. The
trustee and its affiliates will be permitted to engage in other transactions with us. However, if the trustee or any affiliate continues to have any conflicting interest and a default occurs with
respect to the notes, the trustee must eliminate such conflict or resign. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;American
Stock Transfer and Trust Company,&nbsp;LLC is the transfer agent and registrar for our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Governing Law  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The notes and the indenture, and any claim, controversy or dispute arising under or related to the indenture or the notes, will be governed by,
and construed in accordance with, the laws of the State of New York. The indenture will provide that we, the trustee and each holder (by its acceptance of any note) will irrevocably waive, to the
fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of, or relating to, the indenture, the notes or any transaction contemplated thereby. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Calculations in Respect of the Notes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will be responsible for making all calculations called for under the notes. These calculations include, but are not limited to,
determinations of the closing sale price of our common stock, the VWAP of our common stock, accrued interest payable on the notes, any additional interest due on the notes, the conversion rate and
conversion price, the daily conversion values and the additional shares. We or our agents will make all these calculations in good faith and, absent manifest error, such calculations will be final and
binding on holders of the notes. We will provide a schedule of these calculations to each of the trustee and the conversion agent, and each of the trustee and conversion </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=62,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=637017,FOLIO='S-55',FILE='DISK128:[20ZBC1.20ZBC76301]DK76301A.;8',USER='CHE106460',CD='24-FEB-2020;00:34' -->
<A NAME="page_dk76301_1_56"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>agent
is entitled to rely upon the accuracy of our calculations without independent verification. The trustee will forward these calculations to any holder of the notes upon the request of that
holder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> No Stockholder Rights for Holders of Notes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of notes, as such, will not have any rights as stockholders of the Company (including, without limitation, voting rights and rights to
receive any dividends or other distributions on our common stock). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> No Personal Liability of Directors, Officers, Employees or Stockholders  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of our past, present or future directors, officers, employees, incorporators, shareholders or partners, as such, will have any liability
for any of our obligations under the notes or the indenture or for any claim based on, or in respect of or by reason of, such obligations or their creation. By accepting a note, each holder waives and
releases all such liability. This waiver and release is part of the consideration for the issue of the notes. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> Form, Denomination and Registration  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The notes will be issued:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in fully registered form; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> without interest coupons; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in minimum denominations of $1,000 principal amount and integral multiples of $1,000 in excess thereof. </FONT></DD></DL>
</UL>
<UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Global Notes, Book-Entry Form  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The notes will be evidenced by one or more global notes. We will deposit the global notes with DTC and register the global notes in the name of
Cede&nbsp;&amp;&nbsp;Co. as DTC's nominee.
Except as set forth below, global notes may be transferred, in whole or in part, only to another nominee of DTC or to a successor of DTC or its nominee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
interests in a global note may be held through organizations that are participants in DTC (called "participants"). Transfers between participants will be effected in the
ordinary way in accordance with DTC rules and will be settled in clearing house funds. The laws of some states require that certain persons take physical delivery of securities in definitive form. As
a result, the ability to transfer beneficial interests in the global notes to such persons may be limited. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
interests in a global note held by DTC may be held only through participants, or certain banks, brokers, dealers, trust companies and other parties that clear through or
maintain a custodial relationship with a participant, either directly or indirectly (called "indirect participants"). So long as Cede&nbsp;&amp;&nbsp;Co., as the nominee of DTC, is the registered
owner of global notes, Cede&nbsp;&amp;&nbsp;Co. for all purposes will be considered the sole holder of such global notes. Except as provided below, owners of beneficial interests in a global note
will:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> not be entitled to have certificates registered in their names; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> not receive physical delivery of certificates in definitive registered form; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> not be considered holders of the global notes. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will pay principal of and interest on, and the fundamental change repurchase price of, the global notes to Cede&nbsp;&amp;&nbsp;Co., as the registered owner of the global notes, by
wire transfer of immediately available funds on the maturity date, each interest payment date or repurchase date, as the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=63,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=721865,FOLIO='S-56',FILE='DISK128:[20ZBC1.20ZBC76301]DK76301A.;8',USER='CHE106460',CD='24-FEB-2020;00:34' -->
<A NAME="page_dk76301_1_57"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>case
may be. Neither we, the trustee, conversion agent nor any paying agent will be responsible or liable:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for any aspect of the records relating to, or payments made on account of, beneficial ownership interests in a global note; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for maintaining, supervising or reviewing any records relating to the beneficial ownership interests. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DTC
has advised us that it will take any action permitted to be taken by a holder of the notes, including the presentation of the notes for conversion, only at the direction of one or
more participants to whose account with DTC interests in the global notes are credited, and only in respect of the principal amount of the notes represented by the global notes as to which the
participant or participants has or have given such direction. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DTC
has advised us that it is:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a limited purpose trust company organized under the laws of the State of New York, and a member of the Federal Reserve System; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a "clearing corporation" within the meaning of the Uniform Commercial Code; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a "clearing agency" registered pursuant to the provisions of Section&nbsp;17A of the Exchange Act. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DTC
was created to hold securities for its participants and to facilitate the clearance and settlement of securities transactions between participants through electronic book-entry
changes to the accounts of its participants. Participants include securities brokers, dealers, banks, trust companies and clearing corporations and other organizations. Some of the participants or
their representatives, together with other entities, own DTC. Indirect access to the DTC system is available to others such as banks, brokers, dealers and trust companies that clear through or
maintain a custodial relationship with a participant, either directly or indirectly. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DTC
has agreed to the foregoing procedures to facilitate transfers of interests in a global note among participants. However, DTC is under no obligation to perform or continue to
perform these procedures, and may discontinue these procedures at any time. Unless we agree otherwise, notes in physical, fully-registered certificated form will be issued and delivered to, and
registered in the name of, each person that DTC identifies as a beneficial owner of the related notes if:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> DTC notifies us at any time that it is unwilling or unable to continue as depositary for the global notes and a successor depositary is not
appointed within 60&nbsp;days; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> DTC ceases to be registered as a clearing agency under the Exchange Act and a successor depositary is not appointed within 60&nbsp;days; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an event of default with respect to the notes has occurred and is continuing and such beneficial owner requests that its notes be issued in
physical, certificated form. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None
of the Company, trustee, registrar, paying agent, conversion agent or any of our or their agents will have any responsibility or liability for the performance by DTC or its
participants or indirect participants of their respective obligations under the rules and procedures governing their operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=64,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=645423,FOLIO='S-57',FILE='DISK128:[20ZBC1.20ZBC76301]DK76301A.;8',USER='CHE106460',CD='24-FEB-2020;00:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dm76301_1_58"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DM"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section is a summary of material U.S. federal income tax considerations relating to the ownership and disposition of the notes and any
shares of our common stock into which the notes may be converted. This summary does not provide a complete analysis of all potential tax considerations. The information provided below is based on
existing U.S. federal income tax authorities, all of which are subject to change or differing interpretations, possibly with retroactive effect. There can be no assurance that the Internal Revenue
Service (the "IRS") will not challenge one or more of the tax consequences described herein, and we have not obtained, and do not intend to obtain, a ruling from the IRS with respect to the U.S.
federal income tax consequences of owning or disposing of the notes or common stock. This summary generally applies only to beneficial owners of the notes that purchase notes in this offering for an
amount equal to the "issue price" of the notes, which is the first price at which a substantial amount of the notes is sold for money to the public (not including sales to bond houses, brokers or
similar persons or organizations acting in the capacity of underwriter, initial purchasers, placement agents or wholesalers), and that hold the notes and common stock as "capital assets" (generally,
held for investment). This discussion does not purport to deal with all aspects of U.S. federal income taxation that may be relevant to a particular beneficial owner of notes and
common stock in light of the beneficial owner's circumstances (for example, persons subject to the alternative minimum tax provisions of the Internal Revenue Code of 1986, as amended (the "Code"), a
U.S. holder (as defined below) whose "functional currency" is not the U.S. dollar or purchasers of notes in this offering whose shares of common stock we are repurchasing in certain privately
negotiated transactions). Also, it is not intended to be wholly applicable to all categories of investors, some of which may be subject to special rules (such as dealers in securities, traders in
securities that elect to use a mark-to-market method of accounting, banks, thrifts, regulated investment companies, real estate investment trusts, insurance companies, tax-exempt entities,
tax-deferred or other retirement accounts, certain former citizens or residents of the United States, persons that are participating in the exchange transactions described above under "Use of
Proceeds," persons holding notes or common stock as part of a conversion or integrated transaction or straddle, or persons deemed to sell notes or common stock under the constructive sale provisions
of the Code). Finally, this summary does not address the potential application of the Medicare contribution tax, U.S. federal estate and gift tax laws or any non-U.S., state or local laws. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;INVESTORS
CONSIDERING THE PURCHASE OF NOTES SHOULD CONSULT THEIR OWN TAX ADVISORS REGARDING THE APPLICATION OF U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AND THE
CONSEQUENCES OF U.S. FEDERAL ESTATE AND GIFT TAX LAWS, NON-U.S., STATE AND LOCAL LAWS, AND TAX TREATIES. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
used herein, the term "U.S. holder" means a beneficial owner of notes or the common stock into which the notes may be converted that, for U.S. federal income tax purposes, is
(1)&nbsp;a citizen or individual resident of the United States, (2)&nbsp;a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or organized in or
under the laws of the United States or any state thereof or the District of Columbia, (3)&nbsp;an estate the income of which is subject to U.S. federal income taxation regardless of its source, or
(4)&nbsp;a trust if it (x)&nbsp;is subject to the primary supervision of a U.S. court and the control of one of more U.S. persons or (y)&nbsp;has a valid election in effect under applicable U.S.
Treasury Regulations to be treated as a U.S. person. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
"non-U.S. holder" means a beneficial owner (other than a partnership for U.S. federal income tax purposes) of notes or the common stock into which the notes may be converted that is
not a U.S. holder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a partnership (including any entity or arrangement treated as a partnership for U.S. federal income tax purposes) is a beneficial owner of a note or shares of our common stock
acquired upon conversion of a note, the tax treatment of a partner in the partnership will depend upon the status of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=65,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=266994,FOLIO='S-58',FILE='DISK128:[20ZBC1.20ZBC76301]DM76301A.;8',USER='CHE105948',CD='26-FEB-2020;12:36' -->
<A NAME="page_dm76301_1_59"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
partner and the activities of the partnership. Beneficial owners of notes or shares of our common stock acquired upon conversion of a note that is a partnership, and partners in such a
partnership, should consult their own tax advisors about the U.S. federal income tax consequences of owning and disposing of the notes and the shares of our common stock into which the notes may be
converted. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


U.S. Holders  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following discussion is limited to U.S. federal income tax consequences relevant to a U.S. holder (as defined above). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Issue Price and Basis in the Notes  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The "issue price" of a note is generally the first price at which a substantial amount of the notes is sold for money to the public (not
including sales to bond houses, brokers, or similar persons or organizations acting in the capacity of underwriters, initial purchasers, placement agents or wholesalers). In this offering, the
underwriters will buy the notes from us for a fixed price but with no limitation on the price at which the underwriters can resell the notes to investors. As a result, at the time of the original
issuance of the notes we may not know the "issue price" of the notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
general, if the stated principal amount of a debt instrument exceeds its issue price by at least a statutorily defined </FONT><FONT SIZE=2><I>de minimis</I></FONT><FONT SIZE=2>
amount, a U.S. holder will be required to include such excess in income as "original issue discount" over the term of the instrument in accordance with a constant-yield method, irrespective of the
U.S. holder's regular method of tax accounting. Generally, original issue discount is considered to be </FONT><FONT SIZE=2><I>de minimis</I></FONT><FONT SIZE=2> if it is less than 0.25% of the
instrument's stated principal amount multiplied by the number of complete years from the issue date to maturity. We anticipate, and therefore this discussion assumes, that the notes will not be issued
with original issue discount for U.S. federal income tax purposes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the IRS were to successfully challenge our determination of the issue price for the notes, the income tax consequences for a U.S. holder might be materially different than as
described below. For example, the notes may be considered to have original issue discount (or a greater amount of original issue
discount) which may adversely affect the market value of the notes. U.S. holders should consult their own tax advisors as to the income tax consequences to them of such a successful challenge under
the circumstances of this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
U.S. holder's initial tax basis in the notes should be equal to the price paid by the holder. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interest  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A U.S. holder will be required to recognize as ordinary income any stated interest paid or accrued on the notes, in accordance with its regular
method of tax accounting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may be required to make payments of additional interest to holders of the notes if we do not make certain filings, as described under "Description of the Notes&#151;Events of
Default; Notice and Waiver" above. We believe that there is only a remote possibility that we would be required to pay additional interest, and therefore we do not intend to treat the notes as subject
to the special rules governing certain "contingent payment debt instruments" (which, if applicable, would affect the timing, amount and character of income with respect to a note). Our determination
in this regard, while not binding on the IRS, is binding on U.S. holders unless they disclose their contrary position in the manner prescribed under U.S. Treasury Regulations. If, contrary to
expectations, we pay additional interest, although it is not free from doubt, such additional interest should be taxable to a U.S. holder as ordinary interest income at the time it accrues or is paid,
in accordance with the U.S. holder's regular method of tax accounting. In the event we pay additional interest on the notes, U.S. holders </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=66,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=697035,FOLIO='S-59',FILE='DISK128:[20ZBC1.20ZBC76301]DM76301A.;8',USER='CHE105948',CD='26-FEB-2020;12:36' -->
<A NAME="page_dm76301_1_60"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>should
consult their own tax advisors regarding the treatment of such amounts. The remainder of this discussion assumes that the notes are not treated as contingent payment debt instruments. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sale, Exchange or Other Taxable Disposition of the Notes  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A U.S. holder generally will recognize capital gain or loss if it disposes of a note in a sale, exchange or other taxable disposition (other
than conversion of a note, the U.S. federal income tax consequences of which are described under "&#151;Conversion of Notes" below). The U.S. holder's gain or loss generally will equal the
difference between the amount realized by it (other than amounts attributable to accrued but unpaid interest) and its tax basis in the note. The U.S. holder's tax basis in the note generally will
equal the amount it paid for the note. The portion of any amount realized that is attributable to accrued interest will not be taken into account in computing the U.S. holder's capital gain or loss.
Instead, that portion will be recognized as ordinary interest income to the extent that the U.S. holder has not previously included the accrued interest in income. The gain or loss recognized by the
U.S. holder on the disposition of the note will be long-term capital gain or loss if it has held the note for more than one year, or short-term capital gain or loss if it has held the note for one
year or less, at the time of the disposition. Long-term capital gains of non-corporate taxpayers currently are taxed at preferential rates. Short-term capital gains are taxed at ordinary income rates.
The deductibility of capital losses is subject to limitations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion of Notes  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If a U.S. holder receives solely cash in exchange for notes upon conversion, the U.S. holder's gain or loss will be determined in the same
manner as if the U.S. holder had disposed of the notes in a taxable disposition (as described above under "&#151;Sale, Exchange or Other Taxable Disposition of the Notes"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
U.S. holder generally should not recognize any gain or loss on the conversion of a note solely into shares of our common stock, except with respect to (i)&nbsp;cash received in lieu
of a fractional share of common stock and (ii)&nbsp;the fair market value of any common stock attributable to accrued and unpaid interest. The U.S. holder's tax basis in the common stock received
(including any fractional share for which cash is paid, but excluding shares attributable to accrued and unpaid interest) generally will equal its tax basis in the converted note. The U.S. holder's
holding period in the common stock (other than shares attributable to accrued and unpaid interest) will include the holding period in the converted note. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
tax consequences of the conversion of a note into a combination of cash and shares of our common stock are not entirely certain. A U.S. holder may be treated as exchanging the note
for our common stock and cash in a recapitalization for U.S. federal income tax purposes. In such case, the U.S. holder would not be permitted to recognize loss, but would be required to recognize
capital gain. The amount of any capital gain recognized by a U.S. holder would equal the lesser of (i)&nbsp;the excess (if
any) of (A)&nbsp;the amount of cash received (excluding any cash received in lieu of a fractional share of our common stock or attributable to accrued and unpaid interest) plus the fair market value
of our common stock received (treating a fractional share of our common stock as issued and received for this purpose and excluding any such common stock that is attributable to accrued and unpaid
interest) upon conversion over (B)&nbsp;the U.S. holder's tax basis in the converted note, and (ii)&nbsp;the amount of cash received upon conversion (other than any cash received in lieu of a
fractional share of our common stock or attributable to accrued and unpaid interest). The gain recognized by a U.S. holder upon conversion of a note would be long-term capital gain if the U.S. holder
held the note for more than one year, or short-term capital gain if the U.S. holder held the note for one year or less, at the time of the conversion. Long-term capital gains of non-corporate
taxpayers currently are taxed at preferential rates. Short-term capital gains are taxed at ordinary income rates. The U.S. holder's tax basis in the common stock received (including any fractional
share for which cash is paid, but excluding shares </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=67,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=248105,FOLIO='S-60',FILE='DISK128:[20ZBC1.20ZBC76301]DM76301A.;8',USER='CHE105948',CD='26-FEB-2020;12:36' -->
<A NAME="page_dm76301_1_61"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>attributable
to accrued and unpaid interest) generally would equal its tax basis in the converted note, decreased by the amount of cash received (other than cash in lieu of a fractional share of
common stock or attributable to accrued and unpaid interest), and increased by the amount of gain (if any) recognized upon conversion (other than any gain recognized as a result of cash received in
lieu of a fractional share of common stock). The U.S. holder's holding period in the common stock (other than shares attributable to accrued and unpaid interest) would include the holding period in
the converted note. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alternatively,
the conversion of a note into a combination of cash and shares of our common stock may be treated as in part&nbsp;a payment in redemption for cash of a portion of the
note and in part&nbsp;a conversion of a portion of the note into common stock. In such case, a U.S. holder's aggregate tax basis in the note would be allocated between the portion of the note
treated as redeemed and the portion of the note treated as converted into common stock on a pro rata basis. The U.S. holder generally would recognize capital gain or loss with respect to the portion
of the note treated as redeemed equal to the difference between the amount of cash received by the U.S. holder (other than amounts attributable to accrued and unpaid interest) and the U.S. holder's
tax basis in the portion of the note treated as redeemed. See "&#151;Sale, Exchange or Other Taxable Disposition of the Notes" above. With respect to the portion of the note treated as
converted, a U.S. holder generally would not recognize any gain or loss (except with respect to cash received in lieu of a fractional share of common stock). The tax basis allocated to the portion of
the note treated as converted into common stock would be the U.S. holder's tax basis in the common stock (including any fractional share for which cash is paid). The U.S. holder's holding period in
the common stock (other than shares attributable to accrued interest) would include the U.S. holder's holding period in the converted note. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to cash received in lieu of a fractional share of our common stock, a U.S. holder will be treated as if the fractional share were issued and received and then immediately
redeemed for cash. Accordingly, the U.S. holder generally will recognize gain or loss equal to the difference between the cash received for the fractional share and that portion of the holder's tax
basis in the common stock (determined as discussed above) attributable to the fractional share, which will be long-term capital
gain or loss if the U.S. holder held the note for more than one year, or short-term capital gain or loss if the U.S. holder held the note for one year or less, at the time of the conversion. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
cash and the fair market value of any portion of our common stock that is attributable to accrued and unpaid interest on the notes not yet included in income by a U.S. holder will
be taxed as ordinary income. A U.S. holder's basis in any shares of common stock attributable to accrued and unpaid interest will equal the fair market value of such shares when received. A U.S.
holder's holding period in any shares of common stock attributable to accrued and unpaid interest will begin on the day after they are received. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we undergo a transaction of the type described under "Description of the Notes&#151;Conversion Rights&#151;Change in the Conversion Rights Upon Certain
Reclassifications, Business Combinations, Asset Sales and Corporate Events," the conversion obligation may be adjusted so that holders would be entitled to convert the notes into the type of
consideration that they would have been entitled to receive upon such transaction had the notes been converted into shares of our common stock immediately prior to such transaction. Depending on the
facts and circumstances at the time of such transaction, such adjustment may result in a deemed exchange of the outstanding notes, which may be a taxable event for U.S. federal income tax purposes.
U.S. holders are urged to consult their tax advisors regarding the U.S. federal income tax consequences of such an adjustment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Distributions  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, after a U.S. holder acquires shares of our common stock upon a conversion of a note, we make a distribution in respect of such common stock
from our current or accumulated earnings and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-61</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=68,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=855484,FOLIO='S-61',FILE='DISK128:[20ZBC1.20ZBC76301]DM76301A.;8',USER='CHE105948',CD='26-FEB-2020;12:36' -->
<A NAME="page_dm76301_1_62"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>profits
(as determined for U.S. federal income tax purposes), the distribution will be treated as a dividend and will be includible in a U.S. holder's income as ordinary income when received. If the
distribution exceeds our current and accumulated earnings and profits, the excess will be treated first as a tax-free return of the U.S. holder's tax basis in its shares of common stock and any
remaining excess will be treated as capital gain from the sale or exchange of the common stock. If the U.S. holder is a corporation, it generally will be able to claim a dividends-received deduction
on a portion of any distribution taxed as a dividend, provided that certain holding period requirements are satisfied. Subject to certain exceptions, dividends received by certain non-corporate U.S.
holders currently are taxed at
the preferential rates applicable to long-term capital gains, provided that certain holding period requirements are met. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Constructive Distributions  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The terms of the notes allow for changes in the conversion rate of the notes under certain circumstances. A change in conversion rate that
allows beneficial owners of notes to receive more shares of common stock on conversion may increase such beneficial owners' proportionate interests in our earnings and profits or assets. In that case,
the beneficial owners of notes may be treated as though they received a taxable distribution in the form of our common stock or additional rights to acquire our common stock. A taxable constructive
distribution would result, for example, if the conversion rate is adjusted to compensate beneficial owners of notes for distributions of cash or property to our stockholders. The adjustment to the
conversion rate of notes converted in connection with a make-whole fundamental change, as described under "Description of the Notes&#151;Conversion Rights&#151;Adjustment to Conversion
Rate Upon a Make-Whole Fundamental Change," also may be treated as a taxable distribution. If an event occurs that dilutes the interests of stockholders or increases the interests of beneficial owners
of the notes and the conversion rate of the notes is not adjusted (or not adequately adjusted), this also could be treated as a taxable stock distribution to beneficial owners of the notes.
Conversely, if an event occurs that dilutes the interests of beneficial owners of the notes and the conversion rate is not adjusted (or not adequately adjusted), the resulting increase in the
proportionate interests of our stockholders could be treated as a taxable stock distribution to the stockholders. Not all changes in the conversion rate that result in beneficial owners of notes
receiving more common stock on conversion, however, increase such beneficial owners' proportionate interests in us. For instance, a change in conversion rate could simply prevent the dilution of the
beneficial owners' interests upon a stock split or other change in capital structure. Changes to the conversion rate made pursuant to a </FONT><FONT SIZE=2><I>bona fide</I></FONT><FONT SIZE=2>
reasonable adjustment formula are not treated as constructive distributions. Any taxable constructive distribution would be treated for U.S. federal income tax purposes in the same manner as an actual
distribution on our common stock as described in "&#151;Distributions" above. A taxable constructive distribution would result in a taxable dividend to beneficial owners to the extent of our
current or accumulated earnings and profits (with the beneficial owner's tax basis in its note or common stock (as the case may be) being increased by the amount of such dividend), with any excess
treated first as a tax-free return of the beneficial owner's tax basis in its note or common stock (as the case may be) and then as capital gain from the sale or exchange of its note or common stock
(as the case may be). Non-corporate U.S. holders should consult their tax advisors regarding whether any taxable constructive dividend would be eligible for preferential rates and corporate holders
should consult their tax advisors regarding the dividends-received deduction, both described in "&#151;Distributions" above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
April&nbsp;12, 2016, the IRS issued proposed U.S. Treasury Regulations that address the amount and timing of constructive distributions, obligations of withholding agents and
filing and notice obligations of issuers. The proposed U.S. Treasury Regulations, if adopted as proposed, would provide generally that (1)&nbsp;the amount of a constructive distribution is the
excess of (a)&nbsp;the fair market value of the right to acquire shares immediately after an "applicable adjustment," over (b)&nbsp;the fair market value of the right to acquire shares without the
adjustment, (2)&nbsp;the constructive distribution occurs at the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-62</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=69,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=56915,FOLIO='S-62',FILE='DISK128:[20ZBC1.20ZBC76301]DM76301A.;8',USER='CHE105948',CD='26-FEB-2020;12:36' -->
<A NAME="page_dm76301_1_63"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>earlier
of (a)&nbsp;the date the adjustment occurs under the terms of the notes, and (b)&nbsp;the date of the actual distribution of cash or property that results in the constructive distribution,
and (3)&nbsp;information reporting is required regarding the amount of any constructive distribution. Although the proposed U.S. Treasury Regulations would be effective for constructive
distributions occurring on or after the date on which the proposed U.S. Treasury Regulations are adopted as final, investors and withholding agents may rely on them prior to that date under certain
circumstances. Any backup withholding required with respect to such a constructive distribution may be satisfied by withholding such amounts from shares or current or subsequent payments of cash
payable to such U.S. holder. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sale, Exchange or Other Disposition of Common Stock  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A U.S. holder generally will recognize capital gain or loss on a sale, exchange or other disposition of shares of our common stock. The U.S.
holder's gain or loss will equal the difference between the amount realized by the holder and its tax basis in the shares of common stock. The amount realized by the U.S. holder will include the
amount of any cash and the fair market value of any other property received for the shares of common stock. The gain or loss recognized by a U.S. holder on a sale, exchange or other disposition of
shares of our common stock will be long-term capital gain or loss if its holding period in the shares of common stock is more than one year, or short-term capital gain or loss if its holding period in
the shares of common stock is one year or less, at the time of the transaction. Long-term capital gains of non-corporate taxpayers are currently taxed at preferential rates. Short-term capital gains
are taxed at ordinary income rates. The deductibility of capital losses is subject to limitations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-U.S. Holders  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following discussion is limited to U.S. federal income tax consequences relevant to a non-U.S. holder (as defined above). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interest  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the discussions below regarding backup withholding and FATCA and under "&#151;Income or Gains Effectively Connected with a
U.S. Trade or Business," payments of interest on the notes to non-U.S. holders generally will qualify as "portfolio interest," and thus will be exempt from U.S. federal income tax, including
withholding of such tax, if the non-U.S. holder certifies its non-U.S. status as described below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
portfolio interest exemption will not apply to payments of interest to a non-U.S. holder that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> owns, actually or constructively, shares of our stock representing at least 10% of the total combined voting power of all classes of our stock
entitled to vote; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> is a "controlled foreign corporation" that is related, directly or indirectly, to us through sufficient actual or constructive stock ownership. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>The
portfolio interest exemption applies only if the non-U.S. holder certifies its non-U.S. status. A non-U.S. holder can meet this certification requirement by providing a properly completed and
executed IRS Form&nbsp;W-8BEN or W-8BEN-E or appropriate substitute form prior to the payment. If the non-U.S. holder holds the note through a financial institution or other agent acting on its
behalf, it will be required to provide appropriate documentation to the agent. Special certification rules apply to non-U.S. holders that are pass-through entities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-63</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=70,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=228481,FOLIO='S-63',FILE='DISK128:[20ZBC1.20ZBC76301]DM76301A.;8',USER='CHE105948',CD='26-FEB-2020;12:36' -->
<A NAME="page_dm76301_1_64"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Distributions  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the discussion below under "&#151;Income or Gains Effectively Connected with a U.S. Trade or Business" and the discussions
below regarding backup withholding and FATCA, dividend distributions paid to a non-U.S. holder with respect to shares of our common stock into which the notes may be converted, as well as any taxable
constructive dividends resulting from certain adjustments (or failure to make, or adequately make, adjustments) to the number of shares of common stock to be issued upon conversion of a note (as
described under "&#151;U.S. Holders&#151;Constructive Distributions" above), generally will be subject to U.S. withholding tax at a 30% rate. The withholding tax on dividends (including
any taxable constructive dividends), however, may be reduced under the terms of an applicable income tax treaty between the United States and the non-U.S. holder's country of residence. A non-U.S.
holder should demonstrate his, her or its eligibility for a reduced rate of withholding under an applicable income tax treaty by timely delivering a properly completed and executed IRS
Form&nbsp;W-8BEN or W-8BEN-E or appropriate substitute form prior to the payment. A non-U.S. holder that is eligible for a reduced rate of withholding under the terms of an applicable income tax
treaty may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Because a taxable constructive dividend received by a non-U.S. holder would not
give rise to any cash from which any applicable withholding tax could be satisfied, if a withholding agent pays withholding taxes on the non-U.S. holder's behalf with respect to amounts which are
includible in the non-U.S. holder's income but which are not paid in cash, the withholding agent may set off any such withholding tax against any other payments owed to the non-U.S. holder, including
cash payments of interest payable on the notes, shares of our common stock or cash payable upon conversion, or proceeds from a sale subsequently paid or credited to the non-U.S. holder. Non-U.S.
holders should consult their tax advisors as to whether they can obtain a refund for all or a portion of any tax withheld. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sale, Exchange, Conversion or Other Taxable Dispositions of Notes or Common Stock  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the discussion below regarding backup withholding, non-U.S. holders generally will not be subject to U.S. federal income or
withholding tax on any gain realized on the sale, exchange, conversion or other disposition of notes or shares of our common stock (other than with respect to payments attributable to accrued
interest, which will be taxed as described under "&#151;Interest" above) unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the gain is effectively connected with the conduct by the non-U.S. holder of a U.S. trade or business (and, generally, if required by an
applicable income tax treaty, is attributable to a U.S. permanent establishment or fixed base maintained by the non-U.S. holder), in which case the gain would be subject to tax as described below
under "&#151;Income or Gains Effectively Connected with a U.S. Trade or Business"; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the non-U.S. holder is an individual who is present in the United States for 183&nbsp;days or more in the year of disposition and certain
other conditions apply, in which case, except as otherwise provided by an applicable income tax treaty, the gain, which may be offset by certain U.S.-source capital losses, would be subject to a flat
30% tax, even though the individual is not considered a resident of the United States; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the rules of the Foreign Investment in Real Property Tax Act (or "FIRPTA") (described below) treat the gain as effectively connected with a
U.S. trade or business. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FIRPTA rules may apply to a sale, exchange or other disposition of notes or shares of our common stock by a non-U.S. holder if, at any time during the five-year period ending on the
date of the sale, exchange or other disposition (or, if shorter, the non-U.S. holder's holding period for the notes or common stock disposed of), we are or were a "United States real property holding
corporation" (or "USRPHC") for U.S. federal income tax purposes. In general, we would be a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-64</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=71,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=410281,FOLIO='S-64',FILE='DISK128:[20ZBC1.20ZBC76301]DM76301A.;8',USER='CHE105948',CD='26-FEB-2020;12:36' -->
<A NAME="page_dm76301_1_65"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>USRPHC
if interests in U.S. real estate composed at least 50% of the fair market value of our worldwide real property interests and assets used or held for use in a trade or business. We believe that
we currently are not, and will not become in the future, a USRPHC. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income or Gains Effectively Connected with a U.S. Trade or Business  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any interest or constructive dividends on the notes, dividends on shares of our common stock, or gain from the sale, exchange, conversion or
other disposition of the notes or shares of our common stock is effectively connected with a U.S. trade or business conducted by a non-U.S. holder, then the income or gain will be subject to U.S.
federal income tax on a net-income basis at the regular graduated rates and generally in the same manner applicable to U.S. holders. If the non-U.S. holder is eligible for the benefits of a tax treaty
between the United States and the non-U.S. holder's country of residence, any "effectively connected" income or gain generally will be subject to U.S. federal income tax on a net-income basis only if
it is also attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United States. Payments of interest or dividends that are effectively connected with a U.S.
trade or business conducted by the non-U.S. holder (and, if an applicable tax treaty requires, attributable to a U.S. permanent establishment or fixed base), and therefore included in the gross income
of a non-U.S. holder, will not be subject to 30% withholding, provided that it claims exemption from withholding by timely filing a properly completed and executed IRS Form&nbsp;W-8ECI, or any
appropriate substitute or successor form as the IRS designates, as applicable, prior to payment. If the non-U.S. holder is a corporation for U.S. federal income tax purposes, that portion of its
earnings and profits that is effectively connected with its U.S. trade or business generally also will be subject to a "branch profits tax." The branch profits tax rate is generally 30%, although an
applicable income tax treaty might provide for a lower rate. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Backup Withholding and Information Reporting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Code and U.S. Treasury Regulations generally require persons who make specified payments to report the payments to the IRS. Among the
specified payments are interest, dividends, and proceeds paid by brokers to their customers. This reporting regime is reinforced by "backup withholding" rules, which generally require the payor to
withhold from payments subject to information reporting if the recipient has failed to provide a taxpayer identification number to the payor, furnished an incorrect identification number, failed to
comply with applicable certification requirements or been repeatedly notified by the IRS that it has failed to report interest or dividends on its U.S. federal income tax returns. The backup
withholding rate is currently 24%. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments
of interest or dividends (including constructive dividends) to U.S. holders of notes or shares of our common stock and payments made to U.S. holders by a broker upon a sale of
notes or common stock generally will be subject to information reporting and backup withholding, unless the U.S. holder (1)&nbsp;is an exempt recipient, or (2)&nbsp;in the case of backup
withholding, provides the payor with a correct taxpayer identification number and complies with applicable certification requirements. If a sale is made through a foreign office of a foreign broker,
however, the sale generally will not be subject to either information reporting or backup withholding. This exception may not apply if the foreign broker is owned or controlled by U.S. persons, or is
engaged in a U.S. trade or business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
applicable withholding agent must report annually to the IRS the interest and/or dividends (including constructive dividends) paid to each non-U.S. holder and the amount of tax
withheld, if any, with respect to such interest and/or dividends, including any tax withheld pursuant to the rules described under "&#151;Non-U.S. Holders&#151;Interest" and
"&#151;Non-U.S. Holders&#151;Dividends" above and "&#151;FATCA" below. Copies of these reports may be made available to tax authorities in the country where the non-U.S. holder
resides. Payments to non-U.S. holders of dividends on our common stock or interest or constructive dividends on the notes may be subject to backup withholding unless the non-U.S. holder certifies its
non-U.S. status on a properly completed and executed IRS Form&nbsp;W-8BEN </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-65</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=72,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=740519,FOLIO='S-65',FILE='DISK128:[20ZBC1.20ZBC76301]DM76301A.;8',USER='CHE105948',CD='26-FEB-2020;12:36' -->
<A NAME="page_dm76301_1_66"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>or
W-8BEN-E or appropriate substitute form. Payments made to non-U.S. holders by a broker upon a sale of the notes or our common stock will not be subject to information reporting or backup
withholding as long as the non-U.S. holder certifies its non-U.S. status or otherwise establishes an exemption. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
amounts withheld from a payment to a U.S. holder or non-U.S. holder with respect to the notes or shares of our common stock under the backup withholding rules generally will be
allowed as a refund or can be credited against any U.S. federal income tax liability of the holder, provided the required information is timely furnished to the IRS. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FATCA  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Foreign Account Tax Compliance Act (commonly referred to as "FATCA") and the U.S. Treasury Regulations promulgated thereunder generally
impose a withholding tax of 30% on payments of certain U.S.-source income ("Withholdable Payments") to foreign financial institutions (whether as a beneficial owner or intermediary), unless such
institution (i)&nbsp;enters into an agreement with the U.S. Treasury Department to collect and provide to the Treasury Department substantial information regarding its U.S. account holders,
including certain account holders that are foreign entities with U.S. owners, (ii)&nbsp;satisfies the requirements of an intergovernmental agreement entered into by such institution's country of
residence and the United States, or (iii)&nbsp;qualifies for an exemption. FATCA also generally imposes a withholding tax of 30% on Withholdable Payments made to a non-financial foreign entity
unless such entity provides the withholding agent with certification that it does not have any substantial U.S. owners or a certification identifying the direct and indirect substantial U.S. owners of
the entity, or unless an exemption applies. An intergovernmental agreement between the United States and the non-U.S. entity's jurisdiction may modify these requirements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FATCA withholding requirements generally currently apply to payments of interest and dividends (including constructive dividends) on the notes or shares of our common stock. If
FATCA withholding is imposed, a beneficial owner (other than certain foreign financial institutions) generally will be entitled to a refund of any amounts withheld by filing a U.S. federal income tax
return and, in the case of a non-financial foreign entity, providing the IRS with certain information regarding its substantial U.S. owners (unless an exception applies). Under recently proposed U.S.
Treasury Regulations (the preamble to which specifies that taxpayers are permitted to rely on them pending finalization), no withholding will apply on payments of gross proceeds. Holders of our notes
and common stock are urged to consult with their own tax advisors regarding the effect, if any, of the FATCA provisions to them based on their particular circumstances. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-66</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=73,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=117662,FOLIO='S-66',FILE='DISK128:[20ZBC1.20ZBC76301]DM76301A.;8',USER='CHE105948',CD='26-FEB-2020;12:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_do76301_1_67"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DO1"></A>UNDERWRITING  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions set forth in the underwriting agreement, dated February&nbsp;24, 2020, between us and BofA
Securities,&nbsp;Inc., as representative of each of the underwriters named below, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to
purchase from us, the principal amount of notes set forth opposite its name below. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="83pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Underwriter

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Principal<BR>
Amount of<BR>
Notes </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BofA Securities, Inc.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>900,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert W. Baird &amp; Co. Incorporated</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cowen and Company, LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Blair &amp; Company, L.L.C.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BTIG, LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,500,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stifel, Nicolaus &amp; Company, Incorporated</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,500,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,000,000,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed, severally and not jointly, to purchase all of the notes sold under the
underwriting agreement (other than the notes covered by the over-allotment option described below) if any of these notes are purchased. The obligations of the underwriters under the underwriting
agreement are subject to the satisfaction of certain conditions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required
to make in respect of those liabilities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters are offering the notes, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, including the
validity of the notes, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer's certificates and legal opinions. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Commissions and Discounts  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The underwriters propose initially to offer the notes at a price of 100.0% of the principal amount of notes, plus accrued interest from the
original issue date of the notes, if any, and to dealers at that price less a concession not in excess of 1.320% of the principal amount of the notes, plus accrued interest from the original issue
date of the notes, if any. After the initial offering, the public offering price, concession or any other term of the offering may be changed. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows the public offering price, underwriting discount and proceeds before expenses to us. The information assumes either no exercise or full exercise by the
underwriters of their option to purchase additional notes pursuant to the over-allotment option described below. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="83pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="83pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per Note </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Without<BR>
Option </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>With<BR>
Option </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Public offering price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,000,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,150,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discount</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,300,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds, before expenses, to us</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>97.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>978,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,124,700,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-67</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=74,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=609559,FOLIO='S-67',FILE='DISK128:[20ZBC1.20ZBC76301]DO76301A.;31',USER='CHE107555',CD='26-FEB-2020;11:06' -->
<A NAME="page_do76301_1_68"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
expenses of the offering, not including the underwriting discount, are estimated at $2.45&nbsp;million and are payable by us. We have agreed to reimburse the underwriters in an
amount of up to $15,000 for expenses relating to the compliance of this offering with the rules of the Financial Industry Regulatory Authority,&nbsp;Inc. ("FINRA"). In accordance with FINRA
Rule&nbsp;5110, this reimbursed FINRA fee is deemed underwriting compensation for this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters have agreed to reimburse us for certain fees, costs and expenses and other amounts related to or in connection with this offering in the amount of approximately
$2.45&nbsp;million. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Over-allotment Option  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have granted an option to the underwriters to purchase up to an additional $150.0&nbsp;million principal amount of the notes at the public
offering price, less the underwriting discount, solely to cover over-allotments, if any. The underwriters may exercise this option for 30&nbsp;days from the date of this prospectus supplement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


New Issue of Notes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The notes are a new issue of securities with no established trading market. We do not intend to apply for listing of the notes on any national
securities exchange or for inclusion of the notes on any automated dealer quotation system. We have been advised by certain of the underwriters that they presently intend to make a market in the notes
after completion of the offering. However, they are under no obligation to do so and may discontinue any market-making activities at any time without any notice. We cannot assure the liquidity of the
trading market for the notes or that an active public market for the notes will develop. If an active public trading market for the notes does not develop, the market price and liquidity of the notes
may be adversely affected. If the notes are traded, they may trade at a discount from their initial offering price, depending on prevailing interest rates, the market for similar securities, our
operating performance and financial condition, general economic conditions and other factors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Listing  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on the Nasdaq Capital Market under the trading symbol "EXAS". </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company,&nbsp;LLC. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


No Sales of Similar Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We and our executive officers and directors have agreed, subject to certain exceptions, not to, directly or indirectly, for a period of
60&nbsp;days after the date of the underwriting agreement relating to this offering without the prior written consent of BofA Securities,&nbsp;Inc.:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> sell, offer, contract or grant any option to sell (including without limitation any short sale), pledge, transfer, establish an open "put
equivalent position" within the meaning of Rule&nbsp;16a-1(h) under the Exchange Act, as amended, or otherwise dispose of any common stock, options or warrants to acquire common stock, or securities
exchangeable or exercisable for or convertible into common stock currently or hereafter owned either of record or beneficially (as defined in Rule&nbsp;13d-3 under the Exchange Act, as amended) or
publicly announce the intention to do any of the foregoing, or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> with respect to us, announce the offering of, or file any registration statement or make a confidential submission under the Securities Act in
respect of any shares of common stock, options, rights or warrants to acquire shares of common stock or securities exchangeable or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-68</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=75,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=397420,FOLIO='S-68',FILE='DISK128:[20ZBC1.20ZBC76301]DO76301A.;31',USER='CHE107555',CD='26-FEB-2020;11:06' -->
<A NAME="page_do76301_1_69"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>exercisable
for or convertible into shares of common stock or publicly announce the intention to do any of the foregoing. </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the lock-up period, our executive officers and directors are permitted to sell shares of our common stock pursuant to their trading plans in existence on the date hereof that
satisfy the requirements of Rule&nbsp;10b5-1 under the Exchange Act (a "Rule&nbsp;10b5-1 Plan"); provided, however, if a filing under Section&nbsp;16 of the Exchange Act is required or otherwise
made with respect to such sales,
these individuals will disclose in such filing that the transaction was effectuated pursuant to an existing Rule&nbsp;10b5-1 Plan and no party to such sale shall otherwise voluntarily effect any
public filing or report regarding such sale. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
executive officers and directors may establish Rule&nbsp;10b5-1 Plans during the lock-up period, provided, that (i)&nbsp;such executive officers and directors are not required
to and do not otherwise effect any public filing or report regarding the establishment of such plans during the lock-up period and (ii)&nbsp;no sales are made during the lock-up period pursuant to
such plans. During the lock-up period, we are also permitted to announce the establishment of such plans and that sales will occur after the end of the lock-up period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the lock up restrictions described above, we will be allowed to issue up to an aggregate of 500,000 shares of our common stock and file a prospectus supplement to
register such shares under the Securities Act for the resale thereof, in connection with recent strategic acquisitions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to this offering only, our executive officers and directors waived any registration rights relating to registration under the Securities Act of any common stock owned
either of record or beneficially by the them, including any rights to receive notice of the offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BofA
Securities,&nbsp;Inc. may, in its sole discretion and at any time or from time to time, with or without notice, before the termination of the 60-day period release all or any
portion of the securities subject to lock-up agreements. There are no existing agreements between the underwriters and any of our directors and executive officers who have executed a lock-up
agreement, providing consent to the sale of shares prior to the expiration of the lock-up period. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Price Stabilization, Short Positions, the Exchange Transactions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the offering, the underwriters may purchase and sell the notes or shares of our common stock in the open market. These
transactions may include short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater
principal amount of notes than they are required to purchase in the offering. "Covered" short sales are sales made in an amount not greater than the underwriters' option to purchase additional notes
described above. The underwriters may close out any covered short position by either exercising their option to purchase additional notes or purchasing notes in the open market. In determining the
source of notes to close out the covered short position, the underwriters will consider, among other things, the price of notes available for purchase in the open market as compared to the price at
which they may purchase notes through the option granted to them. "Naked" short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing notes
in the open market. A naked short position is more
likely to be created if the underwriters are concerned that there may be downward pressure on the price of the notes in the open market after pricing that could adversely affect investors who purchase
in the offering. Stabilizing transactions consist of various bids for or purchases of notes or shares of our common stock made by the underwriters in the open market to peg, fix or maintain the price
of the notes or our common stock prior to the completion of the offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Similar
to other purchase transactions, the underwriters' purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of the notes or
preventing or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-69</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=76,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=204903,FOLIO='S-69',FILE='DISK128:[20ZBC1.20ZBC76301]DO76301A.;31',USER='CHE107555',CD='26-FEB-2020;11:06' -->
<A NAME="page_do76301_1_70"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>retarding
a decline in the market price of the notes. As a result, the price of the notes may be higher than the price that might otherwise exist in the open market. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
we nor the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of the
notes or our common stock. In addition, neither we nor the underwriters make any representation that the underwriters will engage in these transactions or that these transactions, once commenced, will
not be discontinued without notice. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Relationships  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The underwriters and their affiliates are full service financial institutions engaged in various activities, which may include sales and
trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial
activities and services. The underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business
with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BofA
Securities, Inc. or certain of its affiliates are holders of the 2025 notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt and equity
securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views
in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Electronic Distribution  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the offering, the underwriters or certain of the securities dealers may distribute this prospectus supplement and the
accompanying prospectus by electronic means, such as e-mail. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-70</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=77,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=72541,FOLIO='S-70',FILE='DISK128:[20ZBC1.20ZBC76301]DO76301A.;31',USER='CHE107555',CD='26-FEB-2020;11:06' -->
<A NAME="page_do76301_1_71"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DO2"></A>NOTICE TO INVESTORS  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


European Economic Area and the United Kingdom  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to
any retail investor in the European Economic Area ("EEA") or in the United Kingdom ("UK"). For these purposes, a retail investor means a person who is one (or more) of: (i)&nbsp;a retail client as
defined in point (11)&nbsp;of Article&nbsp;4(1) of Directive 2014/65/EU (as amended, "MiFID II"); or (ii)&nbsp;a customer within the meaning of Directive (EU) 2016/97 (as amended, the "Insurance
Distribution Directive"), where that customer would not
qualify as a professional client as defined in point (10)&nbsp;of Article&nbsp;4(1) of MiFID II; or (iii)&nbsp;not a qualified investor as defined in Regulation (EU) 2017/1129 (as amended, the
"Prospectus Regulation"). Consequently no key information document required by Regulation (EU) No 1286/2014 (as amended, the "PRIIPs Regulation") for offering or selling the notes or otherwise making
them available to retail investors in the EEA or in the UK has been prepared and therefore offering or selling the notes or otherwise making them available to any retail investor in the EEA or in the
UK may be unlawful under the PRIIPS Regulation. This prospectus supplement has been prepared on the basis that any offer of notes in any Member State of the EEA will be made pursuant to an exemption
under the Prospectus Regulation from the requirement to publish a prospectus for offers of notes. This prospectus supplement is not a prospectus for the purposes of the Prospectus Regulation. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;References
to Regulations or Directives include, in relation to the UK, those Regulations or Directives as they form part of UK domestic law by virtue of the European Union (Withdrawal)
Act 2018 or have been implemented in UK domestic law, as appropriate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
above selling restriction is in addition to any other selling restrictions set out below. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in the United Kingdom  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This document is for distribution only to persons who (i)&nbsp;have professional experience in matters relating to investments and who
qualify as investment professionals within the meaning of Article&nbsp;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion
Order"), (ii)&nbsp;are persons falling within Article&nbsp;49(2)(a) to (d)&nbsp;("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii)&nbsp;are
outside the United Kingdom, or (iv)&nbsp;are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the Financial Services and
Markets Act 2000, as amended ("FSMA")) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being
referred to as "relevant persons"). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment
activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Switzerland  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The notes may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange ("SIX") or on any other stock exchange or
regulated trading facility in
Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure
standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor
any other offering or marketing material relating to the notes or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-71</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=78,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=195122,FOLIO='S-71',FILE='DISK128:[20ZBC1.20ZBC76301]DO76301A.;31',USER='CHE107555',CD='26-FEB-2020;11:06' -->
<A NAME="page_do76301_1_72"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
this document nor any other offering or marketing material relating to the offering, the Company, the notes have been or will be filed with or approved by any Swiss regulatory
authority. In particular, this document will not be filed with, and the offer of the notes will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of
the notes has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes ("CISA"). The investor protection afforded to acquirers of interests in collective
investment schemes under the CISA does not extend to acquirers of the notes. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in the Dubai International Financial Centre  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority
("DFSA"). This prospectus supplement is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any
other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify
the information set forth herein and has no responsibility for the prospectus supplement. The notes to which this prospectus supplement relates may be illiquid and/or subject to restrictions on their
resale. Prospective purchasers of the notes offered should conduct their own due diligence on the notes. If you do not understand the contents of this prospectus supplement you should consult an
authorized financial advisor. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Australia  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and
Investments Commission ("ASIC"), in relation to the offering. This prospectus supplement does not constitute a prospectus, product disclosure statement or other disclosure document under the
Corporations Act 2001 (the "Corporations Act"), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the
Corporations Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
offer in Australia of the notes may only be made to persons (the "Exempt Investors") who are "sophisticated investors" (within the meaning of section&nbsp;708(8) of the
Corporations Act), "professional investors" (within the meaning of section&nbsp;708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section&nbsp;708 of
the Corporations Act so that it is lawful to offer the notes without disclosure to investors under Chapter&nbsp;6D of the Corporations Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
notes applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12&nbsp;months after the date of allotment under the offering, except
in circumstances where disclosure to investors under Chapter&nbsp;6D of the Corporations Act would not be required pursuant to an exemption under section&nbsp;708 of the Corporations Act or
otherwise or where the offer is pursuant to a disclosure document which complies with Chapter&nbsp;6D of the Corporations Act. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
any shares of our common stock issued upon conversion of the notes must not be offered for sale in Australia in the period of 12&nbsp;months after the date of issue of those
shares of our common stock except in circumstances where disclosure to investors under Chapter&nbsp;6D of the Corporations Act would not be required pursuant to an exemption under section&nbsp;708
of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter&nbsp;6D of the Corporations Act. Any person acquiring notes or shares of our
common stock must observe such Australian on-sale restrictions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus supplement contains general information only and does not take account of the investment objectives, financial situation or particular needs of any particular person. It
does not contain any securities recommendations or financial product advice. Before making an investment </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-72</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=79,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=558180,FOLIO='S-72',FILE='DISK128:[20ZBC1.20ZBC76301]DO76301A.;31',USER='CHE107555',CD='26-FEB-2020;11:06' -->
<A NAME="page_do76301_1_73"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>decision,
investors need to consider whether the information in this prospectus supplement is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those
matters. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Hong Kong  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The notes have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
"professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong (the "SFO") and any rules made under that Ordinance; or (b)&nbsp;in other circumstances S-76 which
do not result in the document being a "prospectus" as defined in the Companies Ordinance (Cap. 32)&nbsp;of Hong Kong or which do not constitute an offer to the public within the meaning of that
Ordinance. No advertisement, invitation or document relating to the notes has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong
Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong)
other than with respect to the notes which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" as defined in the SFO and any rules made under
that Ordinance. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Japan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The notes have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for re-offering or resale, directly or indirectly, in
Japan or to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect
at the relevant time. For the purposes of this paragraph, "Japanese Person" shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Singapore  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, the notes were not
offered or sold or caused to be made the subject of an invitation for subscription or purchase and will not be offered or sold or caused to be made the subject of an invitation for subscription or
purchase, and this prospectus supplement or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of notes, has not been circulated or
distributed, nor will it be circulated or distributed, whether directly or indirectly, to any person in Singapore other than (i)&nbsp;to an institutional investor (as defined in Section&nbsp;4A of
the Securities and Futures Act (Chapter&nbsp;289) of Singapore, as modified or amended from time to time (the "SFA")) pursuant to Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as
defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified
in Section&nbsp;275 of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where
the notes are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire
share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-73</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=80,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=425662,FOLIO='S-73',FILE='DISK128:[20ZBC1.20ZBC76301]DO76301A.;31',USER='CHE107555',CD='26-FEB-2020;11:06' -->
<A NAME="page_do76301_1_74"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an
accredited investor, </FONT></DD></DL>
</UL>
<UL>
<UL>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>Securities
or securities-based derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in
that trust shall not be
transferred within six months after that corporation or that trust has acquired the Non-CIS notes pursuant to an offer made under Section&nbsp;275 of the SFA except: </FONT></P>

</UL>
</UL>
</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of
the SFA;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>where
no consideration is or will be given for the transfer;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(e)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>where
the transfer is by operation of law; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(f)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>as
specified in Section&nbsp;276(7) of the SFA. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Canada  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The notes may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument&nbsp;45-106 </FONT><FONT SIZE=2><I>Prospectus Exemptions</I></FONT><FONT SIZE=2> or subsection&nbsp;73.3(1) of the </FONT><FONT SIZE=2><I>Securities
Act</I></FONT><FONT SIZE=2> (Ontario), and are permitted clients, as defined in National Instrument&nbsp;31-103 </FONT><FONT SIZE=2><I>Registration Requirements, Exemptions and Ongoing Registrant
Obligations</I></FONT><FONT SIZE=2>. Any resale of the notes must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities
laws. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any
amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of
the purchaser's province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or
consult with a legal advisor. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to section&nbsp;3A.3 (or, in the case of securities issued or guaranteed by the government of a non-Canadian jurisdiction, section&nbsp;3A.4) of National
Instrument&nbsp;33-105 </FONT><FONT SIZE=2><I>Underwriting Conflicts</I></FONT><FONT SIZE=2>&nbsp;(NI&nbsp;33-105), the underwriters are not required to comply with the disclosure requirements
of NI&nbsp;33-105 regarding underwriter conflicts of interest in connection with this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-74</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=81,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=696509,FOLIO='S-74',FILE='DISK128:[20ZBC1.20ZBC76301]DO76301A.;31',USER='CHE107555',CD='26-FEB-2020;11:06' -->
<A NAME="page_do76301_1_75"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DO3"></A>LEGAL MATTERS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;K&amp;L Gates&nbsp;LLP, Charlotte, North Carolina, will pass upon certain legal matters relating to this offering. Shearman&nbsp;&amp;
Sterling&nbsp;LLP, New York, New York, is counsel to the underwriters in connection with this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DO4"></A>EXPERTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements of Exact Sciences Corporation as of December&nbsp;31, 2019 and 2018 and for each of the three years in
the period ended December&nbsp;31, 2019 and management's assessment of the effectiveness of internal control over financial reporting as of December&nbsp;31, 2019 incorporated by reference in this
prospectus supplement have been so incorporated in reliance on the reports of BDO USA,&nbsp;LLP, an independent registered public accounting firm (the report on the effectiveness of Exact Sciences
Corporation's internal control over financial reporting contains an explanatory paragraph due to the exclusion of certain elements of the internal control over financial reporting of Genomic Health,
Inc.'s business which Exact Sciences Corporation acquired during 2019), incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
consolidated financial statements of Genomic Health,&nbsp;Inc. as of December&nbsp;31, 2018 and 2017 and for each of the three years in the period ended December&nbsp;31,
2018, included as Exhibit&nbsp;99.2 to Exact Sciences Corporation's Current Report on Form&nbsp;8-K, dated November&nbsp;8, 2019, have been audited by Ernst&nbsp;&amp; Young&nbsp;LLP,
independent registered public accounting firm, as set forth in their report thereon, included as Exhibit&nbsp;99.2 to Exact Sciences Corporation's Current Report on Form&nbsp;8-K, dated
November&nbsp;8, 2019, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such
firm as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DO5"></A>WHERE YOU CAN FIND MORE INFORMATION  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are currently subject to the information requirements of the Exchange Act, and in accordance therewith, file periodic reports, proxy
statements and other information with the SEC. We also filed a registration statement on Form&nbsp;S-3, including exhibits, under the Securities Act, with respect to the securities offered by this
prospectus supplement. This prospectus supplement and the accompanying prospectus are a part of the registration statement but do not contain all of the information included in the registration
statement or the exhibits. Our SEC filings, including the registration statement, are publicly available on the SEC's website located at </FONT><FONT SIZE=2><I>www.sec.gov</I></FONT><FONT SIZE=2>.
You can also find our public filings on our website at </FONT><FONT SIZE=2><I>www.exactsciences.com</I></FONT><FONT SIZE=2>. Our website and the information contained therein or connected thereto are
not part of this prospectus supplement or the accompanying prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DO6"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate by reference" information into this prospectus supplement and the accompanying prospectus, which means that
we can disclose important information about us by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be a part of this
prospectus supplement and the accompanying prospectus. We incorporate by reference the documents and reports listed below:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1124140/000112414020000010/0001124140-20-000010-index.htm">Our Annual Report on
Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2019, filed with the SEC on February&nbsp;21, 2020;</A></FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1124140/000110465920009268/0001104659-20-009268-index.htm">Our Current Report on
Form&nbsp;8-K filed with the SEC on January&nbsp;31, 2020;</A> </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-75</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=82,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=87668,FOLIO='S-75',FILE='DISK128:[20ZBC1.20ZBC76301]DO76301A.;31',USER='CHE107555',CD='26-FEB-2020;11:06' -->
<A NAME="page_do76301_1_76"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1124140/000104746919002769/a2238648zdef14a.htm">The information contained in the
following sections of our amended definitive proxy statement for our 2019 Annual Meeting, filed with the SEC on April&nbsp;30, 2019: "Information Concerning Directors and Nominees for Director,"
"Information Concerning Executive Officers," "Section&nbsp;16(a) Beneficial Ownership Reporting Compliance,"&nbsp;"Corporate Governance Principles, Board Matters and Non-Employee Director
Compensation," "Compensation and Other Information Concerning Named Executive Officers," "Report of the Compensation and Management Development Committee," "Equity Compensation Plan Information,"
"Securities Ownership of Certain Beneficial Owners and Management," "Certain Relationships and Related Transactions," "Independent Registered Public Accounting Firm," and "Executive Compensation
Tables";</A></FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1131324/000155837019001300/ghdx-20181231x10k.htm">Audited Consolidated Balance
Sheets of Genomic Health as of December&nbsp;31, 2018 and 2017 and the Audited Consolidated Statements of Operations, Comprehensive Income (Loss), Stockholders' Equity and Cash Flows of Genomic
Health for the years ended December&nbsp;31, 2018, 2017 and 2016, filed as Exhibit&nbsp;99.2 to our Current Report on Form&nbsp;8-K filed with the SEC on November&nbsp;8, 2019</A>; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1131324/000155837019009440/ghdx-20190930x10qfe8a5d.htm">Unaudited Condensed
Consolidated Financial Statements of Genomic Health as of September&nbsp;30, 2019, filed as Exhibit&nbsp;99.3 to our Current Report on Form&nbsp;8-K filed with the SEC on November&nbsp;8,
2019</A>; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Unaudited Pro Forma Condensed Combined Balance Sheet as of June&nbsp;30, 2019, and the Unaudited Pro Forma Condensed Combined Statement of
Operations for the six months ended June&nbsp;30, 2019 and the year ended December&nbsp;31, 2018, included in Amendment No.&nbsp;1 to our Registration Statement on Form&nbsp;S-4 (Registration
No.&nbsp;333-233538) filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1124140/000104746919005451/a2239766zs-4a.htm">September&nbsp;26, 2019)</A>; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The description of the Company's Common Stock contained in the Company's Registration Statement on Form&nbsp;8-A, filed with the SEC pursuant
to Section&nbsp;12(g) of the Exchange Act on December&nbsp;26, 2000, including any amendment or reports filed for the purpose of updating such description; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> All documents filed after the date of this prospectus supplement and prior to the termination of the offering hereunder pursuant to
Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information
in this prospectus supplement supersedes related information in the documents listed above, and information in subsequently filed documents supersedes related information in
each of this prospectus supplement, the prospectus and the incorporated documents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will promptly provide, without charge to you, upon written or oral request, a copy of any or all of the documents incorporated by reference in this prospectus supplement or the
prospectus, other than exhibits to those documents, unless the exhibits are specifically incorporated by reference in those documents. Requests should be directed to: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>Corporate Secretary<BR>
Exact Sciences Corporation<BR>
441 Charmany Drive<BR>
Madison, Wisconsin 53719<BR>
(608)&nbsp;284-5700</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
can also find these filings on our website at </FONT><FONT SIZE=2><I>www.exactsciences.com</I></FONT><FONT SIZE=2>. Our website and the information contained therein or connected
thereto are not part of this prospectus supplement or the accompanying prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-76</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=83,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=822233,FOLIO='S-76',FILE='DISK128:[20ZBC1.20ZBC76301]DO76301A.;31',USER='CHE107555',CD='26-FEB-2020;11:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76302a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g962760.jpg" ALT="LOGO" WIDTH="196" HEIGHT="69">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>EXACT SCIENCES CORPORATION  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Common Stock<BR>
Preferred Stock<BR>
Debt Securities<BR>
Warrants  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus relates to common stock, preferred stock, debt securities and warrants that Exact Sciences Corporation may sell from time to time
in one or more offerings on terms to be determined at the time of sale. We will provide specific terms of these securities in supplements to this prospectus. You should read this prospectus and any
supplement carefully before you invest. This prospectus may not be used to offer and sell securities unless accompanied by a prospectus supplement for those securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock trades on the NASDAQ Capital Market under the symbol "EXAS." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
securities may be sold directly by us, through dealers or agents designated from time to time, to or through underwriters or through a combination of these methods. See "Plan of
Distribution" in this prospectus. We may also describe the plan of distribution for any particular offering of these securities in any applicable prospectus supplement. If any agents, underwriters or
dealers are involved in the sale of any securities in respect of which this prospectus is being delivered, we will disclose their names and the nature of our arrangements with them in a prospectus
supplement. The net proceeds we expect to receive from any such sale will also be included in a prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B>INVESTING IN OUR SECURITIES INVOLVES RISKS. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING "RISK FACTORS"
CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS, AND UNDER SIMILAR HEADINGS IN OTHER DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS OR ANY
SUCH PROSPECTUS SUPPLEMENT. SEE "RISK FACTORS" ON PAGE 4 OF THIS PROSPECTUS.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=3><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The date of this prospectus is June&nbsp;6, 2017. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=84,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=1024998,FOLIO='blank',FILE='DISK129:[20ZBC2.20ZBC76302]BC76302A.;2',USER='CHE107256',CD='21-FEB-2020;15:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76302a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="BG76302A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg76302_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  Table of Contents    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG76302_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da76302_about_this_prospectus"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da76302_about_this_prospectus"><FONT SIZE=2>1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da76302_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da76302_where_you_can_find_more_information"><FONT SIZE=2>1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da76302_incorporation_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION BY REFERENCE</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da76302_incorporation_by_reference"><FONT SIZE=2>1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da76302_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da76302_forward-looking_statements"><FONT SIZE=2>2</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da76302_the_company"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>THE COMPANY</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da76302_the_company"><FONT SIZE=2>3</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da76302_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da76302_use_of_proceeds"><FONT SIZE=2>3</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da76302_ratio_of_earnings_to_fixed_charges"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RATIO OF EARNINGS TO FIXED CHARGES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da76302_ratio_of_earnings_to_fixed_charges"><FONT SIZE=2>4</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da76302_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da76302_risk_factors"><FONT SIZE=2>4</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da76302_description_of_securities_we_may_offer"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF SECURITIES WE MAY OFFER</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da76302_description_of_securities_we_may_offer"><FONT SIZE=2>4</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da76302_description_of_common_stock_we_may_offer"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF COMMON STOCK WE MAY OFFER</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da76302_description_of_common_stock_we_may_offer"><FONT SIZE=2>5</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da76302_description_of_preferred_stock_we_may_offer"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF PREFERRED STOCK WE MAY OFFER</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da76302_description_of_preferred_stock_we_may_offer"><FONT SIZE=2>5</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da76302_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da76302_plan_of_distribution"><FONT SIZE=2>8</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da76302_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da76302_legal_matters"><FONT SIZE=2>9</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da76302_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da76302_experts"><FONT SIZE=2>9</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=85,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=881147,FOLIO='blank',FILE='DISK129:[20ZBC2.20ZBC76302]BG76302A.;2',USER='CHE107256',CD='21-FEB-2020;15:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_da76302_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76302a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da76302_about_this_prospectus"> </A>
<A NAME="toc_da76302_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement on Form&nbsp;S-3 that we filed with the SEC utilizing a "shelf" registration process.
Under this shelf process, we may from time to time sell any combination of securities described in this prospectus in one or more offerings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement that will contain specific
information about the terms of the securities being offered. That prospectus supplement may include a discussion of any risk factors or other special consideration that apply to those securities. The
prospectus supplement may also add, update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus and a prospectus supplement, you
should rely on the information in that prospectus supplement. You should read both this prospectus and any applicable prospectus supplement together with additional information described above under
the headings "Where You Can Find More Information" and "Incorporation by Reference." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
acquiring any securities discussed in this prospectus, you should rely on the information provided in this prospectus and the prospectus supplement, including the information
incorporated by reference. Neither we, nor any underwriters or agents, have authorized anyone to provide you with different information. We are not offering the securities in any state where such an
offer is prohibited. You should not assume that the information in this prospectus, any prospectus supplement, or any document incorporated by reference, is truthful or complete at any date other than
the date mentioned on the cover page of those documents. You should also carefully review the section entitled "Risk Factors", which highlights certain risks associated with an investment in our
securities, to determine whether an investment in our securities is appropriate for you. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;References
in this prospectus to "Exact", the "Company", "we", "us" and "our" are to Exact Sciences Corporation and its subsidiaries. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da76302_where_you_can_find_more_information"> </A>
<A NAME="toc_da76302_2"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We file annual, quarterly and special reports, proxy statements and other information with the Securities and Exchange Commission (the "SEC").
You can inspect and copy these reports, proxy statements and other information at the SEC's Public Reference Room at 100&nbsp;F Street, N.E., Washington, D. C. 20549. Please call the SEC at
1-800-SEC-0330 for further information on the Public Reference Room. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding issuers,
such as Exact Sciences Corporation (www.sec.gov). Our web site is located at www.exactsciences.com. The information contained on our web site is not part of this prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will provide, upon written or oral request, without charge to you, including any beneficial owner to whom this prospectus is delivered, a copy of any or all of the documents
incorporated herein by reference other than the exhibits to those documents, unless the exhibits are specifically incorporated by reference into the information that this prospectus incorporates. You
should direct a request for copies to us at Attention: Secretary, 441 Charmany Drive, Madison, WI 53719 or you may call us at (608)&nbsp;284-5700. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da76302_incorporation_by_reference"> </A>
<A NAME="toc_da76302_3"> </A>
<BR></FONT><FONT SIZE=2><B>  INCORPORATION BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus "incorporates by reference" certain information that we have filed with the SEC under the Securities Exchange Act of 1934, as
amended (the "Exchange Act"). This
means we are disclosing important information to you by referring you to those documents. We incorporate by </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=86,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=261427,FOLIO='1',FILE='DISK129:[20ZBC2.20ZBC76302]DA76302A.;3',USER='CHE106795',CD='21-FEB-2020;17:27' -->
<A NAME="page_da76302_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76302a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>reference
the documents listed below and any future filings made by us with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act until the offering is
terminated:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1124140/000155837017000714/exas-20161231x10k.htm">Annual Report on Form&nbsp;10-K
for the fiscal year ended December&nbsp;31, 2016 filed with the SEC on February&nbsp;21, 2017</A>; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1124140/000155837017002956/exas-20170331x10q.htm">Quarterly Report on
Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2017 filed with the SEC on April&nbsp;27, 2017</A>; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Current Report on Form&nbsp;8-K filed with the SEC on
<A HREF="http://www.sec.gov/Archives/edgar/data/1124140/000110465919025317/a19-9140_18k.htm">April&nbsp;27, 2017</A>; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1124140/000104746917003065/a2232009zdef14a.htm">The information contained in the
following sections of the proxy statement for our 2016 Annual Meeting filed with the SEC on April&nbsp;28, 2017: "Information Concerning Directors and Nominees for Director," "Information Concerning
Executive Officers," "Section&nbsp;16(a) Beneficial Ownership Reporting Compliance," "Corporate Governance Principles and Board Matters," "The Board of Directors and Its Committees," "Compensation
and Other Information Concerning Directors and Officers," "Report of the Compensation Committee," "Equity Compensation Plan Information," "Securities Ownership of Certain Beneficial Owners and
Management," "Certain Relationships and Related Transactions," "Independent Registered Public Accounting Firm" and "Pre-Approval Policies and Procedures</A>;" </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1124140/000091205700054713/a2033604z8-a12g.txt">The description of the Company's
Common Stock contained in the Company's Registration Statement on Form&nbsp;8-A, filed with the SEC pursuant to Section&nbsp;12(g) of the Exchange Act on December&nbsp;26, 2000, including any
amendment or reports filed for the purpose of updating such description</A>; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1124140/000110465911009366/a11-5751_28a12b.htm">The description of the Company's
preferred stock purchase rights contained in the Company's Registration Statement on Form&nbsp;8-A filed with the SEC pursuant to Section&nbsp;12(b) of the Exchange Act on February&nbsp;23,
2011</A>. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information incorporated by reference or provided in this prospectus. We have authorized no one to provide you with different information. You should not
assume that the information in this prospectus is accurate as of any date other than the date on the front of this document. All documents that we file pursuant to Sections&nbsp;13(a), 13(c), 14 or
15(d) of the Exchange Act after the date of this prospectus or after the date of the registration statement of which this prospectus forms&nbsp;a part and prior to the termination of the offering
will be deemed to be incorporated in this prospectus by reference and will be a part of this prospectus from the date of the filing of the document. Any statement contained in a document incorporated
or deemed to be incorporated by reference in this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or
in any other subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus modifies or supersedes that statement. Any statement that is modified or
superseded will not constitute a part of this prospectus, except as modified or superseded. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da76302_forward-looking_statements"> </A>
<A NAME="toc_da76302_4"> </A>
<BR></FONT><FONT SIZE=2><B>  FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain information set forth in this prospectus or incorporated by reference in this prospectus may contain forward-looking statements within
the meaning of Section&nbsp;27A of the Securities Act of&nbsp;1933, as amended (the "Securities Act"), and Section&nbsp;21E of the Exchange Act, that are intended to be covered by the "safe
harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use
of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "estimate," "goal," "anticipate," "project" or other comparable terms. All
statements other than statements of historical facts included in this prospectus regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=87,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=493630,FOLIO='2',FILE='DISK129:[20ZBC2.20ZBC76302]DA76302A.;3',USER='CHE106795',CD='21-FEB-2020;17:27' -->
<A NAME="page_da76302_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76302a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>forward-looking
statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales and marketing
efforts, expectations concerning payor reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projects, anticipated events and
trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are
difficult to predict and many of which are outside our control. Our actual results and financial condition may differ materially from those in the forward-looking statements, as a result of various
factors, including those risks and uncertainties included in this prospectus under the caption "Risk Factors," and those risks and uncertainties described in the documents incorporated by reference
into this prospectus. Therefore, you should not rely on any of these forward-looking statements. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. All
subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the applicable cautionary statements. We
further caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we
undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or
otherwise. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da76302_the_company"> </A>
<A NAME="toc_da76302_5"> </A>
<BR></FONT><FONT SIZE=2><B>  THE COMPANY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a molecular diagnostics company currently focused on the early detection and prevention of some of the deadliest forms of cancer. We have
developed an accurate, non-invasive, patient-friendly screening test called Cologuard&reg; for the early detection of colorectal cancer and pre-cancer, and we are currently working on the
development of additional tests for other types of cancer, with the goal of becoming a leader in cancer diagnostics. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Cologuard test is a non-invasive stool-based DNA (sDNA) screening test which utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal
cancer and pre-cancer. Eleven biomarkers are targeted that have been shown to be strongly associated with colorectal cancer and pre-cancer. Methylation, mutation, and hemoglobin results are combined
in the laboratory analysis through a proprietary algorithm to provide a single positive or negative reportable result. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da76302_use_of_proceeds"> </A>
<A NAME="toc_da76302_6"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently intend to use the estimated net proceeds from the sale of these securities for general corporate and working capital purposes,
including to fund expansion of our Cologuard commercialization activities and to fund our product development efforts. Accordingly, our management will have significant discretion and flexibility in
applying the net proceeds from the sale of these securities. Our plans to use the estimated net proceeds from the sale of these securities may change, and if they do, we will update this information
in a prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=88,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=502903,FOLIO='3',FILE='DISK129:[20ZBC2.20ZBC76302]DA76302A.;3',USER='CHE106795',CD='21-FEB-2020;17:27' -->
<A NAME="page_da76302_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76302a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da76302_ratio_of_earnings_to_fixed_charges"> </A>
<A NAME="toc_da76302_7"> </A>
<BR></FONT><FONT SIZE=2><B>  RATIO OF EARNINGS TO FIXED CHARGES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our earnings are inadequate to cover fixed charges. The following table sets forth the dollar amount of the coverage deficiency (in thousands)
for the periods indicated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 Q1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2012 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ratio of Earnings to Fixed Charges</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deficiency of Earnings to Cover Fixed Charges</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(34,946</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(167,211</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(157,803</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(100,048</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(46,514</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(52,421</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>During
each of these periods, our earnings were less than our fixed charges. The amount of the deficiency for each period is set forth in the above table under the
caption "Deficiency of Earnings to Cover Fixed Charges."  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da76302_risk_factors"> </A>
<A NAME="toc_da76302_8"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing in our securities involves risk. See the risk factors described in our Annual Report on Form&nbsp;10-K for our most recent fiscal
year (together with any material changes thereto contained in subsequent filed Quarterly Reports on Form&nbsp;10-Q) and those contained in our other filings with the SEC, which are incorporated by
reference in this prospectus and any accompanying prospectus supplement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
prospectus supplement applicable to each type or series of securities we offer may contain a discussion of risks applicable to the particular types of securities that we are offering
under that prospectus supplement. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the caption "Risk Factors" in the
applicable prospectus supplement, together with all of the other information contained in the prospectus supplement or appearing or incorporated by reference in this prospectus. These risks could
materially affect our business, results of operations or financial condition and cause the value of our securities to decline. You could lose all or part of your investment. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da76302_description_of_securities_we_may_offer"> </A>
<A NAME="toc_da76302_9"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF SECURITIES WE MAY OFFER    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue from time to time, in one or more offerings, the following securities:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> shares of common stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> shares of preferred stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> debt securities, which may include senior debt securities, subordinated debt securities and senior subordinated debt securities; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> warrants for the purchase of debt securities, preferred stock or common stock. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set
forth below is a description of the common stock and preferred stock that may be offered under this prospectus. We will set forth in the applicable prospectus supplement and/or free
writing prospectus a description of the debt securities and warrants that may be offered under this prospectus. The terms of the offering of our common stock, preferred stock or any such other
securities, the initial offering price and the net proceeds to us will be contained in the prospectus supplement, and other offering material, relating to such offer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may sell the securities being offered pursuant to this prospectus directly to purchasers, to or through underwriters, through dealers or agents, or through a combination of such
methods. The prospectus supplement with respect to the securities being offered will set forth the terms of the offering of those securities, including the names of any such underwriters, dealers or
agents, the purchase price, the net proceeds to us, any underwriting discounts and other items constituting </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=89,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=6565,FOLIO='4',FILE='DISK129:[20ZBC2.20ZBC76302]DA76302A.;3',USER='CHE106795',CD='21-FEB-2020;17:27' -->
<A NAME="page_da76302_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76302a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>underwriters'
compensation, the initial public offering price, any discounts or concessions allowed or reallowed or paid to dealers and any securities exchanges on which such securities may be listed. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da76302_description_of_common_stock_we_may_offer"> </A>
<A NAME="toc_da76302_10"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF COMMON STOCK WE MAY OFFER    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following summary description of our common stock is based on the provisions of our certificate of incorporation and bylaws and the
applicable provisions of the General Corporation Law of the State of Delaware. This information may not be complete in all respects and is qualified entirely by reference to the provisions of our
certificate of incorporation, bylaws and the General Corporation Law of the State of Delaware. For information on how to obtain copies of our certificate of incorporation and bylaws, see the
discussion above under the heading "Where You Can Find More Information." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may offer our common stock issuable upon the conversion of debt securities or preferred stock and upon the exercise of warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Authorized Capital  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have authority to issue 200,000,000 shares of our common stock, par value $0.01 per share. As of March&nbsp;31, 2017, 111,197,740
shares of our common stock were issued and outstanding. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Rights  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each outstanding share of our common stock is entitled to one vote on all matters submitted to a vote of shareholders. There is no cumulative
voting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividend and Liquidation Rights  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of outstanding shares of our common stock are entitled to receive dividends out of assets legally available for the payment of
dividends at the times and in the amounts as our board of directors may from time to time determine. The shares of our common stock are neither redeemable nor convertible. Holders of our common stock
have no preemptive or subscription rights to purchase any securities of Exact. Upon the liquidation, dissolution or winding up of Exact, the holders of our common stock are entitled to receive pro
rata the assets of Exact which are legally available for distribution, after payment of all debts and other liabilities and subject to the prior rights of any holders of preferred stock then
outstanding. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have never paid any cash dividends on our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da76302_description_of_preferred_stock_we_may_offer"> </A>
<A NAME="toc_da76302_11"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF PREFERRED STOCK WE MAY OFFER    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section describes the general terms and provisions of the preferred stock we may offer. This information may not be complete in all
respects and is qualified entirely by reference to our certificate of incorporation, with respect to each series of preferred stock. The specific terms of any series will be described in a prospectus
supplement. Those terms may differ from the terms discussed below. Any series of preferred stock we issue will be governed by our certificate of incorporation and by the certificate of designations
relating to that series. We will file the certificate of designations with the SEC and incorporate it by reference as an exhibit to our registration statement at or before the time we issue any
preferred stock of that series. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Authorized Preferred Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation authorizes us to issue 5,000,000 shares of undesignated preferred stock, par value $0.01 per share. We may
issue preferred stock from time to time in one or more series, without shareholder approval, when authorized by our board of directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=90,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=455805,FOLIO='5',FILE='DISK129:[20ZBC2.20ZBC76302]DA76302A.;3',USER='CHE106795',CD='21-FEB-2020;17:27' -->
<A NAME="page_da76302_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76302a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
issuance of a particular series of preferred stock, our board of directors is authorized, to specify:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares to be included in the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the annual dividend rate for the series, if any, and any restrictions or conditions on the payment of dividends; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the redemption price, if any, and the terms and conditions of redemption; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any sinking fund provisions for the purchase or redemption of the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if the series is convertible, the terms and conditions of conversion; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amounts payable to holders upon our liquidation, dissolution or winding up; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other rights, preferences and limitations relating to the series, including voting rights. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors' ability to authorize, without shareholder approval, the issuance of preferred stock with conversion and other rights, may adversely affect the rights of holders
of our common stock or other series of preferred stock that may be outstanding. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
shares of our preferred stock are currently issued and outstanding. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Specific Terms of a Series of Preferred Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preferred stock we may offer will be issued in one or more series. The preferred stock will have the dividend, liquidation, redemption and
voting rights discussed below, unless otherwise described in a prospectus supplement relating to a particular series. A prospectus supplement will discuss the following features of the series of
preferred stock to which it relates:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the designations and stated value per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares offered; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amount of liquidation preference per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the public offering price at which the preferred stock will be issued; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the dividend rate, the method of its calculation, the dates on which dividends would be paid and the dates, if any, from which dividends would
cumulate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any redemption or sinking fund provisions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any conversion or exchange rights; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any additional voting, dividend, liquidation, redemption, sinking fund and other rights, preferences, privileges, limitations and restrictions. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rank  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise stated in the prospectus supplement, the preferred stock will have priority over our common stock with respect to dividends and
distribution of assets, but will rank junior to all our outstanding indebtedness for borrowed money. Any series of preferred stock could rank senior, equal or junior to our other capital stock, as may
be specified in a prospectus supplement, as long as our certificate of incorporation so permits. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of each series of preferred stock shall be entitled to receive cash dividends to the extent specified in the prospectus supplement when,
as and if declared by our board of directors, from funds </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=91,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=638811,FOLIO='6',FILE='DISK129:[20ZBC2.20ZBC76302]DA76302A.;3',USER='CHE106795',CD='21-FEB-2020;17:27' -->
<A NAME="page_da76302_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76302a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>legally
available for the payment of dividends. The rates and dates of payment of dividends of each series of preferred stock will be stated in the prospectus supplement. Dividends will be payable to
the holders of record of preferred stock as they appear on our books on the record dates fixed by our board of directors. Dividends on any series of preferred stock may be cumulative or
non-cumulative, as discussed in the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Convertibility  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of a series of preferred stock may be exchangeable or convertible into shares of our common stock, another series of preferred stock or
other securities or property. The conversion or exchange may be mandatory or optional. The prospectus supplement will specify whether the preferred stock being offered has any conversion or exchange
features, and will describe all the related terms and conditions. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Redemption  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The terms, if any, on which shares of preferred stock of a series may be redeemed will be discussed in the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon any voluntary or involuntary liquidation, dissolution or winding up of the affairs of Exact, holders of each series of preferred stock will
be entitled to receive distributions upon liquidation in the amount described in the related prospectus supplement. These distributions will be made before any distribution is made on any securities
ranking junior to the preferred stock with respect to liquidation, including our common stock. If the liquidation amounts payable relating to the preferred stock of any series and any other securities
ranking on a parity regarding liquidation rights are not paid in full, the holders of the preferred stock of that series will share ratably in proportion to the full liquidation preferences of each
security. Holders of our preferred stock will not be entitled to any other amounts from us after they have received their full liquidation preference. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of preferred stock of each series will have no voting rights, except as required by law and as described below or in a prospectus
supplement. Our board of directors may, upon issuance of a series of preferred stock, grant voting rights to the holders of that series to elect additional board members if we fail to pay dividends in
a timely fashion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
the affirmative vote of a majority of the shares of preferred stock of any series then outstanding, we may not:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> increase or decrease the aggregate number of authorized shares of that series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> increase or decrease the par value of the shares of that series; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> alter or change the powers, preferences or special rights of the shares of that series so as to affect them adversely. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


No Other Rights  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares of a series of preferred stock will not have any preferences, voting powers or relative, participating, optional or other special
rights except:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> as discussed above or in the prospectus supplement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> as provided in our certificate of incorporation and in the certificate of designations; and </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as
otherwise required by law. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=92,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=686634,FOLIO='7',FILE='DISK129:[20ZBC2.20ZBC76302]DA76302A.;3',USER='CHE106795',CD='21-FEB-2020;17:27' -->
<A NAME="page_da76302_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76302a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da76302_plan_of_distribution"> </A>
<A NAME="toc_da76302_12"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may sell the securities offered by this prospectus to one or more underwriters or dealers for public offering, through agents, directly to
purchasers or through a combination of any such methods of sale. The name of any such underwriters, dealers or agents involved in the offer and sale of the securities, the amounts underwritten and the
nature of its obligation to take the securities will be specified in the applicable prospectus supplement. We have reserved the right to sell the securities directly to investors on our own behalf in
those jurisdictions where we are authorized to do so. The sale of the securities may be effected in transactions (a)&nbsp;on any national or international
securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, (b)&nbsp;in the over-the-counter market, (c)&nbsp;in transactions otherwise than on
such exchanges or in the over-the-counter market or (d)&nbsp;through the writing of options. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
and our agents and underwriters may offer and sell the securities at a fixed price or prices that may be changed, at market prices prevailing at the time of sale, at prices related to
such prevailing market prices or at negotiated prices. The securities may be offered on an exchange, which will be disclosed in the applicable prospectus supplement. We may, from time to time,
authorize dealers, acting as our agents, to offer and sell the securities upon such terms and conditions as set forth in the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we use underwriters to sell securities, we will enter into an underwriting agreement with them at the time of the sale to them. In connection with the sale of the securities,
underwriters may receive compensation from us in the form of underwriting discounts or commissions and may also receive commissions from purchasers of the securities for whom they may act as agent.
Any underwriting compensation paid by us to underwriters or agents in connection with the offering of the securities, and any discounts, concessions or commissions allowed by underwriters to
participating dealers, will be set forth in the applicable prospectus supplement to the extent required by applicable law. Underwriters may sell the securities to or through dealers, and such dealers
may receive compensation in the form of discounts, concessions or commissions from the underwriters or commissions (which may be changed from time to time) from the purchasers for whom they may act as
agents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dealers
and agents participating in the distribution of the securities may be deemed to be underwriters, and any discounts and commissions received by them and any profit realized by
them on resale of the securities may be deemed to be underwriting discounts and commissions under the Securities Act. Unless otherwise indicated in the applicable prospectus supplement, an agent will
be acting on a best efforts basis and a dealer will purchase debt securities as a principal, and may then resell the debt securities at varying prices to be determined by the dealer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
so indicated in the prospectus supplement, we will authorize underwriters, dealers or agents to solicit offers by certain specified institutions to purchase offered securities from us
at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. Such contracts will be
subject to any conditions set forth in the applicable prospectus supplement and the prospectus supplement will set forth the commission payable for solicitation of such contracts. The underwriters and
other persons soliciting such contracts will have no responsibility for the validity or performance of any such contracts. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Underwriters,
dealers and agents may be entitled, under agreements entered into with us, to indemnification against and contribution towards certain civil liabilities, including any
liabilities under the Securities Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
facilitate the offering of securities, certain persons participating in the offering may engage in transactions that stabilize, maintain, or otherwise affect the price of the
securities. These may include over-allotment, stabilization, syndicate short covering transactions and penalty bids. Over-allotment </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=93,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=920529,FOLIO='8',FILE='DISK129:[20ZBC2.20ZBC76302]DA76302A.;3',USER='CHE106795',CD='21-FEB-2020;17:27' -->
<A NAME="page_da76302_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg76302a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>involves
sales in excess of the offering size, which creates a short position. Stabilizing transactions involve bids to purchase the underlying security so long as the stabilizing bids do not exceed a
specified maximum. Syndicate short covering transactions involve purchases of securities in the open market after the distribution has been completed in order to cover syndicate short positions.
Penalty bids permit the underwriters to reclaim selling concessions from dealers when the securities originally sold by the dealers are purchased in covering transactions to cover syndicate short
positions. These transactions may cause the price of the securities sold in an offering to be higher than it would otherwise be. These transactions, if commenced, may be discontinued by the
underwriters at any time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
securities other than our common stock issued hereunder may be new issues of securities with no established trading market. Any underwriters or agents to or through whom such
securities are sold for public offering and sale may make a market in such securities, but such underwriters or agents will not be obligated to do so and may discontinue any market making at any time
without notice. No assurance can be given as to the liquidity of the trading market for any such securities. The amount of expenses expected to be incurred by us in connection with any issuance of
securities will be set forth in the applicable prospectus supplement. Certain of the underwriters, dealers or agents and their associates may engage in transactions with, and perform services for, us
and certain of our affiliates in the ordinary course of business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
such time as we may be engaged in a distribution of the securities covered by this prospectus we are required to comply with Regulation&nbsp;M promulgated under the Exchange
Act. With certain exceptions, Regulation&nbsp;M precludes us, any affiliated purchasers, and any broker-dealer or other person who participates in such distribution from bidding for or purchasing,
or attempting to induce any person to bid for or purchase, any security which is the subject of the distribution until the entire distribution is complete. Regulation&nbsp;M also restricts bids or
purchases made in order to stabilize the price of a security in connection with the distribution of that security. All of the foregoing may affect the marketability of our shares of common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da76302_legal_matters"> </A>
<A NAME="toc_da76302_13"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The validity and legality of the securities offered hereby and certain other legal matters will be passed upon for the Company by K&amp;L
Gates&nbsp;LLP, Charlotte, North Carolina 28202. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da76302_experts"> </A>
<A NAME="toc_da76302_14"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements as of December&nbsp;31, 2016 and 2015 and for each of the three years in the period ended December&nbsp;31, 2016
and management's assessment of the effectiveness of internal control over financial reporting as of December&nbsp;31, 2016 incorporated by reference in this prospectus have been so incorporated in
reliance on the reports of BDO USA,&nbsp;LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and
accounting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=94,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=694999,FOLIO='9',FILE='DISK129:[20ZBC2.20ZBC76302]DA76302A.;3',USER='CHE106795',CD='21-FEB-2020;17:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg76301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=1><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>$1,000,000,000  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>
<IMG SRC="g1018787.jpg" ALT="LOGO" WIDTH="325" HEIGHT="114">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>Exact Sciences Corporation  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>0.3750% Convertible Senior Notes due 2028  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="19%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="19%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> PROSPECTUS SUPPLEMENT  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="19%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="19%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>BofA Securities  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>Baird  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B> Cowen  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B> William Blair  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B> BTIG  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B> Stifel  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>February&nbsp;24, 2020  </B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=95,EFW="2240838",CP="EXACT SCIENCES CORPORATION",DN="1",CHK=533365,FOLIO='blank',FILE='DISK128:[20ZBC1.20ZBC76301]HO76301A.;13',USER='CHE106460',CD='25-FEB-2020;23:13' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g930856.jpg
<DESCRIPTION>G930856.JPG
<TEXT>
begin 644 g930856.jpg
M_]C_X  02D9)1@ ! 0$ @@""  #__@!*35),3%]'4D%02$E#4SI;15A!0U1?
M4T-)14Y#15-?0T]24$]2051)3TY=15A!0U1?4T-)14Y#15-?3D577S1#7TQ/
M1T\N15!3_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  $0@ 0P## P$B  (1 0,1 ?_$ !T   (# 0$! 0$
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M<G[Q-U88'$NY$P46!<Z9-?OD>+#(FG].;%[/'&Z3A1EZR@=VZ<C;6!BZT"Q
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g188286.jpg
<DESCRIPTION>G188286.JPG
<TEXT>
begin 644 g188286.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!#1$E32S$R.#I;,C!:0D,Q+C(P6D)#
M-S8S,#$N3U544%5473DV-C-?,5]#3TY?4D%415]!1$I?,5]+7T5152Y%4%/_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  +"  G '(! 1$ _\0 '@   @("
M @,               @'"00% 08" PK_Q  M$  !! ,  @$"!0,%       %
M P0&!P$""  1"1(A%187,4$3%%$8(F%RD?_:  @! 0  /P#[^/#P\/#P\/#P
M\/#Q>^G^EZXY-J$Q;]E;&'S- O&8=#X7$V:!>?VG9T^.LHE6U3UM'UW;'0_/
MK"EQ,;'8Z/6>L1R"SI4L>)AXZ,+F&"I61UY?'-\QY&<]'U]58R ]:7[&>8E0
MU=2>5GIO2=MV9'):?JO0B;+"V<<MV,%BD0<PJ:D00.NW$1*%1\C%(2V--R2K
M;1T9W!<O1!"722M*TKLK$87V[-^0I_6R\FD[>[J7"5E-RD3DML6LT0$O 0XG
M(1H72=Q:L-1PQNE7DT@<H5LTPN3=@TK3,9SG&,YQG&<XQG.,_OC.<?MG_G'[
M>+W:73M553-XY5)%^;EEQ2^/DY?&Z?KF.E)U9#Z&A7J PM-W\>")*ZQ>",2C
MEN%4G,R>QR)*R!RUCC0RYD#IN+5@28?)+SW!:T,6C(PUWLQ$=Z*C'*!Z/ZT;
M8*LZ'WU,](JC%H.E"]1FIPTE(#$WB4>"2N.-S,,,EY /P)D+X;NH238RA.C:
MIZ2 2TY5QHD\6KR?'*JLF,R.-2&&3.NK,C3(03.P::Q.4C19D&>8C#X,NCJH
MW5'%P9D.?!$"@,J/(N9S]X_SC_W'G/G2[%L:!5%!I39EHS&-U]7L("O9'+YI
M,##&/QF- AR65GI4R9)+-V3!DWT]?6LNMKC;?9-%/&ZRJ2>ZZ >U*Q.2ZIHG
MO#+WC_Z[GW<<J"12VB[&B\9F1)A#)'8CS18B9#M74'TUA$3/2)GBS!T)<&&K
M!1J#;$BFVK#R.J:^3+EZZYR"KX(^LR)');;-J4-"GMET_8,"BDUNND/S/^K%
M6Q>:F WY3)S.&?DN697%Y,(:G<1H_B*+G]@A75G8)C.,X]XS[QG[XSC]LX_S
MYZE%T$=T4U5DTU'&^R2&F^^NNZRFB2B^^B6NV<;*;:(I*K;ZZ8VSJDFHIMC&
MFFVV!-P@MNLFDLDHHV4U2<::*:[;H*;I)KZ)K:ZYSLGON@LDMKKOC7.R2J:F
MN,Z;Z;9KA^0[GRS;?*<36I6\;_4K_2+V=!>CI=3>AT3'R=BQ5A7EF5F]<0]]
M(R B*K6%7+BQFMDPX3*38 +(7,;>Q_>0!GQ-B\UAKHZDNG>I+3AE]:5HG#HG
MQ3$+2M?DFCYV;B"DRO/MV15?)H%6EC6AD1()/"*ZJJHQLC*-H6-<GB,P.2N7
M&);)&$8%0X*'ENXK;GNT9#\A-?\ 9 :HC_,JA#F655?VBW*GH*_%],SO1S 5
M:-1:A8%*#[&3EJ*<#K(58W=(AT;-;0R4!Z^#-2@M^490^W#RB;ERU*LY^^0;
MY4WW7L_B]27=;%UU$5I8I:QMI#@%B\80F@H()J,?2IJ5.& J6M(E99.YD;!B
M<'</WP"Q#+Q\=%(DY&W=/M/W<?+=4]6\*<JT'(F-938:WOKY%21.2Q06W>,)
MY25:.*OY0S-8C)&BFI1.46O:K&S7,8,-&\O6A]0+/\)QQ\*1(!VE^'C%?GN*
M8A;0%&08N.^Y&;MSL-U-BFI&P5^Q'Z(V'WN.FB"+86S!.(C(86C!8I&A "-@
M E=QB'LP01 7A!=UD'N-;B)ECKYM.98D@2*&7C9-/NOY&1.B2)!\Z<H)ICPM
MS-A@K1--?371@&0;#ANNN&HI%NS;MDT[+@+%<8##CG*FZKA@*',G"JA F644
M6:,T&ZJFY0TNZ,$=]U$]MMGY5RX)/-LY<OUE7:JRFU07S%M%\ N$9+/&AMSR
M;7OR"TA8_8*X@8\,B E9PN.SXS6LHM :U0<Z*TM%NB4*C/V4^?-EQ(!DP&20
M[JD"$$G;9E+S[WYM@7/MV]$0^80>Z ?/52S6W=9# B@B<0_>7"8R42BD$%S6
M-N2 =6P[!>/%(\&C<?(.Y"NR)N/[Y!BQ*,<DZ1^,X.QY0GW+T?[2G!VQHA1/
MQW&?D:YH<--XX-A;;J24-;./?(L176"M!B=OVF'86RV/U"^E4D*:Q^O; GY%
MJ.=EVI.8,[R^.^PGG2)B80V31 9#YI%JAYDO?=@#-N3@O6 =40F2RB%CUG;]
MB-=;2"-F(+-8R;61:X%E$AHHZ/PQV*N@8B1NN:@D%W5L%A4.9I#)OB>QPW"K
M;T+X$&N=Y()1)J-[SBNJ?MW(9/%&2CX0,@F=%(Y8VLD<P.R4U*ID,Y24.0Z^
ML"L*N(PZTP8=.PATYDJDKLL.8_%\=!DW6![C]>BB3E14S&STZ:;MFQN!E]]V
MM=$0:\'@[A[5X""OW*F7/SUVV)-6%9.WR^2"CZI5D1H\-!F^4N/'$7K6+%3.
M_P"!QEQ.IQ']"!)D$1>,0;8[)B&Q0LKJ@H]66?NLXWB*'5%V+8,>DTK@GSMK
M2V,0IT08S(Z Y+X8?C(@]%#TRY1G*W*,>SI&78\4LB5>MSOX>JW%K(DU=-6"
MR3G<KVH^P[6VTUK'YW-[!W4&)G-48=R=PL?<*!556Z2)C#89'W#K\(=;NVG]
MF5RCA@^3>-%V3EPBZ044:X1S3VZR$BV1/Y(YH:)-!S)J0,*\L\T,%"SYNV22
M=DU&+*.Z,F6[]QHHZW:---&K?97*+?75+33&'^79-'6Z"CEL@X4;*ZKMMUDD
MU=FZ^N,XU7;Y4UVR@MC&<XPLE]"F,?;&WKS(^C3&??TX]^_?OU_/KZ?J_P"W
MT_[?J_?U]O?K[>&-==??K&,9SZ]Y_G/K'K'O/[Y]8^V/><^L?;'V\\O#SC;7
M&V,Z[8]XS]LX_P X_G'V_C./MG'\X]XS]LY\QFS)FS0T;-&K=JW3SME-!LBF
M@BGG;;;?;*:2.NB:>=M]MM]LZ:ZYVVVSMMG.<YSYK)+& $QCIV)286U,QN3!
M2L=/!WFFVS(H$.#W(HL-=)Z;:9V;/QSQTS7QIMIOE%=377?7.?>%]YQY/KCF
M?$D<Q!_*I&>DP&M84\DTS*-"1I"NZ7C+B'U% 6V1@T,/P#@@!^6T:/%F"T@.
M%CIV02<P8+DU7.C/^'E/NQ(MTC\P$ZJZQ\K8IS@KF2A[GJZM"R>V@:=="=+2
MZVA'Z_+#\J)HRS-+PJJG< KW9\S(,83-)C+I$PRA*M@KT6FLKK6$=W=G_*)%
M]["*U=0?1M&T_P#%_$9Y#/Z>S>Y^MZ8C_0]ZVU,(^WWW2'S<ASG&2.U5R94G
M_5!G'47F=5O"?TA"C%*=.?>V6L#>6(4ZPII-QWW4,Z(\,68I0S <0!7;%J$I
MU]V@E;=6-Y"3![A*^6I6SG5ED8 6*['XI,S:57AV18X7C"1>[*%3*,V+#8E8
M,*+MI!#9W& ,RB1YEA75F;C,G%-#8$NTU7327PV)"GS1ZAA9))7"2^F%$]-_
MJUQV;P\/#P\/#P\/#P\@BS>9J.M^5")W/:^%E)R#CA2&L)L.?'8M,<0HV[1(
M&(.\E,0+ #Q2$$R+= D_AI8@^C#HFBD15%;/M,./,20<I\XR:*5M!RE,5_K%
M:9>Y*T\%%1]K'6E2FL#7@9&05A^7?PE:OY(T$$2@QA)(DL(.CV)8NV9$4$BQ
M+5TKE_\  04^%K1[S>XBE0S:M"%_;,GAD>3-!Y!GIZKS]96;+I8[RJ0DDIL!
MF^)@+%9GI 0)OY66B6(D?+#QDC5/@W6I2K0M&4U4E)QAR\?1JGJR@561YZ45
ETW)O =?145$A+HCNDGJEN^<,!#=5WLGKJGLXW4SIKC7.,8__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g601999.jpg
<DESCRIPTION>G601999.JPG
<TEXT>
begin 644 g601999.jpg
M_]C_X  02D9)1@ ! 0$!K@&N  #__@!#1$E32S$R.#I;,C!:0D,Q+C(P6D)#
M-S8S,#$N3U544%5473DV-C-?,5]#3TY?4D%415]!1$I?,E]+7T5152Y%4%/_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  +"  F (X! 1$ _\0 '0   @,
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8;[[\..^^T;;EMMMRY;;9SGGIG60_/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g827456.jpg
<DESCRIPTION>G827456.JPG
<TEXT>
begin 644 g827456.jpg
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8-6K=)-!NW03T1013T22TT3TUUQF>?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g971860.jpg
<DESCRIPTION>G971860.JPG
<TEXT>
begin 644 g971860.jpg
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MXADF8A5H7:2+Q(K6CC5Q+HXV>R4>)33V7,-7S*E:A!U1,"$/-_<-Z7 1:2Q
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I74TZ'N]BT=ML?6)&M*;1&B%@CY^BS7BL/"C(DA]I:Z.RSN;WAX>?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g244632.jpg
<DESCRIPTION>G244632.JPG
<TEXT>
begin 644 g244632.jpg
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MLW\"*R2H0_.,GUEL=%;1\<8:7[1X>R'H? /9\4^CB+RA&2LQC[#_ '5=QIZ
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M)V#Q6GZK_$FB#V+5_(WTQL5Y+'6I:1VL3V1V>-1"+U?7\9GZ3_1VJ4W/V.K
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K/%SQY$8\ZF@UAKA;75D/E:XU0^R::X77QJV:D4D=<+*XUTQA3?&5[Y__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g702783.jpg
<DESCRIPTION>G702783.JPG
<TEXT>
begin 644 g702783.jpg
M_]C_X  02D9)1@ ! 0$!K@&N  #__@!#1$E32S$R.#I;,C!:0D,Q+C(P6D)#
M-S8S,#$N3U544%5473DV-C-?,5]#3TY?4D%415]!1$I?-E]+7T5152Y%4%/_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  +"  F ,$! 1$ _\0 '@   @(#
M  ,!              <("0$%!@(#! K_Q  [$  !! ,  0,!!00(!04    %
M P0&!P$""  )$2$3$A46,5$487&!%QDC.$%8D988)":8UE:QT=3P_]H " $!
M   _ /W\>'AX>'AX>'AX>'F,YQC'OG_]G/QC'\<Y^,?KGX\K!">HI'GG1_9<
M?D2(>)<O\:<HUGT'*KE)*KJ*2=*9R6_])/(@[37.-U:^C,;H(Y]Q%V;=WB9O
MMWY(8MD-D X*_5 IQW?TASIIT=7SVJJ'DEC0;>Q>>J$L.O'L]<-(W(@^35;,
M>BIBTG\;<M)E+ KH,5E,>K=$",JLD37C2A^R]P;HN4L"DDVB5=!1Q*Q)K%8L
MS<.6(?4W*38>*#2!A9OOOANV6+OFK3+MUJV=NT1Z"RJ_T45OIZ;IH;[ZJKGC
MI:M>BX@)D$1E4'>''K$F3(1*.3N/RTJ''L)&2CJ;UXD+6T>)LW*S%%31TL/;
MH:J/$FVJBF^-=E.,M_HAVROBM^2:J2:O[GL"(&K9F)D@EJX TM0<;,M8P2L<
M\TVWT^]9),9B_:P*I8HILF@>/(RF3D]EXS7DA'D(=<4]8=*]6OF$AR?JZ+2*
M =&V=4G:?*IV!$1]H\MA(P/LI:M&#&3+SAD_DIV9[AZR+?CU[%C$$L>)S0I*
M*V&QM@'7;-(RTQZH/0MC N2K%CIRA[E3ZR[BGM,0WGFOH*=&6\CQL$MRRH.T
MZE)%V]M2?:,N*_K:#C;GLQS(X6G 2 PXRA YS%I,; JJW'7?T[77.96'J7%@
MO#:\EZ94?I<+UEHM7$=FC=0?K&(!+"#1=P7 2:R]G;H;6670C8/,I@R:UN-*
M9L:5P.*RMGQ.=Z'J_'6#) !FM&;P.ZD+\-8.PL,:C(9'#EUHXEB;<B^8@'*8
M=!,J6'NWV74?U468&-6Q%B^;H5H0GJ+I#J?F*P.SJ7D%:4'2^8U/9[S&VMNN
MS$U(6O7,%:FG8*X[E4TF,+<P&N[=0"+G(C#(BDE- %<O 4V/350R=7@L=5(/
MU+YK;F_IA/G6H3E"MO4-YI0M:.6K/HJM8D?<],&P==R."<DCRKDO%H]'2TKC
M<AG,OBYZ49:E;>&P]&+5WH$E+AUMB:M&WW;VEPUYSMT8W@[>ZI?R<E?,B85T
MR>,8P%DT/M%" V2Q&)D3DE(:QU12?UTG&='YXL]RL+DJBQ)Y]375O.WR)=@]
M9QT%=>.:JQATENJ]F4(&V9,XG$7001'JIKTZ2?B(O*;7GDD?,H_%-IN4#FQ\
M"B;+603Z7Y"FS N)YB@(W)!J&MSU##5/UHE,Y#RM<69:[Z\K[C,)6.\FJQA(
MIM85F[19A$IC 2[F5;1N15F_-RMLBL:=$ L@&! THD1B+C6\??,])$<M=70S
MJ@;<>L=C,Q@\NY\O.7<Z7#")L@"R4BUH0T%%)2_9,C$5.22+R4$2B\XBL@"G
M0AEPFLR+Z,RC40=9$Q#&4GOC]_\ IG_X\SXF[]ORK.9*IE%T7+),1>!Q/46D
M^>HC29PL2+R$RPC<5BT8C8)H0/RJ83"3EA$7B$4CX\@<DDB*CA IDX=ND]/%
M(!Z3L]U+*?!RKE"W86%NF2$(\)/OI+51I:N,CH)*[!_:[F!QV9$7,/3?C(FY
M!L-(R]GVFDP("X^5<BMG>CO,8:+]5>'6Q,*IC<LH:VJK WOTAT#RG3ECE#%9
M3*$3:WN;=K&2G;1'>&3%_*!T6-KU)8B<$F*\86!F_P -+Y+N(YD@'U(6N8SC
M.,9Q\XSC&<9_=GYQYS1R9Q*-%HH"D,D"!#,[,.X]#!A4DT8/I4>8@R<F=A8^
MV<JIJ%RS>.A#)Q0<QU6>8%"B3_".6S%RHE[@$LC,JR;Q&CPD]^&Y 1BA[(E^
MV?ZB)*(U;Y+ 7^[9131L6%Y=()D6"FV'+%??+9TFDXT42T3/0\3M.PP,7KZO
MG42%P^72QB(O8V6E4CC4S8TVJV=9E0JK-X]'B^N\VE/_ "L>V(DRT7U!1Q\=
M(!3#:38"/1]; [TM'1TQZI]?2\M$HISOW?S]37.-5M(?-+ FUA59"JKI^PJR
MT>%TK 9IL&^6Y2?+2.(Q<!*",8"#Q+8 NVWV=/R#J8O.8_N$!%ZTK:\QW-C!
MO7H>/ 99;]8S>='R%L-8LR:C6[T)3TDK**L*E<2]!B@[D+9]9UCI1/=R]&1Q
M20_;9'1\UWS,43321(MQ[Y-%=)TDF\0;.DTW".<_363T7U4U35UQMMKJKKC"
MFN-]L:[8]\^ZQI>IX[3,%!0L2LP?;!$"C;[Y3%#Q+MV@3D!4_E%1)KNMG1)%
M8GLEJGAPIIOE'"^===]\ZZUXRRA+OSTSZD$[J":1B+7E>_-W(D1Y]FTSR2<Q
MR#1ZNG=WCB^BZ8--4[LT%SJ52:2EQX=5NZ>N3T?TPJP570):\O<W&G35EV[T
M;U'6F:5HGH*P.$9YQC!4F-AS$]'Y3)II*4Y)'+OM^2"ZR#NE,T/NT49T['!D
M.-R%TRETR;')0"8N!@QI83R]0$%YKHVG:EBL9BT?WK&GZQJM5R"18K+O&5<Q
M 3%V2;J0IA@1&0)Z?=N[A-^28,UG2JZCM1@S7642UWMN4'5M[JAVUMBOQU$P
MX^0M-:Y/.]75>%'\B:(CMY#((O\ 8U;'Y %&8?,HL^*JN4HON8)%@C5G(=F1
MECI3O/H ]S)+>7B,[GY>,2RHII3*\VDLFQ([*0C,QC)J):O7$M>-T7IR0@@I
MC1LPD!S]M.DE!K-_(RADTL1+/J]!/&?5$RX6JCTY+#DU1UG4<9J"!<V7;<E/
M2F3D9U;= 02*CX(;BM9P0W!@(RFCMVP<,C')Q(C$MG.:T&2*4LH&/E150'+
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KJT!BAXAJHXRGHEE?=N.;-D=ULI))IY5VTRIG3333.WV=-<8WGAX>'G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g1018787.jpg
<DESCRIPTION>G1018787.JPG
<TEXT>
begin 644 g1018787.jpg
M_]C_X  02D9)1@ ! 0$ UP#7  #__@!&35),3%]'4D%02$E#4SI;15A!0U1?
M4T-)14Y#15-?0T]24$]2051)3TY=15A!0U1?4T-)14Y#15-?-$-?3$]'3RY%
M4%/_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0'_P  1" !Q 44# 2(  A$! Q$!_\0 'P   P " @,! 0
M  H+" D$!P$%!@(#_\0 :1    8" 0("! ,-#@X/"0$  0(#! 4&!P@ "1$*
M$A,4(3$507@6&1HB.#E16%EQF+?7%Q@S-G6!D9.6L[6VU=8C*#(W4U=A<G1W
ME[&RM"4G-#5&2'-VDL+1TM/B\"0F0T1'8H.'H=3_Q  < 0$!  ,  P$
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M:7#6?($L$Q+1M59XDQ!-M()JY!!#R1Z$K.2SY-$2CY7+]R<# "@%+TO]!?\
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M7X\9-2H2+2M,)FUKBD5)>0N5C;I3-F>.1\A#J'"2=J,F_I0](BP9,VOL*W*
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M5R*>KMUE?(F9KN0>IQS![(*D.HFR:NG:A$_+Z0Y&J"BYRD\QBE\QBI"4OF,
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M7PFNB&Y-ML66<#6.P:898L[M]+3[?'U=B[;A.P3;X?3.)9UB)\_KXU5\[<E
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M:T0?,CN-:D%$/;'.14%'%3/(SDHQB6)%5 12,^E'B+%F"BI@$J:?K+E+TAQ
M0*3S&'V!RY_I9JSCW2O5G!NK^,H>-B:OAS'L!4_/'( @$[8D&:;FY6]^(@!G
M$U<[<XFK1-O5 !5Y)2BZIP /(0@$S///A$>K;AFDO+G5H[ &PRL<S=/G].PE
MDZ84O";9D@9PN,;"Y/I.-6MB<F3(8C6*@)5_-OW D;,(MTNJFF99F0C[9CVU
MOXF58S],NM,L#F/DXR1:R5<M%5M%=D3MW;%^R<D93$#8(*6:*(.&RZ;.4B9)
MJ=,Y6SM 0)?3$ , E, " AV$!#N A_=#DUWQ9?31R;(]0FEY^U<URRWD1#8+
M#,?.Y>_,?Q%>;Q&HY4HT^_IZ]AF7%-KTHPC9:U4Q.GBZ06,@[D7L(^FW15G4
MBNZ6 8I\,-U=;=U'=5;/B#8"RJ67:/5=2O0EHMLDJ!IK*V++&1ZC0<ARZQ@3
M&1MD<ZB9.FWE^F155^]CX"RRBYY2UN>^'7C8_J"=5/E?I?B2R=S2]X4O"6YN
MM?54B3Y%UIV3QEC7*V!LPX_M]CON'\I4>E-#QK&'R+6EI>4L5<BH,7AIZE(1
M<.#U<5A=2YT60>F<"4^Z'QL?U!.JGROTOQ)9.X C9T<OKKG3C^6MK=^-.N<M
M9V?]+<_^HTQ_!SOD4SHY?77.G'\M;6[\:=<Y:SL_Z6Y_]1IC^#G? (&+X.[U
MT >\7+@/V5U.;2-=>B3U2=LL.4[8#7G46YY,P_D!.95I]VBK=BJ,83:=>L$K
M59@R#&Q7Z&F4 8S\)*1JGKD:V%15FHH@"K<R2RFKEY_N]Q_A:_\ K"G*_7AB
MBD'H?:0>8@#_ +'9S'VD[^_9++W<?</O[ '?^YV^+@$[?Z&]ZV/VA.0_W>X0
M_*ES]%\-]UL0,41T)R'V P#^GW"'V?\ &ERQGY$O[&7]K_\ +P\B7]C+^U_^
M7@&H[H3:\YEU3Z3^I& =@J+(8UR_CROY.:7.DRCZ%DG\$XG,V9*M$4DX>UZ3
MF(=<7D#-Q<B06<BY B3LB:PI."*HIRO^M?\ 7;>HQ\L'.7\='_+61@ "&
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MTA?N6R:QTTU!4+@EXV/Z@G53Y7Z7XDLG< 1LZ.7UUSIQ_+6UN_&G7.6L[/\
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M1VQGY3>?T1\*ST1FZJ2Z6J5E*JBJFLF?\\;L6/E42.50@B Y,$H@!B@(E$!
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M7J-%,8,E@DHF).X2>V!.0=%=R#< C6+U1(5%B$2.LP'C8="S&\A-4]P#F$1
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MD6F2F; +<Q#(F$@@20M;>J%U"M0S-4]=-P<]8SB6?JPH5-A?I:=H BS351:
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ML_Z6Y_\ 4:8_@YWR/=TE]']T:7U/.G[;;AJ)M!5:K6]P]?)NQ66R8 RS!5^
MA8S)< \D9>:F92HM(Z+BX]JDJY>OWSE!HT;IG7<*II$.<MA2R)J*UZ<22(=1
M12(EB$3(4QSG.=@Z*0I"% 3&,<Q@*4I0$3&$  !$0#@$"]Z/9\Y$?<#I<?V'
M"G*)70[\0GTN=)NEYJ]K+L)FJXU3,&,V>4T;A 1>%<K6M@P/9\TY#N4,"$]7
M*P_AGX.("PQCI0S-XL""JQVJX)N$%2 CB]Z?6^9G;HQ=)MN1 7+@0$-;,SB
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M1W^MCS9<3]%5^\G_ )C<.'(N<O/\(']>'#AR@.'#AP X<.' #APX< .'#AP
MX<.' / ^[]<O^<.>>'#@!PX<. <-?]#>_P"#F_>E.:I;;_7^3_YP1?\ I$X<
M. ;3(K_>J)_Y-#][/SW7#AP X<.' #APX< .'#AP#\G_ *@W]Z;_ ##SX6]?
MI7/_ 'I_]3<\.'!8\UYK[F*^NG^_<Q^K"7^DOS-TG^Z%?[Q/_K<.',8\OE_Q
*B0_OPX<.9 __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g962760.jpg
<DESCRIPTION>G962760.JPG
<TEXT>
begin 644 g962760.jpg
M_]C_X  02D9)1@ ! 0$ @@""  #__@!&35),3%]'4D%02$E#4SI;15A!0U1?
M4T-)14Y#15-?0T]24$]2051)3TY=15A!0U1?4T-)14Y#15-?-$-?3$]'3RY%
M4%/_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0'_P  1" !$ ,0# 2(  A$! Q$!_\0 '@   @,!  ,! 0
M  D("@L' @0&!0'_Q !+$   !@(! P($ @,)"PT    " P0%!@<!" D "A$2
M$Q05%B$7,2)!<1@:(SE15W>!MQDD.%AA9Y>AL;C8)S-%1U5VDYBRP=;7\/_$
M !H! 0$  P$!               ! P0&!P7_Q  M$0 " @$"! 4#! ,
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MQZ8VE1)I3'D[F['-S02V'$MR,2DT6"$9)F2R !P7C(LAR,2_.\*U@V6N_?\
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MAN.4('1J<T"@A8@7HCSDRI,<6<28, \9Z.JV/;S5AR6Z=<?(=<ML-<Y"QO\
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MF&FA)!C(L^D.,F#$ .,BSGQC&18\YSXQYSGQUGJ=N1W%VH6H&H37I!O$_O\
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MV);]X]=Y6-$J+CKX"03]/:0B49N,XP<*&662^0Z0H,&A4%9;B50R2T3NVF*
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M8;_859[!.+=,;:2)VR4H6OYY )XC:L2.?(QMS\UFNT5?&QGD*!43('%K=BV
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MLFYO#CK'KOM)(*3A$YO5QB;6_IVQ,MD\DKQ>_P"4Y[X:W"R:L;*N9T)AH4X
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&HZ.@/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
